Effective and efficient use of bDMARDs in Rheumatoid Arthritis by Verhoef, L.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/207784
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
Lise Verhoef
Effective and efficient 
use of bDMARDs 
in rheumatoid arthritis
Lise Verhoef
Effective and efficient 
use of bDMARDs 
in rheumatoid arthritis
32
Effective and efficient use 
of bDMARDs in rheumatoid arthritis
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op donderdag 31 oktober 2019
om 10.30 uur precies
door
Lise Maria Verhoef
geboren op 6 februari 1989
te Amersfoort
Colofon
Cover design and layout by: burorub grafisch ontwerp, Nijmegen
Artwork cover:  Jeroen Derks
Printing: Koninklijke Van der Most BV, Heerde
ISBN: 978-90-9032286-5
Publication of this thesis was financially supported by the Sint Maartenskliniek, Nijmegen, 
The Netherlands.
The work presented in this thesis was carried out within the Radboud Institute for Health 
Sciences.
© Lise Verhoef 2019
 
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system of 
any nature, or transmitted in any form or by any means, electronic, mechanical, photocopying, 
recording or otherwise without the prior written permission of the holder of the copyright. 
54
Table of contentsPromotoren: 
Prof. dr. F.H.J. van den Hoogen
Prof. dr. M.E.J.L. Hulscher 
Copromotoren:
Dr. A.A. den Broeder (Sint Maartenskliniek)
Dr. J.E. Vriezekolk (Sint Maartenskliniek)
Manuscriptcommissie:
Prof. dr. E.M.G.J. de Jong
Prof. dr. P. Verschueren (Universitair Ziekenhuis Leuven, België)
Prof. dr. C. Kramers
Chapter 1 General introduction
Chapter 2 bDMARD dose reduction in rheumatoid arthritis: a narrative 
review with systematic literature search
Chapter 3 Down-titration and discontinuation strategies of tumour 
necrosis factor-blocking agents for rheumatoid arthritis in 
patients with low disease activity
Chapter 4 Cost-effectiveness of five different anti-tumour necrosis factor 
tapering strategies in rheumatoid arthritis: a modelling study
Chapter 5.1  Ultra-low dose of rituximab in rheumatoid arthritis:
 study protocol for a randomised controlled trial 
Chapter 5.2 Ultra-low doses of rituximab for retreatment of rheumatoid
 arthritis
Chapter 6  The patient perspective on biologic DMARD dose reduction in 
rheumatoid arthritis: a mixed methods study
Chapter 7 Implementation of protocolized tight control and biological dose 
optimization in daily clinical practice: results of a pilot study
Chapter 8 General discussion
Chapter 9 Summary
Chapter 10 Nederlandse samenvatting
 Dankwoord
  Curriculum Vitae
  List of publications
  Research Data Management
  PhD Portfolio
 Theses Sint Maartenskliniek
7
17
45
101
117
133
151
167
175
193
199
205
211
215
219
223
227
76
Chapter 1
General introduction
98
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects between 0.5 and 
1.0% of the population in Western countries.1,2 The disease is characterised by persistent 
inflammation of the synovium of joints which, when untreated, leads to pain, disability, 
decreased quality of life, and joint damage. Next to this, patients with RA have an increased 
risk for developing infections, malignancies and cardiovascular diseases like myocardial 
infarction and stroke.3,4 In RA, mostly peripheral joints such as the hands and feet are involved. 
The disease affects women at least twice as often as men and manifests mainly between the 
age of 40 and 60 years.1-3 
The aetiology of RA remains largely unknown. It is estimated that 50% of the risk to develop RA 
comes from genetic factors in which the HLA-DRB1 region seems to plays a role.2,5 Next to this, 
smoking is a major environmental risk factor for the development of the disease.2,3 Although 
advances have been made, elucidating the pathophysiology of RA remains challenging 
probably because the disease might be considered a syndrome consisting of several disease 
subsets involving different inflammatory cascades.3,6 In between 50% and 80% of individuals 
with RA rheumatoid factor (RF) and/or anti-citrullinated peptide antibodies (ACPA) can be 
detected. These patients generally have a more severe disease course than patients that are 
negative for these antibodies.2,3,7
Pharmacological treatment of rheumatoid arthritis
There are various pharmacological treatment options for patients with RA.3,8,9 Analgesics and 
non-steroidal anti-inflammatory drugs (NSAIDs) reduce pain and stiffness but fail to inhibit 
long-term damage to the joints.3 Next to the former, glucocorticoids are widely used. While 
they are effective in treating symptoms and inhibiting joint damage, it is advised that they 
are used at the lowest possible dose and for the shortest possible time due to risk for adverse 
effects.10 Lastly, Disease Modifying Anti-Rheumatic drugs (DMARDs) are a heterogeneous 
group of drugs that interfere with the inflammation process of RA and thereby reduce 
symptoms, improve function and inhibit structural damage.9
DMARDs can be divided into two classes: synthetic DMARDs (sDMARDs) and biological 
DMARDs (bDMARDs).3,8,9,11 sDMARDs are small molecules that are synthetically manufactured 
and can be further classified as being conventional or targeted (csDMARDs and tsDMARDs 
respectively).9 Before 1998, mainly csDMARDs like intramuscular gold, methotrexate (MTX), 
azathioprine, hydroxychloroquine, D-penicilamine and sulfasalazine were available. After 
1998, bDMARDs came to the market, which expanded the treatment possibilities for patients 
with RA.8,12 bDMARDs are complex molecules produced by living cells with various modes 
of action that interfere with the cascade of inflammation. For example inhibition of TNF-
alfa (adalimumab, certolizumab pegol, etanercept, infliximab and golimumab), interleukin 
6 receptor inhibition (tocilizumab, sarilumab) or B-cell depletion (rituximab).12 Next to 
bDMARDs, two tsDMARDs (baricitinib and tofacitinib) are now available for treatment of RA. 
These small molecule compounds show similar efficacy and safety to bDMARDs and inhibit 
inflammation by interfering with the Janus kinase (JAK) pathway.8,13 
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The guidelines of the American College of Rheumatology (ACR) and European League 
against Rheumatism (EULAR) recommend to start pharmacological therapy for RA as soon 
as possible to control disease activity and prevent long-term damage: hit-hard, hit-early.14,15 
Methotrexate as mono-therapy, or in combination with another csDMARD, is advised as first-
choice treatment. When response is insufficient or treatment is not tolerated, a combination 
of csDMARDs or another csDMARD should be attempted. A bDMARD or tsDMARD should be 
started for patients with poor prognostic factors such as presence of RF/ACPA , early erosions 
and/or high acute phase reactant levels. It is advised that a csDMARD is used next to a bDMARD 
or tsDMARD.15 Treatment of patients with RA should follow the principle of treat-to-target as 
this leads to better clinical, functional and structural outcomes.16 Treat-to-target entails that 
a treatment goal is set (remission or low disease activity), that disease activity is monitored 
frequently (once every 1-3 months in case of active disease) and that treatment is adjusted in 
case the treatment target is not reached after 6 months. Preferably, disease activity is assessed 
using a composite disease activity measure that includes joint counts such as the DAS28, CDAI 
or SDAI.9,15 When using the above described strategies for DMARD treatment, most patients 
reach their treatment target of low disease activity or remission.8
Dose reduction of biological DMARDs
Although bDMARDs have been shown to be effective and relatively safe, their use comes with 
some downsides as well. Firstly, bDMARDs are administered by injection or infusion which 
is associated with substantial burden for patients, such as fear for self-injection, hassles 
to keep the syringes refrigerated or travelling to the hospital for an infusion.17 Next to this, 
there is a (dose-related) risk of adverse events, mainly infections.18,19 Lastly, bDMARDs are 
expensive. Costs can rise up to 14.000 euro per patient per year in the EU20, and even more 
in the US21. Recently, biosimilars have been introduced for compounds for which the patents 
have expired, which has reduced costs substantially. However, costs of bDMARDs still weigh 
heavily on the healthcare budget.22,23 Due to the downsides that are also associated with use 
of bDMARDs and the large proportion of patients that is able to reach remission or low disease 
activity nowadays, several studies have investigated the possibility to reduce the dose of these 
medicines after patients have reached their treatment goal.24
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Rationale behind dose reduction
Although the exact mechanism and location of action of bDMARDs is surprisingly not known, 
treatment with a bDMARDs is effective when a certain blood concentration is reached that 
exceeds the minimal effective concentration in that individual patient. Because this minimal 
effective concentration that is needed differs between individuals, each patient has her/his 
own dose-response curve. The rationale behind dose reduction is that the authorised dose 
leads to overtreatment in some patients because this dose should ensure efficacy for the large 
majority of patients. The consequence is that a part of patients can reach their minimal effective 
concentration with a lower dose. In case of suboptimal dose finding by the manufacturer, 
the proportion of patients able to taper treatment might be even higher. Additionally, some 
patients will have no response to a certain bDMARD and can discontinue treatment completely 
because low disease activity is reached due to other factors (concomitant csDMARD use or 
spontaneous improvement).25,26 Furthermore, it might be conceivable that patients need a 
lower dose as maintenance treatment compared to the initial dose. 
Evidence on dose reduction of bDMARDs 
Various studies have been performed on the subject of bDMARD dose reduction in patients 
with RA after their treatment goal (low disease activity or remission) has been reached. These 
studies included different types of patients (e.g. early or established disease) and concerned 
several bDMARDs but mostly the anti-TNF agents adalimumab and etanercept. Furthermore, 
different strategies of dose reduction were investigated including direct discontinuation, 
fixed dose reduction (e.g. 50% reduction) and disease activity-guided tapering (i.e. step-wise 
reduction of the dose until flare).26,27
The evidence shows that discontinuation of the bDMARD is inferior to continuation of the 
drug regarding disease activity and flares, function and radiographic joint damage.27,28 Fixed 
dose reduction and disease activity-guided tapering seem achievable for a large proportion 
of patients with a much lower chance of flare and minimal to no impact on function and 
radiographic joint damage. Furthermore, reinstatement of the bDMARD or increasing the 
dose after tapering is safe and effective.26-28
The current guidelines on treatment of RA with DMARDs have therefore incorporated the 
possibility of dose reduction after remission or low disease activity is reached.14,15 They 
recommend “If a patient is in persistent remission after having tapered glucocorticoids, 
one can consider tapering bDMARDs”15 and “If done, tapering must be conducted slowly and 
carefully, watching for increased disease activity and flares”.14
Despite the evidence described above, several questions remain on the subject of bDMARD 
dose reduction. For example, ‘are there predictors for successful tapering?’, and ‘what are the 
precise effects of discontinuation, dose reduction and tapering on clinical, functional and 
structural outcomes?’. Because this is a fast developing field in which a lot of research is being 
done, narrative and systematic reviews summarizing the most recent evidence are warranted. 
Cost reduction is, next to minimizing the risk of side effects and reducing the burden for 
patients, an important reason to investigate dose reduction of bDMARDs. Because these 
expensive medications weigh heavily on the healthcare budget, cost savings would ensure 
future access for this type of treatment for all eligible patients.22 While it is logical that 
reducing the dose itself will lead to savings, it is of interest whether these savings outweigh 
Definition of dose reduction 
The term dose reduction will be used in this thesis as an overarching term for all treatment 
strategies in which a lower than authorised dose is used. This includes (temporal) 
discontinuation of treatment, fixed reduction of the dose (e.g. 50% reduction) or disease-
activity guided stepwise tapering of treatment until a flare occurs. Dose reduction might 
be achieved by reducing the dose that is administered as well as by increasing the interval 
of administration. Other terms used are dose optimisation, de-escalation, spacing or 
treatment relaxation.
Measuring dose reduction
A measure that is useful to indicate the degree of dose reduction is the daily defined dose 
(DDD). The DDD is the daily amount of medication that is used per the authorised dosing 
regimen. For etanercept this is for example 7.14mg/day (50mg/7 days). The degree of dose 
reduction can be expressed as a percentage of the DDD (e.g. reduction to 50% of the DDD).
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costs resulting from extra consultations, increases in co-medication and possible losses in 
effect (reflected in flares or a decrease in quality of life). It is therefore important to study 
the cost-effectiveness of different dose reduction strategies to be able to advice on a specific 
strategy for clinical practice. 
Rituximab: a special case
Concerning dose reduction of bDMARDs, rituximab (RTX) might be the odd one out. This 
chimeric antibody is directed to CD20 on B-cells and was shown to be effective for treatment 
of RA, probably through depletion of B-cells.29,30 Because RTX was first developed for the 
treatment of Non-Hodgkin Lymphoma, the dose for patients with RA was derived from this 
indication and no formal/standard phase I/II dose-finding was performed. The registered dose 
of RTX in RA is 2 × 1000mg (2 weeks apart) at least every 6 months31 as was used in the first 
randomised controlled trial in RA32. However, a systematic review from 2015 showed that a 
low-dose of RTX (2 × 500mg or 1 x 1000mg) is as effective as this high-dose.33 Both doses are 
currently used in clinical practice.34
Interestingly, three case reports have been published which suggest that even doses below 
1000mg might be sufficient to control RA activity in some patients. In these reports, patients 
that received very low doses (1 × 50mg to 2 × 100mg) showed a deep peripheral B-cell depletion 
and for some also an adequate RA disease control.35-37 Additionally, a small observational open 
label study reported B-cell depletion in 11 of 14 patients after infusion with a single dose of 
100mg RTX.38 It would therefore be of interest to investigate the effectiveness of ultra-low 
doses of RTX in a randomised controlled trial. 
Implementation in clinical practice
Most research regarding dose reduction of bDMARDs is focused on achieving additional 
clinical data on efficacy and safety. However, it is known that the mere publication of new 
insights (e.g. in guidelines) does not guarantee implementation, i.e. uptake of these insights 
in daily clinical practice.39,40 Regarding dose reduction this is illustrated by data from Ferriols-
Lisart et al. that shows that the use of reduced doses of anti-TNF in clinical practice is still 
limited.41 It is therefore essential to investigate which factors might hamper implementation 
of dose reduction in clinical practice. It is conceivable that barriers are for example present 
regarding knowledge and attitudes of the involved patients or physicians (e.g. physicians are 
not aware that dose reduction is possible or patients fear the chance that their disease activity 
will increase again), and there might be organizational/practical barriers (e.g. no protocol on 
dose reduction available or logistic problems to prescribe lower doses of drugs).39,40,42 
The decision on dose reduction is one that is made between the patient and his/her care 
provider (mostly the rheumatologist). This decision is preference sensitive, because dose 
reduction might incur benefits (less side effects, less practical burden and cost savings for 
society) but also comes with the risk of a disease flare. Individual patients will have their 
own valuation of these benefits and risks and shared decision making between patient and 
healthcare provider is needed to discuss options and preferences.43 Up to now, only two small 
studies have focused on the factors that might play a role for patients when considering dose 
reduction.44,45 Further insight into these factors and their impact on health care choices is 
important to facilitate implementation of dose reduction in clinical practice.
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In the context of implementation, the perspective of the involved care providers is at least as 
important as that of the patients since it will mainly be up to the rheumatologists to signal 
that a decision needs to be made and to initiate the conversation.43 Barriers for care providers 
to implement innovations can be categorised into seven domains according to the framework 
of Flottorp et al.: 1) characteristics of the innovation, 2) individual health professional 
factors (e.g. knowledge and attitudes), 3) patient factors (e.g. preferences, behaviour), 4) 
professional interactions, 5) incentives and resources, 6) capacity for organisational change 
and 7) social, political and legal factors.42 Examples of implementation strategies that have 
been recommended in the context of dose reduction are education, audit and feedback and 
reminders.46 Systematic reviews have, however, identified only small to moderate effects of 
these type of interventions47-49. In behavioural sciences, it is assumed that successful change 
can be achieved by interventions that are based on the determinants (barriers and facilitators) 
that influence current behaviour making use of behavioural change theories.50,51 As a result, 
strategies tailored to these determinants will probably be most effective.52-54 In summary, 
there is a need for an implementation strategy aimed at bDMARD dose reduction targeting 
the most important barriers and facilitators among care providers and patients.
 
Aim and outline thesis
Taking into account the current evidence and remaining questions on bDMARD dose reduction 
in RA, we formulated the following research objectives for this thesis:
• To provide a narrative overview of the existing evidence on bDMARD dose reduction 
(chapter 2)
• To systematically review the current evidence on the benefits and harms of down-titration 
(dose reduction, discontinuation or disease activity-guided tapering) of anti-TNF agents 
(chapter 3)
• To investigate the cost-effectiveness of several different anti-TNF tapering strategies 
(chapter 4)
• To assess the efficacy of ultra-low doses rituximab for retreatment of patients with RA 
(chapter 5.1 and 5.2)
• To identify the factors that play a role for patients with RA when considering dose reduction 
and to determine their relative importance (chapter 6)
• To explore the effect of a multi-faceted strategy aimed at implementation of bDMARD dose 
reduction in clinical practice (chapter 7)
General introduction
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Abstract
Introduction
Although bDMARDs are effective in the treatment of RA, they are associated with dose-
dependent side effects, patient burden, and high costs. Recently, many studies have 
investigated the possibility of discontinuing or tapering bDMARDs when patients have 
reached their treatment goal. The aim of this review is to provide a narrative overview of 
the existing evidence on bDMARD dose reduction and to provide answers to specific dose-
reduction-related questions that are of interest to clinicians.
Methods
We systematically searched for relevant studies in four scientific databases. Furthermore, we 
screened the references of reviews and relevant studies.
 
Results
Our searches resulted in 45 original studies of bDMARD dose reduction in RA patients (15 RCTs 
and 30 observational studies). Current evidence shows that bDMARD dose reduction can 
be considered in all RA patients who achieve stable (e.g., ≥6 months) low disease activity or 
remission. The best strategies seem to be disease-activity-guided dose optimization and fixed 
dose reduction, since direct bDMARD discontinuation (without restarting) results in a high 
flare rate, worse physical functioning, and more joint damage. When tapering the bDMARD 
treatment of a patient, disease activity should be monitored closely, and if a flare occurs, the 
dose should be increased to the lowest effective dose. Current evidence shows that restarting 
bDMARD treatment is effective and safe. Unfortunately, no clear predictors of successful dose 
reduction have been identified so far.
Conclusion
The current evidence and rising healthcare costs urge that dose reduction should be 
considered for eligible patients. However, the decision to start dose reduction should be made 
in shared decision-making. Future research should focus not only on a better understanding 
of the effects of dose reduction on clinical outcomes but also on the perspectives of patients 
and physicians as well as the implementation of this new treatment principle.
Keywords 
bDMARDs; Discontinuation; Dose de-escalation; Dose reduction; Dose titration; Drug holiday; 
Rheumatoid arthritis; Spacing; Tapering; Treatment relaxation
Introduction
Background
The introduction of biological disease-modifying antirheumatic drugs (bDMARDs) almost 
two decades ago has improved the treatment of patients with rheumatoid arthritis (RA) by 
offering more treatment options to be used according to the tight control principle. bDMARDs 
improve clinical, functional, and radiographic outcomes, and are a welcome - although not 
clearly superior - addition to existing therapies with synthetic DMARDs (sDMARDs) such as 
methotrexate, leflunomide, and prednisone.1 bDMARDs can be categorized into those that 
act as an inhibitor of tumor necrosis factor (TNFi) and those that have another mechanism of 
action (non-TNFi).
 
Although bDMARDs are effective in the treatment of RA, they are associated with high costs, 
patient burden, and dose-dependent side effects, such as an increased risk of infection.2-5 
Because of these downsides, many studies have recently investigated the possibility of 
discontinuing or tapering bDMARDs when patients have reached their treatment goal, 
which is most often low disease activity (LDA) or remission.6,7 Based on evidence from these 
studies, the EULAR and ACR have incorporated the option of dose reduction into their latest 
guidelines, the central axiom being “maintenance of treatment goal does not necessarily 
mean maintenance of treatment intensity”.8,9
For clinical practice, however, several questions about the optimal strategy for dose 
reduction/discontinuation need to be answered in order to properly implement bDMARD 
dose optimization. Therefore, the goal of this review is to provide a narrative overview of 
the existing evidence on this topic, to provide answers to specific dose-reduction-related 
questions that are of interest to clinicians, and to suggest topics for future research.
Questions
We aimed to answer the following clinically relevant questions when considering dose 
reduction of a bDMARD in an individual RA patient with low disease activity: 
1. What are the mechanisms behind the possibility of bDMARD dose reduction in RA patients?
2. In which patients and when should we consider dose reduction? 
3. What is the best dose-reduction strategy?
4. What proportion of the patients can be stopped or tapered, and can we predict successful 
dose reduction using patient or treatment characteristics?
5. What are the effects of dose reduction on function, quality of life, adverse events, and 
radiographic damage?
6. Which flare criterion is best to use when deciding whether to restart/re-escalate 
treatment, and how often should the patient be monitored?
7. Is it effective and safe to restart treatment?
8. What is the cost-effectiveness of dose reduction?
9. How can dose reduction best be implemented in clinical practice?
10. What is the patient perspective on bDMARD dose reduction?
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Methods
To find relevant studies for this review, we searched CENTRAL, MEDLINE, EMBASE, and Web 
of Science (only for TNFi) from January 1, 1995 to August 17, 2016. We performed separate 
searches for TNFi bDMARDs and non-TNFi bDMARDs. To be included in this review, studies had 
to address RA, dose reduction/discontinuation/tapering of bDMARDs after LDA or remission, 
and at least one of the topics that we identified for this review. Articles describing original 
research, ≥20 participants, and a follow-up of ≥6 months were included. Furthermore, we 
identified relevant reviews on the topic of bDMARD dose reduction. The search strategies are 
provided in Appendix 1 of the Electronic supplementary material (ESM). 
We also sought relevant studies by screening the references included in reviews of this field 
and those included in the studies that had already been accepted for inclusion in this work. In 
addition, studies that were already known to the authors from previous research, meetings/
conferences, or personal communications were considered for inclusion. No meta-analyses 
were performed because our aim was to answer several questions in a narrative manner and 
not to obtain summarized estimates for one or two outcomes. For the same reason, and also 
due to feasibility, we did not formally assess the risk of bias in the included studies. 
Since this article is based on previously conducted studies, and does not involve any new 
studies of human or animal subjects performed by any of the authors, no ethical approval was 
necessary.
Results 
General Results
Our searches and the subsequent reference screening process resulted in 45 original studies 
of bDMARD dose reduction in RA patients after attainment of low disease activity or remission 
(Table 1). Fifteen of these studies were randomized controlled trials (RCTs) that were specifically 
designed to compare dose reduction with continuation of bDMARDs. The other 30 articles 
addressed research in which dose reduction was investigated in a nonrandomized manner 
(observational), or in which one arm of a randomized study fulfilled the inclusion criteria but 
a nontapering control group was not included. The first study of this subject was published in 
2002, and there was an evident increase in the number of studies published on this topic in the 
years that followed. Most of the studies focused on TNFi reduction (especially etanercept and 
adalimumab). None of the studies investigated anakinra or golimumab reduction, and very 
few focused on certolizumab pegol reduction.
 
There is marked methodological heterogeneity among these studies (as has already been 
noted by Yoshida et al. and Fautrel et al.6,10) in terms of, for example, the design itself (RCTs, 
extensions of RCTs, observational studies, and superiority versus non-inferiority designs), 
inclusion criteria for dose reduction (remission or LDA with variety in duration, with or without 
concomitant DMARD, tapering soon after the start of treatment or in a later phase), and the 
definition of flare. However, for the latter, criteria based on the Disease Activity Score in 28 
joints (DAS28) were mostly used.
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We found several reviews on the topic of bDMARD dose reduction. A Cochrane review was 
published in 2014 by van Herwaarden et al. that focused on down-titration and discontinuation 
of TNFi therapy.7 However, its results were based on searches performed in September 
2013. Because many new studies and full texts have been published since then, an update is 
needed. Some reviews have chosen to focus on dose reduction of both biological and synthetic 
DMARDs; examples include the recent reviews of Kuijper et al. and Schett et al. and a narrative 
review by Fautrel et al.6,11,12 Other reviews, such as those by Navarro-Millan et al., Yoshida et al., 
and Galvao et al.,10,13,14 only focus on bDMARD discontinuation.
The terminology used in the studies varies considerably. Therefore, in Table 2 we propose 
definitions of several terms that we will use in this review to describe concepts of interest.
Table 2. Terms used in this field
Terms Definition
Dose reduction, treatment relaxation/ de-
intensification/ de-escalation
Overarching term for all strategies using dose 
reduction or cessation of a bDMARD
Discontinuation, stopping Directly stopping the bDMARD
Treatment holiday Temporary discontinuation of all (or one specific) 
medication
Drug-free remission (DRF) Remission without any type of DMARD treatment 
Fixed dose reduction Directly reducing the dose or increasing the 
interval of the bDMARD
Tapering Reducing the dose or increasing the interval of 
the bDMARD stepwise 
Disease activity guided dose optimization, dose 
titration
Tapering a bDMARD until loss of response. In case 
of loss of response, the dose is increased again 
until response is regained. 
Flare, loss of response, relapse Increase in disease activity of sufficient duration 
and severity to warrant treatment change. When 
this occurs after dose reduction, this is often 
called loss of response or relapse60
Figure 1. Possible dose-response patterns for bDMARD treatment in RA patients (figure adapted from 
Fautrel et al.6)
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1. What are the mechanisms behind the possibility of bDMARD dose reduction in RA 
Patients?
Most bDMARDs are believed to work though the achievement of a certain drug level in the 
blood that remains above the minimal effective drug concentration during the whole interval 
between two administrations.61 The dose needed to obtain such a trough drug level differs 
between patients due to variations in the volume of distribution and the half-life of the drug. 
Furthermore, the minimal effective drug concentration varies significantly between patients. 
Therefore, each patient has their own dose–response curve.6 
Several dose–response patterns might be possible (Fig. 1). While some patients have an 
“average” dose–response curve, other patients will have a curve that is shifted to the left (good 
clinical response on a lower dose) or shifted to the right (good response only on a higher dose). 
Also, it is conceivable that some patients have a partial response to the drug or do not respond 
to the medication at all. The latter patients are doing well irrespective of the drug, possibly due 
to the placebo effect (in RCTs), regression to the mean, or concomitant medication. 
Conceptually, based on the possible response patterns, patients with a flat dose–response 
curve can discontinue the bDMARD, as the clinical effect is unrelated to treatment. For patients 
with an S-shaped dose–response curve, tapering is possible until the minimal effective 
concentration (the concentration below which disease activity increases) is reached. Patients 
with a partial response should be switched to another drug and patients with a dose–response 
curve shifted to the right would need a higher than standard dose. However, administering 
a higher dose is not a realistic option for bDMARDs, as the authorized dose of these drugs is 
based on maximal effect at the group level. So, the chance of response is low, and is in fact 
much lower than the chance of response after switching to another bDMARD. Also, this higher 
dosing will result in lower cost-effectiveness and increased risk of side effects.5,6
2. In which patients and when should we consider dose reduction?
For clinical practice, it is important to know which patients are eligible for dose reduction. 
Logically, dose reduction is only applicable in patients in whom the treatment goal is reached 
and treatment would normally remain unchanged. These are RA patients who have LDA or 
remission on treatment with a bDMARD.
Most of the studies included patients who showed sustained LDA or remission for ≥6 months. 
This period of 6 months seems reasonable, but this is based on expert opinion rather than 
evidence.6,9 It could be argued that dose reduction should only be performed in patients in 
clinical remission and not in patients with a low disease activity state. However, in a recent 
systematic review (mentioned in the section addressing question 4), neither DAS28-ESR nor 
DAS28-CRP at baseline demonstrated high predictive value for successful dose reduction or 
discontinuation of a bDMARD. Although deep remission is very nice to achieve, a less stringent 
goal of remission or low disease activity is a reasonable choice for many patients because (1) 
the patient-acceptable symptom state of RA disease activity is around a DAS28 of 3.2, (2) a 
subset of patients have a favorable prognosis with regard to joint damage, and thus do not 
need more intensive treatment, and (3) remission is not achievable in a subset of patients.
 
So, when the optimal effect of a bDMARD has been attained, it is possible to investigate 
whether this effect can be maintained with a lower dose of the drug. However, it is important 
to check that the bDMARD is not needed for any other condition such as Crohn’s disease or 
psoriasis. Also, it is also important to address the order in which the tapering of medications 
should occur. Many patients use not only a bDMARD but also oral glucocorticoids and one or 
more sDMARDs. According to the EULAR recommendations, oral glucocorticoids should be 
tapered first, bDMARDs next, and sDMARDs last.9 This recommendation is based on the safety 
and cost-effectiveness of each drug.
 
In conclusion, all RA patients with sustained (e.g., ≥6 months) LDA or remission, who do not 
need the bDMARD for any other condition, and who do not use high doses of steroids can be 
considered for bDMARD dose reduction.
3. What is the best dose reduction strategy?
There are several possible strategies for dose reduction of bDMARDs in RA patients. Many 
studies have investigated the possibility of direct discontinuation of the drug when a patient 
is in a low disease activity state. This is also called withdrawal, a “treatment holiday” or, 
when remission is maintained without any medication, drug-free remission (DFR); see also 
Table 2. Another option is a fixed dose reduction, for example halving the dose. The last and 
perhaps most sophisticated strategy is to taper the dose of the bDMARD step by step until 
disease flare or discontinuation of the medication. These last two strategies (fixed dose 
reduction or disease-activity-guided dose optimization) may be realized by either reducing 
the dose or increasing the interval between doses (spacing). Increasing the interval is the most 
practical approach for drugs administered through prefilled syringes, whereas dose reduction 
might be preferable for intravenous medication, as this is pharmacologically more efficient 
when a minimal effective trough concentration must be obtained for a drug with first-order 
pharmacokinetics.6 It should be noted, however, that in RA treatment the overarching strategy 
is characterized by tight control, so this should be incorporated into any dose-reduction 
strategy.62
 
Based on most of the studies and reviews, it is evident that direct discontinuation of a 
bDMARD ultimately leads to a disease flare in many or even most patients 13,17,26,28,29. At 
the group level, this strategy is therefore probably inferior to continuation of the bDMARD 
with respect to disease control, although no studies have investigated a strategy in which 
direct discontinuation was combined with restarting under tight control. However, direct 
discontinuation is feasible for at least a relevant subset of patients, which makes it interesting 
to identify these patients beforehand (see question 4). 
Fixed dose reduction and disease-activity-guided dose optimization have often been found 
to be noninferior to continuation of the drug.7,17,22,24-27,63 These strategies should therefore be 
considered in daily practice, as suggested by the EULAR and ACR in current guidelines.8,9 One 
strategy for disease-activity-guided dose optimization is to attempt tapering only once (as in 
the DRESS study25). Another option is to taper again after remission has been re-achieved (as 
in the STRASS study22). As it seems that patient dose–response curves are relatively stable over 
the short term, repeated tapering attempts are probably not favorable. This may be why the 
spacing arm in the STRASS study has a slightly higher mean DAS28 value than the maintenance 
arm. It may, however, be reasonable to expect (although this should be investigated) that 
another tapering attempt could be considered after a longer period, for example 1 or 2 years.
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There is a discrepancy between the results of blinded fixed dose reduction of etanercept 
and open-label disease-activity-guided dose tapering: having the dose was shown to be just 
as effective as full-dose continuation (and thus feasible in nearly 100% of patients), while 
open-label tapering was not feasible in 30–40% of patients. An explanation for this may be 
that doubling the interval is not exactly the same as halving the dose. Another, more likely, 
explanation might be the nocebo and attribution effects that are introduced when dose 
reduction is not blinded. Patients might perceive dose reduction as being inferior and may feel 
worse as a result (nocebo), or unrelated events may be falsely attributed to the dose reduction 
(causal attribution).6 There are currently no known interventions for countering these effects 
of nocebo and false causal attribution, so open-label dose reduction strategies will probably 
underperform in clinical practice compared to what is biologically and pharmacologically 
possible. 
To summarize the findings, open-label disease-activity-guided dose optimization seems to 
be the best strategy in clinical practice, although this probably underperforms compared to 
blinded dose halving as done in RCTs. It may be best to perform one attempt at tapering and 
thereafter maintain the lowest effective dose that was found, as multiple tapering attempts 
can result in higher disease activity. Fixed dose halving is a good alternative, but disease 
activity should be monitored, and of course the benefits are less compared to tapering until 
stop. Direct stopping can be attempted, but the relapse risk is much higher, and no studies 
have shown noninferiority of a stop strategy with restart in case of flaring compared to 
bDMARD continuation.
4. What proportion of the patients can be stopped or tapered, and can we predict 
successful dose reduction using patient or treatment characteristics? 
Although the percentage of patients who can successfully stop or taper varies considerably 
between studies, and depends on the flare criteria used (see question 6), many more patients 
can taper than can discontinue. For direct bDMARD discontinuation, the relapse risk after one 
year lies between 45% and 88%.6 For fixed bDMARD dose reduction, these numbers are much 
lower - around 40% in the PRESERVE trial, 50% in the DOSERA trial, and 34% in the ALLOW 
study.17,26,27 Two reviews conclude that halving the dose of etanercept and rituximab is as 
effective as continuing with the full dose.7,63
 
For tapering strategies, the relapse rate should be interpreted differently, since tapering is 
continued until a patient flares (in order to find the optimal dose). In the DRESS study, the 
occurrence of short-lived flares was 73% in the tapering arm versus 23% in the continuation 
arm. However, there was no difference in persistent flares (longer than 3 months): 12% versus 
10% in the tapering and continuation arms, respectively. The STRASS trial found comparable 
relapse rates: 77% (tapering) and 47% (continuation), although noninferiority could not be 
established due to lower than projected inclusion rates.22,25
 
The flare rate is thus lower for bDMARD fixed dose reduction versus bDMARD discontinuation. 
Open-label disease-activity-guided dose optimization leads to a high risk of short-lived flare 
versus continuation but comparable long-term disease control. Finally, fixed dose reduction 
seems as effective for two bDMARDs. These quantitative chances of successful dose reduction 
or discontinuation can be communicated to patients, and following shared decision-making 
(SDM), dose reduction can be attempted. 
The chance of a successful dose reduction may differ between patient groups, depending 
on the patient or treatment characteristics. Therefore, many studies have also investigated 
possible predictors of success. Prediction of successful dose reduction or discontinuation 
of a bDMARD would provide several advantages. In patients who cannot use a lower dose, 
flares can be prevented by not tapering at all. For patients who are able to directly stop their 
bDMARD, accurate prediction would save time and medication since the dose-tapering phase 
can be skipped. 
Regarding disease duration, a review by Kavanaugh reports that withdrawal appears possible 
for a subset of patients, especially those with early disease.64 However, their conclusion is 
not consistent with a more recent review by Kuijper et al. in which the flare rate in studies 
including early RA patients was not consistently lower than that in patients with established 
RA.11
Regarding the disease activity state before dose reduction, almost all studies use the DAS28 
definition of LDA or remission when deciding upon patient inclusion.65 Intuitively, it might 
seem logical that patients in remission have a higher chance of successful dose reduction 
compared to patients with low disease activity. However, in the RETRO trial, satisfying the 
ACR/EULAR Boolean remission criteria was not associated with a lower risk of relapse.6,19 Also, 
in the DRESS study, baseline disease activity was not a predictor of successful tapering.6,25 
Therefore, all patients with LDA or in remission can be offered dose reduction with an equal 
chance of success.
 
Several dose-reduction studies have investigated various biomarkers for predicting successful 
tapering of bDMARDs. Some narrative reviews have demonstrated that it remains challenging 
to identify those patients who can taper their bDMARD without risking a flare.12,66,67 In addition, 
the review of Schett et al. concludes that anti-citrullinated protein antibody (ACPA) negativity 
and the presence of “deep” remission such as absence of ultrasound synovitis and/or normal 
serum markers of inflammation are associated with greater chances of achieving drug-free 
remission.12
 
A recent systematic review on this topic included 16 studies with a predefined tapering 
protocol and identified 64 and 52 different biomarkers for successful discontinuation and dose 
reduction, respectively. Among all the biomarkers investigated in more than one study, only 
three biomarkers were identified as predictive in two studies: a higher adalimumab trough 
level to predict successful dose reduction and a lower Sharp/van der Heijde erosion score and 
a shorter symptom duration at the start of a bDMARD to predict successful discontinuation.68 
The strength of this evidence was limited, since the latter two biomarkers (erosion score and 
symptom duration) showed a statistically significant but not strong association, and the first 
biomarker (adalimumab trough level) is questionable considering the extensive multiple 
testing performed in one study69 and the disputed results of another study70,71. Also, new 
data from the STRASS study could not confirm any predictive value of adalimumab level.72 
In contrast to Schett et al., ACPA was not found to be a predictor in this systematic review, 
and ultrasound and several serum markers were only studied once. Some studies have been 
published recently on the Multibiomarker Disease Activity (MBDA) score as a predictor of 
successful tapering, but they report conflicting results.73-76 
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Thus, biomarker-based prediction is not ready for clinical practice yet. Assessment of 
subclinical inflammation by laboratory or imaging testing may provide a useful tool to 
determine a patient’s risk of flare, but these biomarkers need to be validated first in other 
cohorts with a predefined tapering protocol before they can be considered to be predictive.
 
The type of bDMARD used might also be an effect modifier for successful dose reduction. 
Although some bDMARDs have been more extensively investigated than others, there do not 
appear to be any large differences in the effects of dose reduction. This may be due to the fact 
that for all bDMARDs, treatment using the authorized dose leads to overtreatment for at least 
a proportion of patients, since this dose is almost always chosen to be the highest effective 
dose at the group level. Some differences do seem to exist. For example, in the DREAM study 
with tocilizumab, relapse occurred quite rapidly.47
 
Rituximab (RTX) is a rather different type of bDMARD. It is administered at intervals of at least 6 
months due to the long B-cell depletion effect. The authorized RTX dosing for RA is also clearly 
much higher than needed. A recent systematic review revealed that half the authorized dose 
(1 × 1000 mg) is as effective as the full dose (2 × 1000 mg). This low dose is now widely used 
in clinical practice.77 Several case studies and one case series suggest the possibility that 
a much lower dose of rituximab might be effective in the treatment of RA patients.78-81 The 
effectiveness of these ultralow doses should be investigated further. Note that retreatment 
with RTX can be given on demand, but this results in repeated flaring and suboptimal 
disease control compared to fixed retreatment schedules or tight control treatment82, as this 
approach essentially mimics repeated dose reduction attempts. So, while lower dosing can 
and should be used, in our opinion, retreatment should preferably be carried out either with a 
fixed interval or under strict tight control.
 
Regarding sDMARD use, Kavanaugh et al. suggest that patients who are MTX-naïve and 
receive an induction regimen of MTX with a TNF inhibitor may be better suited to dose 
reduction than those who do not respond to MTX sufficiently, improve upon the addition of 
a TNF blocker, and then are withdrawn from the bDMARD.64 This seems logical, as response 
in these patients probably depends on MTX rather than the bDMARD. In the review by Kuijper 
et al., no relationship was observed between the use of a concomitant sDMARD and time to 
flare.11 However, no information was reported on the order in which bDMARD and sDMARDs 
treatment was given before tapering. Therefore, no clear conclusion can be drawn on the 
effect of a concomitant DMARD treatment based on these reviews.
5. What are the effects of dose reduction on function, quality of life, adverse events, and 
radiographic damage?
Since fixed dose reduction and tapering of bDMARDs seem feasible in a large proportion of 
RA patients, and discontinuation for a smaller group, it is important to address the effects 
that are found on other important clinical outcomes such as function, quality of life, adverse 
events, and progression of joint damage.
 
Function (measured with the HAQ-DI) was found to be worse after discontinuation in the 
PRESERVE study, but not in two other RCTs, the OPTIMA and ADMIRE.17,18,28 The ENCOURAGE 
study showed that fewer patients had HAQ<0.5 after discontinuation.21 In the ALLOW study, 
physical function was slightly worse after withdrawal of abatacept, but this improved after 
reinstating treatment.15 Function was found to be comparable to continuation after fixed dose 
reduction and tapering.17,22,25 In the STRASS study, a small difference in quality of life remained 
at the end of the study.22 
The reduction of (dose-dependent) adverse events is one of the reasons to consider dose 
reduction of bDMARDs. Although several studies have monitored adverse events, few have 
found significant differences between dose reduction and continuation.17,18,22,25,26,28,49 This 
might be due to the fact that none of these studies were powered to detect differences in 
side effects, and clinical trials in general have a limited follow-up time. Also, tapering studies 
usually include patients who have been using the bDMARD for quite some time, thus selecting 
the patients who are less prone to adverse effects (healthy survivor bias). However, Raffeiner 
et al. did find fewer infections in the half-dose etanercept group compared to the full-dose 
group.24
 
Several studies have assessed the effect of bDMARD dose reduction on radiographic structural 
damage progression. In the PRESERVE trial, discontinuation of etanercept led to increased 
joint damage. However, progression in the dose-halving group was similar to that in the 
continuation group.17 These findings are in line with other studies which found that dose 
reduction/tapering did not lead to significant radiographic damage progression.22,24,34,35,54,55 In 
the DRESS study, a minimal increase in radiographic progression was found in the tapering 
group, but no patients had an outcome of relevant joint damage progression.25 Kuijper et 
al. conclude in their systematic review that there are limited data on radiographic damage 
but that the current evidence shows that progression remains limited after treatment de-
escalation.11
 
In conclusion, discontinuation results in somewhat worse function and more joint damage. 
Fixed dose reduction and tapering does not seem to result in deterioration in these 
parameters. A reduction in adverse events has not been unequivocally shown, although this 
seems plausible, as bDMARD-induced infections have been shown to be dose-related.4
6. Which flare criterion is best to use when deciding whether to restart/re-escalate 
treatment, and how often should the patient be monitored?
In the included studies, several different criteria for flares were used, although they were 
mostly based on the DAS28. The OMERACT working group performed a validation study of the 
DAS28-based RA flare criteria. They concluded that an increase in DAS28>1.2, or>0.6 if DAS28 
≥3.2, appears to be the most discriminating and valid based on a set of predefined validation 
criteria.83 It is therefore advisable to use this flare criterion in clinical practice. In addition, 
the OMERACT RA Flare group is developing a patient-reported flare questionnaire that could 
also be used in the future84, especially in health care systems where travel distances are much 
higher than generally encountered in Western Europe. Other flare criteria could be used as 
well, but they may be either too sensitive or too specific, resulting in worse patient outcomes 
or conversely unjustified treatment re-escalation.
 
Since dose reduction may lead to a flare in (a proportion of) the patients, it is very important 
to closely monitor patients who are tapering their bDMARDs. When a flare occurs, the dose 
should be increased again to the lowest effective dose. Based on the methods of several trials, 
an interval of no more than 3 months appears necessary, with an extra consultation when 
patients experience a worsening of their symptoms.22,24,25
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7. Is It effective and safe to restart treatment?
When considering discontinuation or tapering until stop, it is essential to know whether 
restarting the bDMARD or intensifying treatment will be effective and safe. Regarding 
effectiveness, most patients are able to regain LDA or remission again after restarting the 
bDMARD treatment. Percentages of between 80% and 100% are described.85 Also, most 
studies show that restarting a bDMARD after withdrawal is well tolerated and not associated 
with more adverse events or higher immunogenicity.15,25,35,38,44,49,55 Data from tight control 
studies also support this notion, as the mean DAS28 for example in the DRESS study is similar 
for continuation and dose reduction after 18 months, while switching to other bDMARDs 
was rare.25 Therefore, based on the current evidence, it seems that restarting bDMARDs after 
discontinuation is effective and safe.
 
It has been suggested in the literature that tapering of bDMARDs may lead to the formation 
of anti-drug antibodies (ADAbs), which could then result in worse outcomes after restarting 
treatment. However, there does not seem any evidence supporting this statement.85,86 It is 
probable that the amount of “free” antibodies that is measured depends on the dose of the 
antigen (the drug). When administering a high dose, most of the ADAbs will be bound to 
the drug. When administering a low dose, more of the ADAbs will be unbound and are thus 
measureable in the blood. This does not automatically imply that the formation of these 
antibodies is increased, or that the presence of the ADAbs leads to a lower effect or side effects.
8. What is the cost-effectiveness of dose reduction?
Next to infection risk and patient burden due to regular self-injection, costs are one of the 
main reasons to look into dose reduction of bDMARDs after LDA or remission is reached. 
Surprisingly, not many of the studies that address this topic report a cost analysis of their 
strategy. This may be because the majority of the studies are funded by pharmaceutical 
companies, so there is perhaps a limited interest in demonstrating that dose reduction 
is cost-effective. While it seems logical that tapering a bDMARD will result in a substantial 
cost saving, the question is whether these savings outweigh the costs induced by increased 
monitoring, patient education, an increase in flares, and a subsequent deterioration in quality 
of life (as reflected in QALYs). 
Only three of the RCTs included in this review describe a cost-effectiveness analysis: the 
STRASS and DRESS studies, which both investigated disease-activity-guided tapering of 
bDMARDs until discontinuation, and the PRESERVE study.22,25,87-89 The STRASS study found that 
spacing resulted in a smaller gain in QALYs during the study period of 18 months compared 
to continuation. They calculated that 53,417 euros were saved per QALY lost. The authors 
indicate that it depends on the willingness to accept whether this is cost-effective.22 In the 
DRESS study, the mean QALY loss was -0.02 in the tapering arm compared to the continuation 
arm, and the dose optimization strategy resulted in savings of approximately 8000 euros per 
patient per year. The savings per QALY lost were 390,493 euros. When the minimal QALY loss 
was adjusted to account for the upper limit of what society is willing to pay or accept in the 
Netherlands, the net savings were still high.25 For the PRESERVE study, a Markov model was 
devised that incorporated data from the trial and extrapolated to 10 years follow-up, allowing 
a dose increase in the case of a flare and dose reduction in the case of remission according 
to tight control. Overall, the fixed dose halving strategy seemed most advantageous, mainly 
because half-dose etanercept showed a similar effectiveness to full-dose.89
Three of the nonrandomized studies that we found reported costs.37,44,52 In an uncontrolled 
study of infliximab tapering by van der Maas et al., a mean reduction of 3474 euro per patient 
was found.37 In a strategy study by Inui et al., patients discontinued etanercept when disease 
activity was low and restarted when a flare occurred. In the 5 patients who maintained low 
disease activity without restarting etanercept, the savings were found to be approximately 
35%.44 Murphy et al. reported a cost saving of 600,000 euros after 2 years in their cohort of 
79 patients (45 RA, 10 psoriatic arthritis, and 24 ankylosing spondylitis) that reduced the 
dose of etanercept or adalimumab.52 That meant a saving of 3800 euros per patient per year - 
comparable to the savings found by van der Maas et al.
 
Overall, disease-activity-guided dose optimization results in large cost savings per patient per 
year and no or a small loss in QALYs. Cost-effectiveness estimates are, however, very sensitive 
to either no or very small changes in quality of life, so the precise cost-effectiveness of different 
strategies remain to be established, although results seem very encouraging.
9. How can dose optimization best be implemented in clinical practice?
An often forgotten aspect of new treatment strategies is their implementation in clinical 
practice. Although several studies have shown the additional value of bDMARD dose 
reduction, and it has been incorporated into international recommendations8,9, this does not 
automatically mean that clinicians will act on it.90,91 
Several studies have investigated the current use of a lower-than-standard dose of bDMARDs 
in routine clinical practice. A systematic review into dose escalation and dose reduction of 
bDMARDs in clinical practice found that, for etanercept, 13.2% of patients used a lower-than-
registered dose. For adalimumab and infliximab, this was 8.9% and 25%, respectively.92 In a 
retrospective cohort of RA patients using Medicare claims (n = 26,510), approximately 10–
20% of patients who initiated and adhered to etanercept and adalimumab for ≥12 months 
subsequently received reduced-dose therapy for an 12 additional months and beyond.93 In 
the Ninja cohort (n = 1037), 7.4% of patients stopped bDMARD treatment due to remission94 
and 40% of patients in a tertiary hospital in Spain (n = 96) used a lower-than-registered dose 
while remaining at a low disease activity or in remission.95 These data show that in routine 
clinical practice, outside of trials, bDMARD dose reduction is still relatively rare, and it is often 
implemented for reasons other than dose optimization (e.g., side effects), and the mean 
percentage of patients on a lower-than-registered dose probably lies somewhere between 
10% and 25%. 
Many factors can impede the use of new insights in clinical practice, such as barriers related to 
the innovation itself (e.g., complexity, relative advantage), the individual health care provider 
or patient (e.g., knowledge, attitude, skills, self-efficacy), incentives and resources (time, 
funding), or the organizational context (work climate, structures).90,96 For dose reduction, 
it is conceivable that rheumatologists are not aware of the possibility of dose reduction 
(knowledge), do not agree with the evidence (attitude), or simply do not have the time or 
tools/protocols to adhere to the guidelines (practical barriers). The same holds true for 
patients. Since it is still difficult to predict successful dose reduction, tapering comes with a 
risk of (short-term) disease flare which makes the decision to taper very dependent on patient 
preference. Gaining insight into barriers and facilitators for patients and physicians could 
facilitate implementation. 
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Recently, a pilot study aiming at the implementation of tight control and bDMARD dose 
optimization was published.97 A multicomponent strategy consisting of education, protocol 
development, and treatment advice was employed to improve the use of these principles 
in a tertiary hospital with two rheumatologists. The results showed an increase in DAS 
measurements and a large decrease in bDMARD use, while mean disease activity levels 
remained unchanged. Larger, preferably controlled, studies are necessary to assess the 
effectiveness of implementation strategies.
10. What is the patient perspective on bDMARD dose reduction?
Since dose reduction of a bDMARD comes with an increased risk of short-lived disease flare, 
the decision to start tapering is also dependent on the preference of each individual patient. 
The physician can inform, educate, and motivate the patient based on the current evidence 
on dose reduction, but the final decision should be SDM-based. It is therefore important to 
investigate what patients’ cognitions and emotions are regarding bDMARD dose reduction. 
Three qualitative studies into the patient perspective on bDMARD dose reduction were 
identified.98-100 These studies all found that dose reduction is associated with both positive and 
negative perceived aspects for patients. Positive aspects include the reduced risk of adverse 
events, reduced frequency of injections, and contributing to savings in the healthcare budget. 
Examples of negative aspects are the risk of a flare, a delay in access to previous doses, and fear 
of a loss of efficacy after restarting treatment.
 
While these qualitative studies all explore factors that are important to patients when 
considering dose reduction of a bDMARD, the preferences of individual patients will differ 
largely. However, the current evidence on dose reduction and the need to reduce medication 
costs urge that tapering in RA patients who reach a stable LDA or remission on bDMARD 
treatment should be discussed in shared decision-making. In clinical practice, a balance must 
be found between patient concerns and the responsibility of hospitals and rheumatologists to 
contribute to savings in the healthcare budget. 
Communication methods could help physicians in their daily work regarding bDMARD dose 
reduction. Patient expectations could be modified by informing them as early as possible 
about the option of dose reduction, for example at the start of their bDMARD treatment. 
Also, motivational interviewing or positive framing can be used in conversations about dose 
reduction with individual patients.
Discussion
Based on the current evidence for this subject, we conclude that bDMARD dose reduction 
can be considered in all RA patients who have stably reached their treatment goals (e.g., ≥6 
months LDA or remission) on treatment with a bDMARD. The best strategy seems to be disease-
activity-guided dose tapering with fixed dose reduction as an alternative, since the risk of 
relapse was found to be highest for direct bDMARD discontinuation, and discontinuation 
results in worse physical functioning and more joint damage. Although bDMARD tapering 
seems to be (very) cost-effective, a reduction in adverse events after dose reduction is yet to 
be clearly demonstrated. 
When tapering the bDMARD treatment of a patient, disease activity should be monitored 
closely, for example with a consultation every 3 months and extra consultations when 
necessary. The validated flare criterion (ΔDAS28 > 1.2 or > 0.6 if DAS28 ≥ 3.2) can be used to 
identify patients who have lost response due to the tapering. When a patient flares, the dose 
should be increased to the lowest effective dose. Current evidence shows that restarting 
bDMARD treatment is effective and safe. Unfortunately, no clear predictors of successful 
tapering have been identified so far. The evidence for bDMARD dose reduction and rising 
healthcare costs urge that dose reduction should be considered and attempted for eligible 
patients. However, patient values and preferences should be respected and a balance may be 
found using SDM. 
This study has some limitations, as our searches for relevant articles were systematic but the 
data extraction and writing were performed in a narrative manner. Also, we did not perform a 
quality assessment of the included articles, and no formal meta-analyses were done. However, 
this review does provide a complete overview of the most important studies that have been 
performed on bDMARD dose reduction, and the questions that we address here could be of 
interest to a large group of clinicians involved in the treatment of RA patients. 
Several new trends are visible regarding bDMARD dose reduction, such as the introduction 
of biosimilars, which will change the cost-effectiveness ratio for tapering.101 Also, evidence 
on bDMARD dose reduction for other diagnoses in rheumatology is emerging, for example 
in relation to psoriatic arthritis and ankylosing spondylitis.102 Furthermore, new methods 
of research are gaining interest, such as noninferiority trials (investigating whether a new 
strategy or treatment is no worse than the old one) and modeling studies (using existing data 
to answer new research questions, thus saving costs and limiting the burden on patients).103,104 
Lastly, it is clear that most of the research done on the topic of dose reduction is “hard science,” 
and studies of the “soft science” associated with dose reduction (e.g., investigations of SDM 
and implementation) are lagging behind. Future research should focus not only on achieving a 
better understanding of the effects of dose reduction on important clinical outcomes but also 
on the perspectives of the patients and physicians as well as the implementation of this new 
treatment principle.
Conclusions
In conclusion, a lot of research has been done on the topic of bDMARD dose reduction in RA. 
The best dose-reduction strategies seem to be disease-activity-guided dose optimization and 
fixed dose reduction. The evidence for bDMARD dose reduction and rising healthcare costs 
urge that dose reduction should be considered for and attempted in RA patients who have 
reached a stable state of LDA or remission. However, patient values and preferences should be 
respected, and a balance may be found using SDM.
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Abstract
Introduction
Anti-tumour necrosis factor (TNF) agents are effective in treating people with rheumatoid 
arthritis (RA), but are associated with (dose-dependent) adverse effects and high costs. To 
prevent overtreatment, several trials have assessed the effectiveness of down-titration 
compared with continuation of the standard dose. This is an update of a Cochrane Review 
published in 2014.
Objectives
To evaluate the benefits and harms of down-titration (dose reduction, discontinuation, or 
disease activity-guided dose tapering) of anti-TNF agents on disease activity, functioning, 
costs, safety, and radiographic damage compared with usual care in people with RA and low 
disease activity.
Search methods
We searched MEDLINE, Embase, Web of Science and CENTRAL (29 March 2018) and four trial 
registries (11 April 2018) together with reference checking, citation searching, and contact with 
study authors to identify additional studies. We screened conference proceedings (American 
College of Rheumatology and European League Against Rheumatism 2005-2017).
Selection criteria
Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing down-
titration (dose reduction, discontinuation, disease activity-guided dose tapering) of anti-TNF 
agents (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) to usual care/
no down-titration in people with RA and low disease activity.
Data collection and analysis
We used standard Cochrane methodology.
Main results
One previously included trial was excluded retrospectively in this update because it was not 
an RCT/CCT. We included eight additional trials, for a total of 14 studies (13 RCTs and one CCT, 
3315 participants in total) reporting anti-TNF down-titration. Six studies (1148 participants) 
reported anti-TNF dose reduction compared with anti-TNF continuation. Eight studies (2111 
participants) reported anti-TNF discontinuation compared with anti-TNF continuation 
(three studies assessed both anti-TNF discontinuation and dose reduction), and three studies 
assessed disease activity-guided anti-TNF dose tapering (365 participants). These studies 
included data on all anti-TNF agents, but primarily adalimumab and etanercept. Thirteen 
studies were available in full text, one was available as abstract. We assessed the included 
studies generally at low to moderate risk of bias; our main concerns were bias due to open-
label treatment and unblinded outcome assessment. Clinical heterogeneity between the 
trials was high. The included studies were performed at clinical centres around the world and 
included people with early as well as established RA, the majority of whom were female with 
mean ages between 47 and 60. Study durations ranged from 6 months to 3.5 years. 
We found that anti-TNF dose reduction leads to little or no difference in mean disease activity 
score (DAS28) after 26 to 52 weeks (high-certainty evidence, mean difference (MD) 0.06, 
95% confidence interval (CI) −0.11 to 0.24, absolute risk difference (ARD) 1%) compared with 
continuation. Also, anti-TNF dose reduction does not result in an important deterioration in 
function after 26 to 52 weeks (Health Assessment Questionnaire Disability Index (HAQ-DI)) 
(high-certainty evidence, MD 0.09, 95% CI 0.00 to 0.19, ARD 3%). Next to this, anti-TNF dose 
reduction may slightly reduce the proportion of participants switched to another biologic 
(low-certainty evidence), but probably slightly increases the proportion of participants with 
minimal radiographic progression after 52 weeks (moderate-certainty evidence, risk ratio 
(RR) 1.22, 95% CI 0.76 to 1.95, ARD 2% higher). Anti-TNF dose reduction may cause little or no 
difference in serious adverse events, withdrawals due to adverse events and proportion of 
participants with persistent remission (low-certainty evidence).
Results show that anti-TNF discontinuation probably slightly increases the mean disease 
activity score (DAS28) after 28 to 52 weeks (moderate-certainty evidence, MD 0.96, 95% CI 
0.67 to 1.25, ARD 14%), and that the RR of persistent remission lies between 0.16 and 0.77 (low-
certainty evidence). Anti-TNF discontinuation increases the proportion participants with 
minimal radiographic progression after 52 weeks (high-certainty evidence, RR 1.69, 95% CI 
1.10 to 2.59, ARD 7%) and may lead to a slight deterioration in function (HAQ-DI) (low-certainty 
evidence). It is uncertain whether anti-TNF discontinuation influences the number of serious 
adverse events (due to very low-certainty evidence) and the number of withdrawals due to 
adverse events after 28 to 52 weeks probably increases slightly (moderate-certainty evidence, 
RR 1.46, 95% CI 0.75 to 2.84, ARD 1% higher).
Anti-TNF disease activity-guided dose tapering may result in little or no difference in mean 
disease activity score (DAS28) after 72 to 78 weeks (low-certainty evidence). Furthermore, anti-
TNF disease activity-guided dose tapering results in little or no difference in the proportion 
of participants with persistent remission after 18 months (high-certainty evidence, RR 0.89, 
95% CI 0.75 to 1.06, ARD −9%) and may result in little or no difference in switching to another 
biologic (low-certainty evidence). Anti-TNF disease activity-guided dose tapering may slightly 
increase proportion of participants with minimal radiographic progression (low-certainty 
evidence) and probably leads to a slight deterioration of function after 18 months (moderate-
certainty evidence, MD 0.2 higher, 0.02 lower to 0.42 higher, ARD 7% higher), It is uncertain 
whether anti-TNF disease activity-guided dose tapering influences the number of serious 
adverse events due to very low-certainty evidence.
Authors’ conclusions
We found that fixed-dose reduction of anti-TNF, after at least three to 12 months of low 
disease activity, is comparable to continuation of the standard dose regarding disease activity 
and function, and may be comparable with regards to the proportion of participants with 
persistent remission. Discontinuation (also without disease activity-guided adaptation) of 
anti-TNF is probably inferior to continuation of treatment with respect to disease activity, 
the proportion of participants with persistent remission, function, and minimal radiographic 
damage. Disease activity-guided dose tapering of anti-TNF is comparable to continuation of 
treatment with respect to the proportion of participants with persistent remission and may 
be comparable regarding disease activity.
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Caveats of this review are that available data are mainly limited to etanercept and 
adalimumab, the heterogeneity between studies, and the use of superiority instead of non-
inferiority designs.
Future research should focus on the anti-TNF agents infliximab and golimumab; assessment of 
disease activity, function, and radiographic outcomes after longer follow-up; and assessment 
of long-term safety, cost-effectiveness, and predictors for successful down-titration. Also, use 
of a validated flare criterion, non-inferiority designs, and disease activity-guided tapering 
instead of fixed-dose reduction or discontinuation would allow researchers to better interpret 
study findings and generalise to clinical practice.
Plain language summary
Lowering the dose of or stopping anti-tumour necrosis factor drugs in people with 
rheumatoid arthritis who are doing well (low disease activity)
We conducted an updated review of studies in which treatment with anti-tumour necrosis 
factor (anti-TNF) drugs (adalimumab, certolizumab pegol, etanercept, golimumab, and 
infliximab) was lowered or stopped in people with rheumatoid arthritis (RA) who use anti-
TNF drugs and are doing well (low disease activity). Our systematic search up to March 2018 
identified 14 studies (3315 participants). The included studies were performed at clinical 
centres around the world and included people with early as well as established RA, the 
majority of whom were female with mean ages varying between 47 and 60. Study durations 
ranged from 6 months to 3.5 years.
What is rheumatoid arthritis? What is stopping or lowering the dose of anti-TNF drugs?
When you have RA, your immune system, which normally fights infection, attacks the lining 
of your joints. This makes your joints swollen, stiff, and painful. There is no cure for RA, so 
treatments aim to relieve pain and stiffness, improve ability to move, and prevent damage to 
the joints.
Anti-TNF agents are biological drugs for RA. They lessen complaints by reducing inflammation 
in the joints, and they reduce radiographic joint damage. Reducing or stopping anti-TNF 
treatment when disease activity is low might reduce dose-dependent side effects (mainly 
infections) and costs.
Key results
Data were available for all anti-TNF agents, but mostly for adalimumab and etanercept.
Disease activity
- People who lowered the dose of anti-TNF showed little or no increase in disease activity 
compared with people who continued anti-TNF (high-certainty evidence).
- People who stopped anti-TNF had a 0.96 unit increase in disease activity on a scale from 0.9 
to 8 compared with people who continued anti-TNF (absolute difference 14%, moderate-
certainty evidence).
- People who gradually lowered the dose of anti-TNF showed little or no increase in disease 
activity compared with people who continued anti-TNF (low-certainty evidence).
Persistent remission
- There was little or no difference in the number of people who had persistent remission 
between those who lowered the dose of anti-TNF compared with continuation of anti-TNF 
(low-certainty evidence).
- Data on how stopping anti-TNF affects persistent remission were not pooled because 
results were not similar across studies (low-certainty evidence). The absolute difference 
varied between 15% and 68% fewer people that remained in remission when stopping anti-
TNF compared to continuation of anti-TNF.
- There was little or no difference in the number of people who had persistent remission 
between those who gradually lowered the dose of anti-TNF compared with continuation of 
anti-TNF (high-certainty evidence).
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X-ray progression
- 24 more people per 1000 had a greater than 0.5 point progression of joint damage after a 
year when lowering the dose of anti-TNF (scale 0 to 448) (absolute difference 2%, moderate-
certainty evidence).
- 73 more people per 1000 who stopped anti-TNF had a greater than 0.5 point progression 
of joint damage after a year than people who continued anti-TNF (absolute difference 7%, 
high-certainty evidence).
- 110 more people per 1000 had greater than 0.5 or greater than 1.0 point progression of 
joint damage after 1.5 years when gradually lowering the dose of anti-TNF (low-certainty 
evidence).
 
Function
- People who lowered the dose of anti-TNF had a 0.09 unit worsening of function (scale 0 to 
3) compared with people who continued anti-TNF (absolute difference 3%, high-certainty 
evidence).
- People stopping anti-TNF had a 0.18 unit worsening of function compared with people who 
continued anti-TNF (absolute difference 6%, low-certainty evidence).
- People gradually lowering the dose of anti-TNF had a 0.2 unit worsening in function 
compared with people who continued anti-TNF (absolute difference 7%, moderate-
certainty evidence).
Side effects
- There was little or no difference in number of serious adverse events in people lowering the 
dose of anti-TNF compared to continuation anti-TNF (low-certainty evidence).
- It is uncertain whether gradually lowering the dose of or stopping anti-TNF influences the 
number of serious adverse events (very low-certainty evidence).
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Background
Description of the condition
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by 
symmetrical joint inflammation that often leads to joint damage. Tumour necrosis factor-
blocking (anti-TNF) agents have proved effective as therapies for RA (Blumenauer 2002; 
Blumenauer 2003; Navarro-Sarabia 2005; Ruiz Garcia 2014; Singh 2009; Singh 2010). They 
improve clinical symptoms and functioning and inhibit joint destruction, and have become an 
important part of treatment prescribed for RA.
Description of the intervention
Treatment of individuals with RA has been evolving from traditional step-up regimens to more 
aggressive step-down strategies. Pivotal to these changes are the early start of treatment (hit 
early), the use of combination therapy including steroids with rapid escalation to biologics 
(hit-hard), and, most important, frequent assessment of disease activity and treatment 
modification based on assessment (tight control). Strategies incorporating these concepts 
lead to the swift achievement of low disease activity or remission in most patients, which 
prevents joint damage and improves function and quality of life (Schipper 2010). An important 
disadvantage of the hit-hard approach compared with the traditional step-up approach, 
however, is that the former method does not allow for individual titration of the minimal 
effective treatment. Indeed, the traditional step-up approach largely prevents overtreatment, 
but high(er) disease activity at the beginning of the disease has to be accepted. To prevent 
overtreatment when high-dose or multidrug strategies are used, treatment must be tapered 
down when low disease activity is reached up to the point that disease activity increases 
again or medication can be stopped. In this way, the minimal effective dose is found and 
overtreatment is prevented. Optimal dosing of biologics is especially important because of 
the risk of dose-dependent adverse effects and the risk of low cost-effectiveness due to high 
cost (den Broeder 2010; Ramiro 2017; Singh 2011). The concept of dose reduction has been 
incorporated into current guidelines for the treatment of RA (Singh 2016; Smolen 2017).
The intervention that is the subject of this review is therefore dose reduction of anti-TNF 
agents (by adaptation of dose or dosing interval) or discontinuation or both in people with RA 
and low disease activity status.
How the intervention might work
Successful dose reduction or discontinuation of anti-TNF agents can be expected for several 
reasons. First, amongst patients who seem to respond to treatment with anti-TNF agents 
are those who show spontaneous improvement (regression to the mean) (den Broeder 
2010; van Vollenhoven 2004); this phenomenon applies to 10% to 30% of all patients, as 
was shown by proportions of placebo group response (Doherty 2009; St Clair 2004). Second, 
often concomitant medication is given that might induce a response. Both mechanisms are 
supported by the fact that a proportion of patients who seem to do well while taking the drug 
have (neutralising) antibodies (less than 5% to 43%) (Bartelds 2007; Klareskog 2011; Wolbink 
2006). Finally, a substantial proportion of patients might need a lower than standard dose 
for a clinical response (Fautrel 2015; Verhoef 2017). Anti-TNF agents are registered at the 
dose that shows the best response for the most patients (top of group level dose-response 
curve). However, individual patients might respond to a lower dose as well, which is reflected 
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in response percentages of lower doses in these initial trials (Genovese 2002; Maini 1998; 
Weinblatt 2003).
Uncontrolled research has shown that down-titration of anti-TNF agents can be successful 
in a relevant proportion of patients. Most data are available for infliximab, adalimumab, and 
etanercept, and most are derived from discontinuation studies (Brocq 2009; den Broeder 
2002; Kavanaugh 2012; Nawata 2008; Saleem 2010; Tanaka 2010; Tanaka 2012; van den Bemt 
2008; van der Bijl 2007; van der Maas 2012).
Why it is important to do this review
Although the adverse effects of anti-TNF agents reported in clinical trials were generally mild 
in severity, these drugs are associated with unintended effects including increased risk of 
infection and perhaps a dose-dependent increased risk of malignancy and rare severe adverse 
events (Bongartz 2006). The introduction of anti-TNF agents - and other biological drugs - has 
also led to an increase in cost because they are much more expensive than traditional disease-
modifying antirheumatic drugs (DMARDs) (van Vollenhoven 2009).
It was appropriate at this time to conduct an update of this Cochrane Review of randomised 
controlled trials (RCTs) of anti-TNF down-titration as well as discontinuation studies, because 
several new RCTs on this topic are emerging, and additional information on the already 
included studies has been published.
Objectives
To evaluate the benefits and harms of down-titration (dose reduction, discontinuation, 
or disease activity-guided dose tapering) of anti-TNF agents (adalimumab, certolizumab 
pegol, etanercept, golimumab, infliximab) on disease activity, functioning, costs, safety, and 
radiographic damage compared with usual care in people with RA and low disease activity.
Methods
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials (RCTs) and controlled clinical trials (CCTs) 
(including cluster randomised and cross-over trials) according to the Cochrane definition 
comparing down-titration of tumour necrosis factor-blocking (anti-TNF) agents versus usual 
care/no down-titration for inclusion. The minimal required follow-up was six months. Both 
superiority and non-inferiority trials were included.
Types of participants
People with RA (1987, Arnett 1988, or 2010, Aletaha 2010 RA criteria, or both) American College 
of Rheumatology (ACR) criteria) using anti-TNF agents in a standard (or lower) dosing regimen 
(adalimumab 40 mg every other week, etanercept 50 mg every week or 25 mg twice a week, 
infliximab 3 mg/kg every eight weeks, golimumab 50 mg every month, certolizumab pegol 
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200 mg every other week) for longer than six months and with a low disease activity state 
(clinical judgement of rheumatologist or disease activity score in 28 joints (DAS28) < 3.2; DAS 
< 2.4; Clinical Disease Activity Index (CDAI) < 10; Simplified Disease Activity Index (SDAI) < 11 or 
DAS28 < 2.6; DAS < 1.6; CDAI < 2.8; SDAI < 3.3, Aletaha 2005; Fransen 2005, or 2011 ACR/European 
League Against Rheumatism (EULAR) remission (Felson 2011)).
Types of interventions
Protocolised down-titration or discontinuation of the anti-TNF agent for optimal dose 
finding (not for other reasons, including reduction of side effects, availability, planned 
surgery, pregnancy). Non-protocolised change in medication (DMARDs, non-steroidal anti-
inflammatory drugs (NSAIDs), corticosteroids) was allowed. Comparison was usual care/no 
down-titration/continuation of anti-TNF.
Types of outcome measures
Major outcomes
• Mean disease activity score; DAS28/DAS/CDAI/SDAI at six, 12, 18, and 24 months (Aletaha 
2005; Prevoo 1995; Smolen 2003; van der Heijde 1990).
• Proportion of participants with persistent remission (as specified above) after six, 12, 18, and 
24 months.
• Proportion of participants that switched to another biologic due to persistent loss of 
response, refractory to re-instalment of the tapered anti-TNF in the intervention group.
• Proportion of participants with minimal radiographic progression, as measured by Larsen 
(Larsen 1973), Sharp (Sharp 1971), or modified Sharp-van der Heijde score (mSvdH score) (van 
der Heijde 2000).
• Function (as measured by Health Assessment Questionnaire (HAQ)/Arthritis Impact 
Measurement Scale (AIMS)).
• Number of serious adverse events.
• Withdrawals due to adverse events.
Minor outcomes
• Proportion of participants with a flare (or loss of response) (defined as any composite 
disease activity index-based flare criteria) during follow-up time.
• Quality of life as measured by Short Form (SF) Health Survey-12/36, Health Utilities Index 
(HUI), or EuroQoL Quality of Life Scale (EQ-5D).
• Costs (direct (e.g. medication, consultations, travel costs) and indirect (e.g. health-related 
absenteeism)).
• Decremental cost-effectiveness ratio (difference in costs divided by difference in quality of 
life expressed as utility, thus the potential savings when accepting the loss of one quality-
adjusted life year (QALY)).
• Time to flare.
• Change in other medication (including DMARDs, NSAIDs, corticosteroids).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases: MEDLINE (1946 to 29 March 2018), Embase 
Cochrane review on anti-TNF down-titrationCochrane review on anti-TNF down-titration
3 3
(1974 to 29 March 2018), Web of Science (1945 to 2018) and the Cochrane Central Register of 
Controlled Trials (CENTRAL) 2018 issue 3. The specific search strategy for each of the databases 
is shown in the appendices ( Appendix 1; Appendix 2; Appendix 3; Appendix 4). Our search was 
not limited by language, year of publication, or publication type. The search period for all 
databases extended from inception to September 2013 for the original review, and from 2013 
to 29 March 2018 for the update.
Searching other resources
We searched proceedings of conferences from 2005 to 2017 of the ACR and from 2005 to 2017 
of the European League Against Rheumatism (EULAR) for abstracts of RCTs and CCTs. We 
searched reference lists of identified clinical trials and performed citation tracking of the 
included trials in the ISI Web of Knowledge citation index. We searched trial registries for 
completed and ongoing trials (Appendix 5). We contacted experts (first authors of included 
studies) to ask about additional trials.
 
Data collection and analysis
Selection of studies
We selected studies based on the inclusion criteria outlined in the Criteria for considering 
studies for this review section. Two review authors (NvH and BJFvdB for the original review; 
LMV and BJFvdB for the update) independently screened titles and abstracts for inclusion, 
obtaining full articles if necessary. Any differences were resolved by discussion and consensus 
or by consultation with a third review author (AAdB) if needed. In case the same study 
population was described in more than one publication, all publications were used, but for 
the analysis, all were grouped, with the most informative publication as the primary reference 
and with other publications as secondary references. We recorded reasons for exclusion of 
studies.
Data extraction and management
Two review authors (NvH and BJFvdB for the original review; LMV and BJFvdB for the update) 
independently abstracted data from each study using a data extraction form. Any differences 
were resolved by discussion and consensus or by consultation with a third review author 
(AAdB) if needed. We pilot-tested the data extraction form on a selection of trials. If necessary, 
we contacted the authors of a given study to ask for missing data.
We extracted the following data.
• General study information: first author, author affiliation, publication source, publication 
year, and source of funding.
• Study characteristics: design, setting, participant selection, method of randomisation, 
allocation procedure, blinding, inclusion/exclusion criteria, and study duration.
• Population characteristics: age, sex, diagnostic criteria, disease duration, DMARD 
comedication, previous DMARD use, previous anti-TNF use, rheumatoid factor status, anti-
cyclic citrullinated peptide (CCP) status, disease activity state, total number of participants 
screened, total number of participants recruited, total number of participants randomly 
assigned, total number of participants followed, and numbers in each group.
• Intervention characteristics: anti-TNF agent, type of ntervention (dose reduction/interval 
widening/discontinuation), treatment comparators.
• Outcome measures as noted above.
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• Analysis: statistical technique used, intention-to-treat analyses and/or per-protocol 
analyses used.
• Results with number, mean and standard deviation.
Assessment of risk of bias in included studies
Two review authors (NvH and BJFvdB for the original review; LMV and BJFvdB for the update) 
assessed risk of bias in the included studies in accordance with the recommendations in the 
Cochrane Handbook for Systematic Reviews of Interventions (Appendix 6) (Higgins 2011).
We assessed the following ’Risk of bias’ domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias (baseline imbalance in possible prognostic variables: DMARD 
comedication, duration of anti-TNF use, and disease duration).
We judged each of these domains as having low, high, or unclear risk of bias.
Measures of treatment effect
We analysed the results of the included studies using Review Manager 2014. Continuous 
data were expressed as mean differences (MDs) or standardised mean differences (SMDs). 
Dichotomous data were expressed as risk ratios (RRs). Rates were expressed as rate ratios 
(RaRs). We summarised data in meta-analyses if the studies were sufficiently homogeneous, 
both clinically and statistically.
Unit of analysis issues
The participant was the unit of analysis. Post-hoc, it was chosen to pool the data from the 
two dose reduction arms in the study by Ibrahim 2017 (OPTTIRA) for outcomes in which data 
from multiple studies could be pooled because this facilitated comparison with the 50% dose 
reduction applied in all other included dose reduction studies (mean dose reduction of 33% 
and 66% being 50%).
Dealing with missing data
We accepted missing clinical data in trials when they represented less than 20% of findings. We 
planned to perform a sensitivity analysis if more than 20% of the data from a given study were 
missing in order to explore the impact of including or excluding such studies. We attempted 
to obtain missing information on parameter variability by contacting the authors of the trial. 
In the event that study authors were not able or were unwilling to provide this information, it 
was estimated from ranges if provided or from comparable trials.
Assessment of heterogeneity
We evaluated heterogeneity first clinically by considering comparability across trials on the 
following variables: type of intervention (dose reduction/discontinuation/disease activity-
guided dose tapering), type of anti-TNF agent, duration of anti-TNF use, baseline disease 
activity (low disease activity versus remission), disease duration, DMARD comedication, and 
presence of anti-TNF rescue strategy. We examined forest plots and tested for heterogeneity 
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using the Chi2 test with a P < 0.10 indicating significant heterogeneity. We used the I2 statistic 
to describe the percentage of variability in effect estimates that is due to heterogeneity 
rather than to chance (Higgins 2003). A value greater than 50% may indicate substantial 
heterogeneity (Higgins 2011). If we detected significant heterogeneity (I2 > 80%), we did not 
pool data but performed subgroup analyses in an attempt to explain the heterogeneity.
Assessment of reporting biases
Publication bias implies that studies that report favourable results are more likely to be 
published than those describing negative or inconclusive (non-significant) results, leading to a 
bias in the overall published literature. To minimise the effect of selective reporting of results, 
we searched trial registries for completed but unpublished studies. We planned to use a funnel 
plot to assess potential publication bias. However, due to the small number of studies, the 
funnel plot was not informative. We also searched the trial registries for ongoing studies that 
are potentially interesting for a future update of this review (see Characteristics of ongoing 
studies for details), and for additional data on included studies. We assessed reporting bias at 
the outcome level by using published protocols of the studies along with published results of 
the study to compare outcomes intended to be analysed with those actually analysed.
Data synthesis
When possible, we analysed data using an intention-to-treat model and, for non-inferiority 
studies, by also using a per-protocol model. Our reason for this was that intention-to-treat 
analyses can lead to false conclusions of non-inferiority in non-inferiority trials. We analysed 
outcomes of included studies using a random-effects model.
Subgroup analysis and investigation of heterogeneity
We planned that if sufficient data were available we would perform subgroup analyses for the 
following candidate effect modifiers: type of intervention (dose reduction/discontinuation/
disease activity-guided dose tapering), type of anti-TNF agent, duration of anti-TNF use, 
baseline disease activity (low disease activity versus remission), disease duration, DMARD 
comedication, and presence of anti-TNF rescue strategy.
 
Sensitivity analysis
We planned to perform the following sensitivity analyses when possible.
• Effect of risk of bias of included studies.
• Effect of imputation of missing data or statistical transformations.
‘Summary of findings’ tables
We completed three separate ’Summary of findings’ tables included in Review Manager 2014 
to improve the readability of the review. We examined seven outcomes in a table for each of 
the three subgroups of down-titration: (1) dose reduction, (2) discontinuation, and (3) disease 
activity-guided dose tapering. The study population consisted of people with RA with low 
disease activity using a standard dose of anti-TNF. The intervention provided was down-
titration (dose reduction, discontinuation, or disease activity-guided dose tapering). The 
intervention was compared with usual care (continuation or no formalised dose reduction of 
anti-TNF). In addition to the absolute and relative magnitude of effect, the number needed 
to treat for an additional beneficial outcome (NNTB) and number needed to treat for an 
additional harmful outcome (NNTH) were calculated by comparing the intervention group 
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with the control group. We used GRADEpro 2015 to conduct an overall grading of the quality 
of evidence.
The GRADE approach specifies four levels of certainty (high, moderate, low, and very low). The 
highest certainty rating is given for randomised trial evidence. Randomised trial evidence can 
be downgraded to moderate, low, or very low depending on the presence of five factors.
• Limitations in the design and implementation of available studies suggesting high likelihood 
of bias.
• Indirectness of evidence.
• Unexplained heterogeneity or inconsistency of results.
• Imprecision of results.
• High probability of publication bias.
Results
Description of studies
The results of the search are presented in Figure 1 and are described in detail in the following 
sections of the review.
 
Figure 1. Flow chart of study selection
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Results of the search
The previous version of this review included seven studies. Database searches for this update 
(2013 to March 2018) resulted in 2352 records, and after de-duplication 1565 search results. 
Reference checking, contact with experts, and performing additional searches in congress 
abstract databases and trial registers resulted in 42 additional records. After title and abstract 
screening of these 1607 records, 21 studies remained. After assessing these 21 studies for 
eligibility, we identified eight new studies for inclusion in the review. One of the previously 
included studies, Harigai 2012 (BRIGHT), was retrospectively excluded for this updated version 
of the review because we considered their method of allocation (at the discretion of the 
physician) as not random or quasi-random, which is a prerequisite for the classification as RCT 
or CCT. Newly found studies that used allocation based on physician or patient preference were 
also not included in this updated version (Tanaka 2013 (HONOR); Tanaka 2014 (HOPEFUL-2)). 
Finally, a total of 14 studies were included in this update of the systematic review, consisting 
of six old studies and eight new studies. All of the old studies were now available as full text. 
Of the eight new studies, one was published as abstract and seven as full text. We contacted 
the authors of 11 studies to obtain missing data or to clarify methods/results. We received a 
response from authors of 10 studies.
The total number of participants in the studies included in this review was 3315. Most 
participants (2111) were included in the eight studies comparing anti-TNF discontinuation 
versus anti-TNF continuation. Six studies (1148 participants) compared anti-TNF dose 
reduction versus continuation. Three studies (365 participants) compared disease activity-
guided anti-TNF dose tapering versus continuation. Eleven studies used a superiority design; 
two studies used a non-inferiority design; and one study reported an equivalence design.
Included studies
Anti-TNF dose reduction versus anti-TNF continuation studies
Design
Six studies compared anti-TNF fixed-dose reduction versus anti-TNF continuation (El Miedany 
2016; Ibrahim 2017 (OPTTIRA); Raffeiner 2015; Smolen 2013 (PRESERVE); van Vollenhoven 2016 
(DOSERA); Weinblatt 2017 (C-EARLY)). Weinblatt 2017 (C-EARLY), Smolen 2013 (PRESERVE), and 
van Vollenhoven 2016 (DOSERA) were randomised, blinded, placebo-controlled, superiority 
studies that reported three arms (discontinuation, dose reduction, and continuation). 
The randomisation ratio was 1:1:1 for Smolen 2013 (PRESERVE) and van Vollenhoven 2016 
(DOSERA); for Weinblatt 2017 (C-EARLY) this was 2:3:2 (stop; dose reduction; continuation). 
El Miedany 2016, Raffeiner 2015, and Ibrahim 2017 (OPTTIRA) were open-label superiority 
studies. The study by Raffeiner 2015 was reported as a prospective long-term follow-up study; 
randomisation was done in a consecutive manner (alternation) in a ratio 1:1, which we defined 
as quasi-random, making the study a CCT. The ran-domisation ratio for Ibrahim 2017 (OPTTIRA) 
was 1:1:2, and for El Miedany 2016 it was 1:1:1:1:1 (only group 1 and group 5 were relevant for 
this review). 
The duration of the included studies was 6 months in Ibrahim 2017 (OPTTIRA); 40 weeks in 
van Vollenhoven 2016 (DOSERA); 52 weeks in Smolen 2013 (PRESERVE), El Miedany 2016, and 
Weinblatt 2017 (C-EARLY); and a mean follow-up of 3.5 ± 1.5 years in Raffeiner 2015. The study 
by Smolen 2013 (PRESERVE) had a total follow-up of 88 weeks, however 52 weeks of follow-up 
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were provided after randomisation for dose reduction or continuation of etanercept. The total 
follow-up for van Vollenhoven 2016 (DOSERA) was 48 weeks, and 40 weeks of follow-up were 
provided after randomisation for dose reduction or continuation of etanercept. The study by 
Weinblatt 2017 (C-EARLY) describes period 2 of the C-EARLY study with a duration of 52 weeks, 
which was a re-randomisation of participants from the first period, which also lasted 52 weeks.
Sample size
The sample size for this comparison varied from 50 participants in the study by van 
Vollenhoven 2016 (DOSERA) (73 participants in total study due to multiple intervention arms) 
to 404 participants in Smolen 2013 (PRESERVE) (604 participants in total study due to multiple 
intervention arms).
Setting
Ibrahim 2017 (OPTTIRA) reported that participants were screened at 20 centres in the 
United Kingdom. The study by Raffeiner 2015 was reported as a single-centre study in Italy. 
Smolen 2013 (PRESERVE) was reported to have been conducted in 80 centres in Europe, Latin 
America, Asia, and Australia. The study by van Vollenhoven 2016 (DOSERA) was performed in 
16 rheumatology units in Sweden (5), Denmark (2), Finland (2), Norway (3), Hungary (3), and 
Iceland (1). Weinblatt 2017 (C-EARLY) reported that it recruited participants at 103 centres in in 
Europe, Australia, North America, and Latin America. El Miedany 2016 did not report a specific 
setting.
Participants
El Miedany 2016 did not provide information on participant characteristics. Most participants 
were female in the studies by van Vollenhoven 2016 (DOSERA), Smolen 2013 (PRESERVE), 
Weinblatt 2017 (C-EARLY), and Raffeiner 2015. Mean age was approximately 47 years in Smolen 
2013 (PRESERVE); 49 years in Weinblatt 2017 (C-EARLY); 56 years in Raffeiner 2015; and 57 years 
in van Vollenhoven 2016 (DOSERA) and Ibrahim 2017 (OPTTIRA). Disease duration ranged from 
around 2.6 months in Weinblatt 2017 (C-EARLY) (median disease duration at baseline of C-EARLY 
period 1) to 14 years in Raffeiner 2015 and van Vollenhoven 2016 (DOSERA). Duration of anti-
TNF agents had to be > 3 months in Ibrahim 2017 (OPTTIRA); ≥ 6 months in El Miedany 2016; ≥ 
12 months in Raffeiner 2015; and ≥ 14 months in van Vollenhoven 2016 (DOSERA). Smolen 2013 
(PRESERVE) started the anti-TNF agent at study start 36 weeks before randomisation for dose 
reduction or discontinuation. In the study by Weinblatt 2017 (C-EARLY), all participants had 
started certolizumab pegol treatment one year earlier (period 1 of C-EARLY). El Miedany 2016 
and Ibrahim 2017 (OPTTIRA) did not report previous use of DMARDs. Participants in Raffeiner 
2015 and Smolen 2013 (PRESERVE) were biologic disease-modifying antirheumatic drug 
(bDMARD) naive before the study. Raffeiner 2015 reported a mean (standard deviation (SD)) of 
2.4 (1.1) previously used DMARDs in the dose reduction group and 2.4 (1.3) in the continuation 
group. Participants in Weinblatt 2017 (C-EARLY) were bDMARD and conventional synthetic 
disease-modifying antirheumatic drug (csDMARD) naive. van Vollenhoven 2016 (DOSERA) 
described that 66% of the participants had used a DMARD other than methotrexate (MTX) 
before the study. 
In all included studies, participants had to have low disease activity, Ibrahim 2017 (OPTTIRA); 
Smolen 2013 (PRESERVE); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY), or 
remission, El Miedany 2016; Raffeiner 2015. Duration of low disease activity/remission had 
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to be > 3 months in Ibrahim 2017 (OPTTIRA); ≥ 6 months in El Miedany 2016; ≥ 12 months in 
Raffeiner 2015; or ≥ 11 months in van Vollenhoven 2016 (DOSERA). Participants in the study 
by Smolen 2013 (PRESERVE) had to have a mean DAS28 ≤ 3.2 in the 24-week period before 
randomisation and a DAS28 ≤ 3.2 at the moment of randomisation. In the study by Weinblatt 
2017 (C-EARLY), participants needed to have a DAS28 ≤ 3.2 12 weeks before randomisation and 
at the moment of randomisation. All included studies used a DAS28-based criterion to define 
low disease activity or remission.
Intervention and comedication
Raffeiner 2015 reported etanercept dose reduction by comparing etanercept 25 mg twice a 
week versus etanercept 25 mg once a week. Smolen 2013 (PRESERVE) and van Vollenhoven 
2016 (DOSERA) reported etanercept dose reduction (25 mg/week) compared with etanercept 
continuation (50 mg/week). Ibrahim 2017 (OPTTIRA) reported 33% and 66% dose reduction 
of adalimumab and etanercept versus 100%. El Miedany 2016 reported 50% dose reduction 
of bDMARDs versus continuation. Weinblatt 2017 (C-EARLY) reported 50% dose reduction of 
certrolizumab pegol (200 mg/4 weeks) versus continuation (200 mg/2 weeks). Participants 
were required to use MTX comedication (dose ranged from 7.5 to 25 mg/week) in Smolen 2013 
(PRESERVE) and van Vollenhoven 2016 (DOSERA). In Raffeiner 2015, steroids, NSAIDs, and 
DMARDs were continued at the same dosages. No intra-articular steroids were permitted 
during the study period. Smolen 2013 (PRESERVE) allowed up to three intra-articular 
corticosteroid injections during the study. In the study by van Vollenhoven 2016 (DOSERA), 
participants continued MTX and other medications at the same dose. Participants in 
Weinblatt 2017 (C-EARLY) used MTX in the maximum tolerated (“opti mised”) dose throughout 
the study. Use of intra-articular, intramuscular, or intravenous corticosteroids at any dose was 
prohibited. The maximum allowed dose of oral corticosteroids during the study was ≥ 10 mg/
day prednisone or equivalent, and no changes in dose were allowed during the study period. 
In the study of El Miedany 2016, participants in the relevant study arms used a stable dose of 
a csDMARD during the trial. No intramuscular or local steroid joint injections were allowed. In 
five studies (El Miedany 2016; Ibrahim 2017 (OPTTIRA); Raffeiner 2015; van Vollenhoven 2016 
(DOSERA); Weinblatt 2017 (C-EARLY)), participants could return to their initial dose of anti-TNF 
after disease flare. In Smolen 2013 (PRESERVE), no attempt was made to recapture low disease 
activity by reintroducing etanercept in participants whose condition had deteriorated after 
etanercept withdrawal.
Outcomes
All studies reported a primary outcome measure. Three studies reported proportion of 
participants with low disease activity or remission as the primary outcome. Raffeiner 2015 and 
El Miedany 2016 used DAS28 ≤ 2.6, and Smolen 2013 (PRESERVE) used DAS28 ≤ 3.2. The primary 
outcome in the study by van Vollenhoven 2016 (DOSERA) was proportion of non-failures for 
etanercept 50 mg/week versus placebo. The primary outcome for Ibrahim 2017 (OPTTIRA) was 
reported to be time to flare. Weinblatt 2017 (C-EARLY) reported maintenance of low disease 
activity (disease activity score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR) 
of ≤ 3.2) for all 5 consecutive study visits to week 52 without flares as the primary outcome 
measure. Secondary outcomes reported in the included studies were very different. None 
of the included studies provided data on costs or change in comedication. All studies were 
analysed with a (modified) intention-to-treat approach.
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Anti-TNF discontinuation versus anti-TNF continuation studies
Design
Eight of the included studies reported anti-TNF discontinuation compared with anti-TNF 
continuation (Chatzidionysiou 2016 (ADMIRE); Ghiti Moghadam 2016 (POEET); Pavelka 2017; 
Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); van Vollenhoven 2016 (DOSERA); Weinblatt 
2017 (C-EARLY); Yamanaka 2016 (ENCOURAGE)). All included studies were randomised 
controlled superiority studies comparing anti-TNF discontinuation versus continuation. 
Smolen 2014 (OPTIMA), Smolen 2013 (PRESERVE), van Vollenhoven 2016 (DOSERA), Pavelka 
2017, and Weinblatt 2017 (C-EARLY) were blinded placebo-controlled studies. The other 
studies were open-label studies (Chatzidionysiou 2016 (ADMIRE); Ghiti Moghadam 2016 
(POEET); Yamanaka 2016 (ENCOURAGE)). Chatzidionysiou 2016 (ADMIRE) was reported to 
be a pilot study. Smolen 2013 (PRESERVE), van Vollenhoven 2016 (DOSERA), and Weinblatt 
2017 (C-EARLY) reported three arms (both discontinuation and dose reduction compared 
with continuation). Smolen 2013 (PRESERVE) and van Vollenhoven 2016 (DOSERA) reported 
a 1:1:1 randomisation ratio, and Weinblatt 2017 (C-EARLY) a randomisation ratio of 2:3:2. 
Chatzidionysiou 2016 (ADMIRE), Pavelka 2017, Smolen 2014 (OPTIMA), and Yamanaka 2016 
(ENCOURAGE) reported a 1:1 randomisation ratio. Ghiti Moghadam 2016 (POEET) randomised 
in a ratio of 2:1 (discontinuation versus continuation). Smolen 2013 (PRESERVE), Smolen 2014 
(OPTIMA), Pavelka 2017, and van Vollenhoven 2016 (DOSERA) reported a “run-in” period in 
which anti-TNF treatment was given open-label, before randomisation was provided for anti-
TNF continuation, discontinuation, or dose reduction in a double-blind phase. 
The duration of the included studies was 48 weeks for van Vollenhoven 2016 (DOSERA) (40 
weeks double-blind period); 52 weeks for Chatzidionysiou 2016 (ADMIRE), Ghiti Moghadam 
2016 (POEET), and Pavelka 2017 (28 weeks double-blind period). Weinblatt 2017 (C-EARLY) 
reported a total follow-up of 104 weeks, in which the second 52-week double blind period was 
of interest for this review. Smolen 2014 (OPTIMA) and Smolen 2013 (PRESERVE) reported a total 
follow-up of 78 weeks and 88 weeks, respectively; however, both described 52-week follow-
up after randomisation for discontinuation or continuation of the anti-TNF agent. Yamanaka 
2016 (ENCOURAGE) described a period of one year in which participants were treated with 
open-label etanercept and MTX before they were randomised to open-label continuation or 
discontinuation.
Sample size
The sample size varied from 31 participants in Chatzidionysiou 2016 (ADMIRE) to 817 in Ghiti 
Moghadam 2016 (POEET).
Setting
All eight studies were reported as multicentre studies. Chatzidionysiou 2016 (ADMIRE) 
was performed in several hospitals in Sweden, and Ghiti Moghadam 2016 (POEET) in 47 
rheumatology centres throughout the Netherlands. Smolen 2013 (PRESERVE) reported that 
the study was conducted in 80 centres in Europe, Latin America, Asia, and Australia. van 
Vollenhoven 2016 (DOSERA) recruited participants at 16 rheumatology units in Sweden (5), 
Denmark (2), Finland (2), Norway (3), Hungary (3), and Iceland (1). Pavelka 2017 was conducted 
at 61 centres in 19 countries in Africa, Asia, Central and Eastern Europe, Latin America, and 
the Middle East. Smolen 2014 (OPTIMA) reported 161 sites around the world. Weinblatt 2017 
(C-EARLY) was conducted at 103 participating sites in Europe, Australia, North America, and 
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Latin America. Yamanaka 2016 (ENCOURAGE) was a co-operation of rheumatology institutes/
departments in Japan and Korea.
Participants
Six studies reported a minimum age of 18 years for inclusion (Chatzidionysiou 2016 (ADMIRE); 
Pavelka 2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); van Vollenhoven 2016 
(DOSERA); Weinblatt 2017 (C-EARLY)). Ghiti Moghadam 2016 (POEET) was reported to include 
people 18 years of age or older. Smolen 2013 (PRESERVE) reported an upper age limit (70 years) 
for inclusion. Yamanaka 2016 (ENCOURAGE) did not report any age criteria. The mean age of 
participants varied from around 47 in Pavelka 2017 and Smolen 2013 (PRESERVE) to early 60s in 
Chatzidionysiou 2016 (ADMIRE) and Ghiti Moghadam 2016 (POEET). Most participants in the 
included studies were female. Mean disease duration ranged from seven to 14 years, except in 
Smolen 2014 (OPTIMA), in which the mean disease duration was only 3.9 months; Weinblatt 
2017 (C-EARLY), in which median disease duration was around 2.7 months (measured one year 
before randomisation); and Yamanaka 2016 (ENCOURAGE), in which mean disease duration 
was two years. Duration of the anti-TNF agent had to be ≥ 6 months in Chatzidionysiou 2016 
(ADMIRE); ≥ 1 year in Ghiti Moghadam 2016 (POEET); and ≥ 14 months in van Vollenhoven 2016 
(DOSERA). Pavelka 2017, Smolen 2014 (OPTIMA), Smolen 2013 (PRESERVE), and Yamanaka 2016 
(ENCOURAGE) started the anti-TNF agent at study start, 24 weeks, 26 weeks, 36 weeks, and 
1 year, respectively before randomisation for dose reduction or discontinuation. In the study 
by Weinblatt 2017 (C-EARLY), participants were treated with certolizumab pegol (blinded) one 
year before randomisation for dose reduction or discontinuation. Participants in Smolen 2013 
(PRESERVE), Smolen 2014 (OPTIMA), and Weinblatt 2017 (C-EARLY) were bDMARD naive before 
study start. Smolen 2014 (OPTIMA) reported that 8.8% of participants in the discontinuation 
group and 9.5% in the continuation group had used ≥ 1 DMARD. Chatzidionysiou 2016 
(ADMIRE) reported a median of 1 (interquartile range (IQR) 0 to 1) number of previous 
bDMARDs and 2 (IQR 1 to 3) previous csDMARDs. In the study by Ghiti Moghadam 2016 (POEET), 
13.4% of participants in the discontinuation group and 15% in the continuation group had 
previously used a bDMARD. In Pavelka 2017, 34% of participants in the discontinuation group 
had previously used a csDMARD versus 38% in the continuation group. van Vollenhoven 2016 
(DOSERA) reported that 66% of all participants had used a DMARD other than MTX before 
study start. Yamanaka 2016 (ENCOURAGE) did not report on prior DMARD use.
Participants in all included studies had to have low disease activity, Ghiti Moghadam 2016 
(POEET); Pavelka 2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); van Vollenhoven 2016 
(DOSERA); Weinblatt 2017 (C-EARLY), or remission, Chatzidionysiou 2016 (ADMIRE); Yamanaka 
2016 (ENCOURAGE). The duration of low disease activity had to be 4 weeks in Smolen 2014 
(OPTIMA); ≥ 3 months in Chatzidionysiou 2016 (ADMIRE); ≥ 6 months in Ghiti Moghadam 2016 
(POEET); or ≥ 11 months in van Vollenhoven 2016 (DOSERA). Participants in the study by Smolen 
2013 (PRESERVE) had to have a mean DAS28 ≤ 3.2 in the 24-week period before randomisation 
and a DAS28 ≤ 3.2 at the moment of randomisation. In the study by Weinblatt 2017 (C-EARLY), 
participants needed to have a DAS28 ≤ 3.2 12 weeks before randomisation and at the moment 
of randomisation. In Yamanaka 2016 (ENCOURAGE), participants had to have a DAS < 2.6 at 
6 and 12 months after study start. Pavelka 2017 reported that participants had to have low 
disease activity after period 1 (24 weeks after study start). All included studies used a DAS28-
based criterion to define low disease activity or remission.
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Intervention and comedication
Smolen 2013 (PRESERVE), van Vollenhoven 2016 (DOSERA), Yamanaka 2016 (ENCOURAGE), and 
Pavelka 2017 reported etanercept discontinuation compared with etanercept continuation. 
The studies by Chatzidionysiou 2016 (ADMIRE) and Smolen 2014 (OPTIMA) reported 
adalimumab discontinuation compared with adalimumab continuation. Ghiti Moghadam 
2016 (POEET) reported discontinuation of all anti-TNF agents versus anti-TNF continuation. 
Weinblatt 2017 (C-EARLY) reported discontinuation of certolizumab pegol compared to 
continuation of the standard dose. 
Participants in most included studies were required to use MTX comedication (dose ranged 
from 6 to 25 mg/week). Ghiti Moghadam 2016 (POEET) included participants using any 
csDMARD comedication. Participants included in Smolen 2014 (OPTIMA) were MTX naive at 
the start of the study (26 weeks before randomisation for discontinuation or continuation of 
adalimumab). Seven studies stated that participants could restart the anti-TNF after disease 
flare (Chatzidionysiou 2016 (ADMIRE); Ghiti Moghadam 2016 (POEET); Pavelka 2017; Smolen 
2014 (OPTIMA); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY); Yamanaka 2016 
(ENCOURAGE)). The study by Smolen 2013 (PRESERVE) allowed up to three intra-articular 
corticosteroid injections during the study; however, no attempt was made to recapture low 
disease activity by reintroducing etanercept in participants whose condition had deteriorated 
after etanercept withdrawal.
Outcomes
All studies reported a primary outcome measure; for most studies this was proportion of 
participants with low disease activity or remission. All studies used DAS28-based criteria, 
but different definitions were employed. Chatzidionysiou 2016 (ADMIRE) and Yamanaka 
2016 (ENCOURAGE) used DAS28 remission (< 2.6). Smolen 2013 (PRESERVE) and Pavelka 2017 
used DAS28 low disease activity (≤ 3.2 for Smolen 2013 (PRESERVE) and < 3.2 for Pavelka 2017). 
Weinblatt 2017 (C-EARLY) reported maintenance of low disease activity (DAS28-ESR of ≤ 3.2) for 
all 5 consecutive study visits to week 52 without flares as the primary outcome measure. Ghiti 
Moghadam 2016 (POEET) reported proportion of participants with a flare (DAS28 ≥ 3.2 plus an 
increase > 0.6) as the primary outcome. The primary outcome in the study by van Vollenhoven 
2016 (DOSERA) was proportion of non-failure. The primary outcome in Smolen 2014 (OPTIMA) 
was the proportion of participants with both low disease activity and radiographic non-
progression; however, this concerned a comparison of study groups that was not of interest 
for this review (adalimumab continuation versus methotrexate monotherapy). Secondary 
outcomes reported in the included studies concerned many different domains, including 
participant-reported outcomes (function, quality of life), radiographic outcomes, number of 
flares, relapse-free survival, and safety outcomes. None of the included studies provided data 
on costs or change in comedication. All studies were analysed with a (modified) intention-to-
treat approach.
Disease activity-guided dose tapering until stop versus anti-TNF continuation studies
Design
Three studies compared disease activity-guided anti-TNF dose tapering with anti-TNF 
continuation (Bejerano 2016 (OPTIBIO) (abstract only); Fautrel 2016 (STRASS); van Herwaarden 
2015 (DRESS)). All studies were open-label RCTs. van Herwaarden 2015 (DRESS) and Bejerano 
2016 (OPTIBIO) were reported to be non-inferiority studies. Fautrel 2016 (STRASS) reported an 
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equivalence design. Randomisation ratio was 2:1 (dose tapering versus continuation) in van 
Herwaarden 2015 (DRESS) and 1:1 in Fautrel 2016 (STRASS) and Bejerano 2016 (OPTIBIO). Study 
duration was 1 year for Bejerano 2016 (OPTIBIO) and 18 months for van Herwaarden 2015 
(DRESS) and Fautrel 2016 (STRASS).
Sample size
The sample size varied from 48 in Bejerano 2016 (OPTIBIO) (66 in the total study, which also 
included other biologics besides anti-TNF) to 180 in van Herwaarden 2015 (DRESS). The 
projected sample size for the study by Fautrel 2016 (STRASS) was 250 participants; however, 
only 137 participants were included. The abstract on Bejerano 2016 (OPTIBIO) reported 
preliminary data.
Setting
van Herwaarden 2015 (DRESS) and Fautrel 2016 (STRASS) were reported to be multicentre 
studies. van Herwaarden 2015 (DRESS) included patients from two hospitals in the Netherlands, 
and Fautrel 2016 (STRASS) recruited participants at 22 rheumatology departments in France 
and one department in Monaco. Bejerano 2016 (OPTIBIO) was a monocentre study conducted 
in a hospital in Spain.
 
Participants
The abstract by Bejerano 2016 (OPTIBIO) provided no information on participant characteristics 
of anti-TNF users only. The mean age of participants was 56 years in the study by Fautrel 2016 
(STRASS) and 59 years in the study by van Herwaarden 2015 (DRESS). Most participants were 
female in Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS). Mean disease duration at 
baseline was about 10 years for both Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS). 
Participants in van Herwaarden 2015 (DRESS) had a median of 2 (IQR 1 to 3) previous DMARDs 
and 0 (IQR 0 to 1) previous anti-TNF agents. Fautrel 2016 (STRASS) reported a mean (SD) of 2.7 
(1.7) previous DMARDs, and 24% of participants had previously used a bDMARD. 
The duration of anti-TNF agents had to be ≥ 6 months in van Herwaarden 2015 (DRESS) and > 
1 year in Fautrel 2016 (STRASS). Bejerano 2016 (OPTIBIO) reported no minimal duration of anti-
TNF use. Participants in Bejerano 2016 (OPTIBIO) had to have clinical remission (DAS < 2.6, SDAI 
< 5, or ACR/EULAR 2011 criteria) for ≥ 6 months. Participants in Fautrel 2016 (STRASS) needed 
to have a DAS28 ≤ 2.6 for ≥ 6 months with no structural damage progression. Participants in 
van Herwaarden 2015 (DRESS) had to have stable low disease activity (DAS28 < 3.2) at two 
subsequent visits.
Intervention and comedication
All three studies reported disease activity-guided dose tapering. Bejerano 2016 (OPTIBIO) 
included all anti-TNF agents, while Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS) 
included adalimumab and etanercept. Dose tapering in Fautrel 2016 (STRASS) was done by 
increasing the interval between two sub-cutaneous injections by 50% every three months up 
to a complete stop in the fourth step; if DAS28 remission (DAS28 ≤ 2.6) was not maintained, 
dose tapering was suspended or was reversed to the previous interval based on DAS28 level. 
The dose reduction strategy in van Herwaarden 2015 (DRESS) consisted of step-wise increases 
of the time interval between injections every three months until complete stop in the third 
step. In the instance of a flare (ΔDAS28-CRP score > 1.2, or DAS28-CRP > 0.6, and a current score 
of ≥ 3.2), the last effective interval was reinstated. The dose reduction strategy in Bejerano 2016 
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(OPTIBIO) consisted of a stepwise increase in interval every year with withdrawal as the third 
step. In case of flare (DAS28 > 2.6 or SDAI > 5 or ACR/EULAR criteria not fulfilled), participants 
returned to the standard dose. In all studies, the dose-tapering intervention was compared 
with unchanged continuation of the anti-TNF agents.
Outcomes
All studies reported a primary outcome measure that was based on the DAS28 score. Fautrel 
2016 (STRASS) reported standardised difference of DAS28 slopes based on a linear mixed-
effects model as the primary outcome compared to an equivalence margin of ±30%. For van 
Herwaarden 2015 (DRESS), this was difference in proportions of participants with major flare 
(DAS28-CRP-based flare longer than three months) compared with a non-inferiority margin 
of 20%. The primary outcome measure in Bejerano 2016 (OPTIBIO) was the proportion of 
participants that maintained clinical remission after one year. The abstract for this study 
did not report on secondary outcome measures. Several secondary measures were reported 
in Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS), including function, radiographic 
progression, and adverse events. Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS) 
primarily performed a per-protocol analysis and additionally performed an intention-to-treat 
analysis. Bejerano 2016 (OPTIBIO) did not specify their analysis approach, which was therefore 
labelled as intention-to-treat.
Excluded studies
We excluded 29 articles from this review (15 for the original publication and 14 from the 
updated version). Fourteen articles (concerning 13 studies) reported anti-TNF down-titration 
without an anti-TNF continuation control arm (Awan 2011; Bejarano 2010; Detert 2013 (HIT-
HARD); Emery 2013 (PRIZE); Heimans 2016 (IMPROVED); Klarenbeek 2011; Oba 2017 (RRRR 
study); Quinn 2005; Seddighzadeh 2014 (NORD-STAR); Smolen 2012 (CERTAIN); van den Broek 
2011; van der Kooij 2009; Villeneuve 2012; Wiland 2016 (PRIZE)). In four studies, allocation 
to anti-TNF continuation or discontinuation was based on patient or physician preference 
(Harigai 2012 (BRIGHT); Rakieh 2013; Tanaka 2013 (HONOR); Tanaka 2014 (HOPEFUL-2)), 
therefore these study were not classified as RCT or CCT. Tada 2012 (PRECEPT) reported low-
dose versus standard-dose etanercept from study start. In the study by Haschka 2016 (RETRO), 
participants were randomised to dose reduction or discontinuation of all DMARDs, therefore 
the intervention was too broad for this review. The studies by Kobelt 2011 and Kobelt 2014 
provided data from a Markov model. Aletaha 2010, Ichikawa 2007, and Keystone 2003 were 
overview articles. Ramírez-Herráiz 2013 was a retrospective study; CADTH Report 2014 
described a literature study; and Greenberg 2014 was a cohort study. In the study by Haraoui 
2014, no doses below standard dose were investigated. See Characteristics of excluded studies 
for more information.
Risk of bias in included studies
See Characteristics of included studies for ’Risk of bias’ tables with information on all aspects 
of risk of bias. Graphic summaries of the risk of bias in included studies are shown in Figure 2 
and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
percentages across all included studies.  
 
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each 
included study.
Allocation
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Seven included studies described an adequate random sequence generation and allocation 
concealment procedure, resulting in an assessment of low risk of selection bias (Fautrel 2016 
(STRASS); Ibrahim 2017 (OPTTIRA); Pavelka 2017; Smolen 2013 (PRESERVE); van Herwaarden 
2015 (DRESS); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY)). The precise 
method of random sequence generation was not described in three studies (Chatzidionysiou 
2016 (ADMIRE); Smolen 2014 (OPTIMA); Yamanaka 2016 (ENCOURAGE)). Ghiti Moghadam 
2016 (POEET) did not describe allocation concealment. The methods of randomisation and 
allocation concealment were not described in the abstract by Bejerano 2016 (OPTIBIO) and 
the study by El Miedany 2016. The study by Raffeiner 2015 described alternation as the method 
of randomisation, which resulted in a judgement of high risk of selection bias.
Blinding
Five studies were reported to be placebo controlled (Pavelka 2017; Smolen 2013 (PRESERVE); 
Smolen 2014 (OPTIMA); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY)). The 
remaining nine studies were open-label (Bejerano 2016 (OPTIBIO); Chatzidionysiou 2016 
(ADMIRE); El Miedany 2016; Fautrel 2016 (STRASS); Ghiti Moghadam 2016 (POEET); Ibrahim 2017 
(OPTTIRA); Raffeiner 2015; van Herwaarden 2015 (DRESS); Yamanaka 2016 (ENCOURAGE)); five 
of these described blinding of X-ray reading (Fautrel 2016 (STRASS); Ibrahim 2017 (OPTTIRA); 
Raffeiner 2015; van Herwaarden 2015 (DRESS); Yamanaka 2016 (ENCOURAGE), and the study 
by Fautrel 2016 (STRASS) also reported blinded DAS28 measurements, which resulted in an 
assessment of low risk of detection bias.
Incomplete outcome data
We used three criteria for judging this item: intention-to-treat analyses, imputation of 
missing data, and attrition rate. Most studies performed an intention-to-treat analysis 
( Chatzidionysiou 2016 (ADMIRE); Fautrel 2016 (STRASS); Ghiti Moghadam 2016 (POEET); 
Ibrahim 2017 (OPTTIRA); Pavelka 2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); 
van Herwaarden 2015 (DRESS); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY); 
Yamanaka 2016 (ENCOURAGE)). The abstract by Bejerano 2016 (OPTIBIO) and the studies by 
Raffeiner 2015 and El Miedany 2016 did not report on the type of analysis. Five studies did not 
report any imputation of missing data (El Miedany 2016; Fautrel 2016 (STRASS); Ibrahim 2017 
(OPTTIRA); Raffeiner 2015; van Herwaarden 2015 (DRESS)). Smolen 2013 (PRESERVE) reported 
a modified non-responder imputation analysis in which participants who discontinued 
early due to poor efficacy were imputed as non-responders for all time points; all other 
participants were analysed by the last observation carried forward (LOCF) method. All other 
postbaseline analyses were based on the LOCF method (except radiographic endpoints). 
Chatzidionysiou 2016 (ADMIRE) used non-responder imputation for participants with no 
available DAS28 at the time of the primary outcome (this included most participants who had 
a flare in the adalimumab discontinuation group). Ghiti Moghadam 2016 (POEET) reported 
imputation of DAS28 components based on the expectation-maximisation algorithm using 
the participant’s values of the remaining components of the DAS28. Pavelka 2017 reported 
that efficacy analyses were conducted in the full analysis set population in each period using 
the last observation before rescue carried forward approach. The study by Smolen 2014 
(OPTIMA) used non-responder imputation for the primary endpoint, and non-responder 
imputation and LOCF, or both, for additional clinical outcomes; LOCF was used for functional 
outcomes. Markov chain Monte Carlo method was used to impute missing radiographic data 
10 times (multiple imputation). Weinblatt 2017 (C-EARLY) reported that missing data from 
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participants who entered period 2 but withdrew before the end of the study were imputed 
using non-responder imputation for the primary and key secondary endpoints. Radiographic 
analyses used linear extrapolation. In post hoc analyses, LOCF imputation was used for the 
proportions of participants achieving low disease activity, remission, and normative physical 
function. The study by Yamanaka 2016 (ENCOURAGE) described LOCF to impute missing data. 
van Vollenhoven 2016 (DOSERA) reported that a non-responder imputation was applied for 
dichotomous clinical outcomes. The abstract by Bejerano 2016 (OPTIBIO) did not describe the 
procedure for handling missing data. Most studies reported some participants that were lost 
to follow-up (Chatzidionysiou 2016 (ADMIRE); El Miedany 2016; Fautrel 2016 (STRASS); Ghiti 
Moghadam 2016 (POEET); Ibrahim 2017 (OPTTIRA); Pavelka 2017; Raffeiner 2015; Smolen 2014 
(OPTIMA); van Herwaarden 2015 (DRESS); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 
(C-EARLY)). The study by Smolen 2013 (PRESERVE) reported that fewer participants completed 
the study in the placebo group than in the etanercept 50 mg and 25 mg groups (141 versus 
181 and 175 participants). Yamanaka 2016 (ENCOURAGE) reported high dropout rates in both 
groups (16/49 in the continuation group and 16/50 in the discontinuation group). The abstract 
by Bejerano 2016 (OPTIBIO) did not describe completion rate.
Selective reporting
Most studies, with the exception of Raffeiner 2015 and El Miedany 2016, had a study protocol 
that was available. Bejerano 2016 (OPTIBIO) was published as abstract only, and therefore did 
not report all prespecified outcomes. All other studies reported the pre-specified outcomes 
(Chatzidionysiou 2016 (ADMIRE); Fautrel 2016 (STRASS); Ghiti Moghadam 2016 (POEET); 
Ibrahim 2017 (OPTTIRA); Pavelka 2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); 
van Herwaarden 2015 (DRESS); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY); 
Yamanaka 2016 (ENCOURAGE)).
Other potential sources of bias
Eight studies appeared to be free of other potential sources of bias (Chatzidionysiou 2016 
(ADMIRE); El Miedany 2016; Ibrahim 2017 (OPTTIRA); Pavelka 2017; Smolen 2013 (PRESERVE); 
Smolen 2014 (OPTIMA); van Herwaarden 2015 (DRESS); van Vollenhoven 2016 (DOSERA)). There 
was insufficient information in the abstract by Bejerano 2016 (OPTIBIO) to assess this domain. 
The study by Ghiti Moghadam 2016 (POEET) reported a different flare criterion in their final 
publication compared to the information in the trial register. No study protocol was present 
for Raffeiner 2015, but information from an earlier abstract indicated that the inclusion 
criteria, outcome measures, and duration of follow-up had changed over time. A lower than 
anticipated number of participants was included in Yamanaka 2016 (ENCOURAGE), Weinblatt 
2017 (C-EARLY), and Fautrel 2016 (STRASS).
Effects of interventions
See: Summary of findings for the main comparison Anti-TNF dose reduction versus anti-TNF 
continuation; Summary of findings 2 Anti-TNF discontinuation versus anti-TNF continuation; 
Summary of findings 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF 
continuation. We have presented study results by type of intervention: (1) dose reduction, (2) 
discontinuation, and (3) disease activity-guided dose tapering.
Anti-TNF dose reduction versus anti-TNF continuation
7372
Major outcomes
See Summary of findings for the main comparison.
• Mean disease activity: Of the six studies included for this comparison (1148 participants), 
two studies, Smolen 2013 (PRESERVE) and Ibrahim 2017 (OPTTIRA), with 501 participants 
provided data on mean disease activity (DAS28). Anti-TNF dose reduction resulted in little or 
no difference in mean disease activity score after 26 to 52 weeks follow-up (mean difference 
(MD) 0.06, 95% confidence interval (CI) −0.11 to 0.24). We pooled data from the two dose 
reduction arms in the study by Ibrahim 2017 (OPTTIRA) for this outcome. Analysis 1.1
• Proportion persistent remission: Of the six studies included for this comparison (1148 
participants), two studies, Smolen 2013 (PRESERVE) and Weinblatt 2017 (C-EARLY), with 612 
participants provided data on persistent remission. Anti-TNF dose reduction may result in 
little or no difference in the proportion of participants with persistent remission (DAS28 < 
2.6) after 52 weeks (risk ratio (RR) 1.01, 95% CI 0.80 to 1.28). Analysis 1.2
• Proportion of participants that switched to another biologic: Of the six studies included for 
this comparison (1148 participants), only one study with 323 participants provided data on 
this outcome (Raffeiner 2015). The data showed that anti-TNF dose reduction may slightly 
reduce the proportion of participants who are switched to another biologic (RR 0.40, 95% 
CI 0.17 to 0.93; mean follow-up period 3.5 ± 1.5 years). This result might be explained by a 
difference in treatment strategy after flare in the two treatment groups. In the continuation 
group, a flare resulted in a switch of biologic treatment, while in the dose reduction group 
the standard dose of etanercept was reinstated first (Raffeiner 2015). Analysis 1.3
• Proportion of participants with minimal radiographic progression: Of the six studies 
included for this comparison (1148 participants), two studies provided data on radiographic 
progression, Smolen 2013 (PRESERVE) and Weinblatt 2017 (C-EARLY), with 553 participants. 
Anti-TNF dose reduction probably slightly increases the proportion of participants with 
minimal radiographic progression (mSvdH > 0.5) after 52 weeks (RR 1.22, 95% CI 0.76 to 1.95). 
Analysis 1.4
• Function: Of the six studies included for this comparison (1148 participants), two studies, 
Smolen 2013 (PRESERVE) and Ibrahim 2017 (OPTTIRA), with 501 participants provided data 
on this outcome. Anti-TNF dose reduction does not result in an important deterioration in 
function (HAQ Disability Index (HAQ-DI)) after 26 to 52 weeks follow-up (MD 0.09, 95% CI 
0.00 to 0.19). We pooled data from the two dose reduction arms in the study by Ibrahim 2017 
(OPTTIRA) for this outcome. Analysis 1.5
• Number of serious adverse events: Of the six studies included for this comparison (1148 
participants), five studies with 1084 participants provided data on this outcome (Ibrahim 
2017 (OPTTIRA); Raffeiner 2015; Smolen 2013 (PRESERVE); van Vollenhoven 2016 (DOSERA); 
Weinblatt 2017 (C-EARLY)). Anti-TNF dose reduction may cause little or no difference in the 
number of serious adverse events after 26 to 52 weeks follow-up (RR 1.09, 95% CI 0.65 to 1.82). 
We pooled data from the two dose reduction arms in the study by Ibrahim 2017 (OPTTIRA) 
for this outcome. Analysis 1.6
• Withdrawals due to adverse events: Of the six studies included for this comparison (1148 
participants), three studies with 937 participants provided data on this outcome (Raffeiner 
2015; Smolen 2013 (PRESERVE); Weinblatt 2017 (C-EARLY)). Anti-TNF dose reduction may 
cause little or no difference in the number of withdrawals due to adverse events after 52 
weeks (RR 1.07, 95% CI 0.51 to 2.24). Analysis 1.7
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Minor outcomes
• Proportion of participants with a flare: Of the six included studies for this comparison (1148 
participants), three studies with 357 participants provided data on this outcome (Ibrahim 
2017 (OPTTIRA); van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY)). The three 
studies used different criteria for flare. Ibrahim 2017 (OPTTIRA) defined a flare as an increase 
in DAS28 scores ≥ 0.6 resulting in a DAS28 > 3.2 together with an increase in the swollen joint 
count; both had to be present on two occasions at least one week apart. An increase in DAS28 
score ≥ 1.2 resulting in DAS28 > 3.2 was defined as flare irrespective of changes in swollen 
joints. van Vollenhoven 2016 (DOSERA) defined a flare as (a) a DAS28-ESR > 5.1; (b) a DAS28-
ESR > 3.2 and an increase ≥ 1.2 from baseline; (c) DAS28-ESR > 3.2 and an increase in DAS28 ≥ 
0.6 from baseline on two consecutive visits at least one to three weeks apart; or (d) disease 
progression as determined by either the investigator or disease flare as experienced by the 
participant. Weinblatt 2017 (C-EARLY) stated that participants reporting a flare also had to 
meet the following three criteria at two consecutive visits two weeks apart: 1) an increase in 
the DAS28-ESR of ≥ 0.6 above the DAS28-ESR at week 52; 2) a DAS28-ESR of > 3.2; and 3) in the 
investigator’s judgement, an increase in the participant’s RA activity. Furthermore, Ibrahim 
2017 (OPTTIRA) included two intervention groups: 33% and 66% dose reduction. Due to 
this heterogeneity data were not pooled. The studies did not show a difference between 
the anti-TNF dose reduction group(s) and the continuation group; risk ratios were found 
between 0.29 and 1.79.
• Quality of life: Of the six studies included for this comparison (1148 participants), two studies, 
Smolen 2013 (PRESERVE) and Ibrahim 2017 (OPTTIRA), with 501 participants provided data 
on this outcome. Anti-TNF dose reduction resulted in little or no difference in mean EQ-5D 
after 26 to 52 weeks’ follow-up (MD 0.00, 95% CI −0.04 to 0.03). We pooled data from the two 
dose reduction arms in the study by Ibrahim 2017 (OPTTIRA) for this outcome.
• Costs: None of the six included studies provided data on this outcome.
• Decremental cost-effectiveness ratio: None of the six included studies provided data on this 
outcome.
• Time to flare: Of the six studies included for this comparison (1148 participants), one study 
with 50 participants provided data on this outcome (van Vollenhoven 2016 (DOSERA)). 
Median time to failure was 48 weeks in the etanercept 50 mg/week continuation group and 
36 weeks in the etanercept 25 mg/week dose reduction group, but no SDs were available.
• Change in other medication: None of the six included studies reported data on this outcome.
Anti-TNF discontinuation versus anti-TNF continuation
See Summary of findings 2.
Major outcomes
• Mean disease activity: Of the eight studies (2111 participants) included for this comparison, 
three studies, Smolen 2013 (PRESERVE), Ghiti Moghadam 2016 (POEET), and Pavelka 2017, 
with 402, 692, and 331 participants, respectively, provided data on mean disease activity. 
We pooled data from Pavelka 2017 and Smolen 2013 (PRESERVE). Anti-TNF discontinuation 
probably increases the mean disease activity score (DAS28) slightly after 28 to 52 weeks’ 
follow-up (MD 0.96, 95% CI 0.67 to 1.25). We considered the study by Ghiti Moghadam 2016 
(POEET) to be different since participants could return to standard dose in case of flare, and 
no LOCF was described, therefore the results will reflect the effect of a discontinuation and 
restarting strategy. This strategy resulted in a small, possibly unimportant increase in mean 
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disease activity score after 52 weeks (MD 0.29, 95% CI 0.14 to 0.44). Analysis 2.1
• Proportion persistent remission: Of the eight studies reporting on this comparison (2111 
participants), six studies with 1188 participants provided data on the proportion of 
participants with persistent remission (Chatzidionysiou 2016 (ADMIRE); Pavelka 2017; 
Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); Weinblatt 2017 (C-EARLY); Yamanaka 
2016 (ENCOURAGE)). We were unable to pool data due to heterogeneity. The RR after 28 
to 52 weeks varied between 0.16 in Chatzidionysiou 2016 (ADMIRE) and 0.77 in Smolen 
2014 (OPTIMA) and Weinblatt 2017 (C-EARLY). The absolute risk difference varied between 
15% fewer in Weinblatt 2017 (C-EARLY) and 68% fewer in Chatzidionysiou 2016 (ADMIRE). 
Analysis 2.2
• Proportion of participants that switched to another biologic due to persistent loss of 
response (refractory to re-instalment of the tapered anti-TNF in the intervention group): 
None of the eight included studies provided data on this outcome. Smolen 2013 (PRESERVE) 
reported that no attempt was made to recapture low disease activity by reintroducing 
etanercept in participants whose condition had deteriorated after etanercept withdrawal, 
raising some ethical issues in our view.
• Proportion of participants with minimal radiographic progression: Of the eight studies 
(2111 participants) included for this comparison, three studies, Smolen 2013 (PRESERVE), 
Weinblatt 2017 (C-EARLY), and Yamanaka 2016 (ENCOURAGE)), with 549 participants 
provided data on this outcome. The meta-analysis showed that anti-TNF discontinuation 
increases the proportion of participants with minimal radiographic progression > 0.5 
mSvdH point after 52 weeks (RR 1.69, 95% 1.10 to 2.59). Analysis 2.3
• Function: Of the eight studies (2111 participants) included for this comparison, four studies 
with 1498 participants provided data on this outcome (Ghiti Moghadam 2016 (POEET); 
Pavelka 2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA)). The results showed that 
anti-TNF discontinuation may lead to a slight deterioration in function after 28 to 52 weeks’ 
follow-up (MD 0.18, 95% CI 0.05 to 0.31). Analysis 2.4
• Number of serious adverse events: All eight studies included for this comparison provided 
data on this outcome, with 2095 participants. Due to the very low certainty of the evidence 
and imprecision of the results, it is uncertain whether anti-TNF discontinuation influences 
the number of serious adverse events after 28 to 52 weeks (RR 1.29, 95% CI 0.82 to 2.03). 
Analysis 2.5
• Withdrawals due to adverse events: Of the eight studies (2111 participants) included for this 
comparison, four studies with 1116 participants provided data on this outcome (Pavelka 
2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); Weinblatt 2017 (C-EARLY)). Anti-
TNF discontinuation probably slightly increases the number of withdrawals due to adverse 
events after 28 to 52 weeks (RR 1.46, 95% CI 0.75 to 2.84). Analysis 2.6
Minor outcomes
• Proportion of participants with a flare: Of the eight studies (2111 participants) included 
for this comparison, five studies provided data on this outcome (Chatzidionysiou 2016 
(ADMIRE); Ghiti Moghadam 2016 (POEET); Pavelka 2017; van Vollenhoven 2016 (DOSERA); 
Weinblatt 2017 (C-EARLY)), with 31, 46, 331, 817, and 163 participants, respectively. We did 
not pool data because of clinical and statistical heterogeneity. The study by Chatzidionysiou 
2016 (ADMIRE) defined flare as DAS28 ≥ 2.6 or an increase of more than 1.2 from baseline. 
After 28 weeks, proportion of flare in the adalimumab discontinuation group was not 
statistically significantly different from that in the adalimumab continuation group (RR 1.6, 
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95% CI 0.92 to 2.78). van Vollenhoven 2016 (DOSERA) defined flare as (a) a DAS28-ESR > 5.1; (b) 
a DAS28-ESR > 3.2 and an increase ≥ 1.2 from baseline; (c) DAS28-ESR > 3.2 and an increase in 
DAS28 ≥ 0.6 from baseline on two consecutive visits at least one to three weeks apart; or (d) 
disease progression as determined by either the investigator or disease flare as experienced 
by the participant. After 48 weeks’ follow-up, the proportion of participants with flare was 
higher in the discontinuation group compared to the continuation group (RR 1.82, 95% CI 
1.15 to 2.87). Ghiti Moghadam 2016 (POEET), Pavelka 2017, and Weinblatt 2017 (C-EARLY) used 
the same criterion for flare: DAS28 ≥ 3.2 and an increase of 0.6 or more. Ghiti Moghadam 
2016 (POEET) found that the proportion of participants with flare was higher in the anti-TNF 
discontinuation group than in the continuation group (after 24 weeks RR 3.37, 95% CI 2.42 to 
4.70; after 52 weeks RR 2.82, 95% CI 2.17 to 3.65). Pavelka 2017 found a higher proportion of 
flare in the participants that stopped anti-TNF after 28 weeks (RR 1.53, 95% CI 1.30 to 1.81). 
Weinblatt 2017 (C-EARLY) found no difference in the proportion of participants with flare 
between the anti-TNF discontinuation group and the continuation group (RR 1.52, 95% CI 
0.61 to 3.80).
• Quality of life: Of the eight studies (2111 participants) included for this comparison, two 
studies, Smolen 2013 (PRESERVE) and Pavelka 2017, with 733 participants provided data on 
this outcome. Anti-TNF discontinuation led to a deterioration in quality of life after 28 to 52 
weeks (MD −0.10, 95% CI −0.13 to −0.07).
• Costs: None of the eight included studies provided data on direct or indirect costs.
• Decremental cost-effectiveness ratio: None of the eight included studies provided data on 
this outcome.
• Time to flare: Of the eight studies included for this comparison (2111 participants), two 
studies, Chatzidionysiou 2016 (ADMIRE) and van Vollenhoven 2016 (DOSERA), provided 
data on this outcome, with 31 and 46 participants, respectively. These two studies used 
different flare/failure criteria. Chatzidionysiou 2016 (ADMIRE) reported that survival curves 
suggested higher flare-free survival over time in participants randomised to continue 
treatment with adalimumab, but that the difference did not reach statistical significance 
(P = 0.07). The study by van Vollenhoven 2016 (DOSERA) reported a median time to failure of 
48 weeks in the etanercept 50 mg/week continuation group and six weeks in the etanercept 
discontinuation (placebo) group, but no SDs were available.
• Change in other medication: None of the eight included studies provided data on change in 
other medication.
Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation
See Summary of findings 3.
Major outcomes
• Mean disease activity: All three studies included in this comparison reported on this 
outcome, with 357 participants (Bejerano 2016 (OPTIBIO) (abstract only); Fautrel 2016 
(STRASS); van Herwaarden 2015 (DRESS)). Anti-TNF disease activity-guided dose tapering 
may result in little or no difference in mean disease activity score (MD 0.25, 95% CI −0.17 to 
0.67). Analysis 3.1
• Proportion persistent remission: Of the three studies included in this comparison (365 
participants), one study with 180 participants reported on this outcome (van Herwaarden 
2015 (DRESS)). Anti-TNF disease activity-guided dose tapering resulted in little or no 
difference in the proportion of participants with persistent remission (DAS28 < 2.6) after 18 
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months (RR 0.89, 95% CI 0.75 to 1.06). Analysis 3.2
• Proportion of participants that switched to another biologic due to persistent loss of 
response (refractory to re-instalment of the tapered anti-TNF in the intervention group): Of 
the three studies included in this comparison (365 participants), two studies, Fautrel 2016 
(STRASS) and van Herwaarden 2015 (DRESS), with 317 participants reported on this outcome. 
Anti-TNF disease activity-guided dose tapering may result in little or no difference in the 
proportion of participants that switch to another biologic after 18 months (RR 0.62, 95% CI 
0.25 to 1.54). Analysis 3.3
• Proportion of participants with minimal radiographic progression: Of the three studies 
included in this comparison (365 participants), two studies, Fautrel 2016 (STRASS) and van 
Herwaarden 2015 (DRESS), with 312 participants reported on this outcome. Although Fautrel 
2016 (STRASS) used a cut-off value of 1 point and van Herwaarden 2015 (DRESS) a cut-off 
value of 0.5 point mSvdH score, data could be pooled. Anti-TNF disease activity-guided dose 
tapering may slightly increase the proportion of participants with minimal radiographic 
progression (mSvdH > 0.5 or > 1.0) after 18 months (RR 1.45, 95% CI 0.77 to 2.73). Analysis 3.4
• Function: Of the three studies included in this comparison (365 participants), one study 
with 123 participants reported on this outcome (Fautrel 2016 (STRASS)). IAnti-TNF disease 
activity-guided dose tapering probably leads to a slight deterioration in function after 18 
months (MD 0.20, 95% CI −0.02 to 0.42). Analysis 3.5
• Number of serious adverse events: Of the three studies included in this comparison (365 
participants), two studies, Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS), 
reported on this outcome, with 137 and 180 participants, respectively. Due to the very low 
certainty of the evidence and imprecision, it is uncertain whether anti-TNF disease activity-
guided dose tapering influences the number of serious adverse events after 18 months. 
Analysis 3.6
• Withdrawals due to adverse events: None of the three included studies provided data on 
this outcome.
Minor outcomes
• Proportion of participants with a flare: All three studies (365 participants) included in 
this comparison reported on this outcome. The studies used different criteria for flare. In 
Bejerano 2016 (OPTIBIO) (abstract only), participants had a flare if DAS28 > 2.6; SDAI > 5; or 
when ACR/EULAR criteria were not fulfilled. Bejerano 2016 (OPTIBIO) (abstract only) found 
no difference in the proportion of participants with a flare between the anti-TNF disease 
activity-guided dose tapering group and the anti-TNF continuation group after 24, 48, 72, 
and 96 weeks’ follow-up (24 weeks: RR 3.25, 95% CI 0.14 to 76.01; 48 weeks: RR 1.09, 95% CI 
0.24 to 4.86; 72 weeks: RR 1.09, 95% CI 0.36 to 3.27; 96 weeks: RR 1.27, 95% CI 0.50 to 3.22). 
Fautrel 2016 (STRASS) defined flare as DAS28 > 2.6 with an increase in DAS28 of > 0.6. They 
reported a higher proportion of participants with flare in the anti-TNF disease activity-
guided dose tapering group compared to the anti-TNF continuation group after 18 months’ 
follow-up (RR 1.64, 95% CI 1.24 to 2.18). In van Herwaarden 2015 (DRESS), participants had 
a flare if DAS28 increased > 1.2, or if DAS28 increased > 0.6 and current DAS28 was ≥ 3.2. 
The authors reported a higher proportion of participants with flare in the anti-TNF disease 
activity-guided dose tapering group compared to the anti-TNF continuation group after 9 
and 18 months (9 months: RR 2.68, 95% CI 1.58 to 4.56; 18 months: RR 2.68, 95% CI 1.74 to 4.13). 
van Herwaarden 2015 (DRESS) found no difference in major flares (duration > 3 months) 
after 9 and 18 months (9 months: RR 1.71, 95% CI 0.37 to 7.96; 18 months: RR 1.22, 95% CI 0.50 
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to 2.98).
• Quality of life: Of the three studies included in this comparison (365 participants), two 
studies, Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS), reported on this outcome, 
with 98 and 180 participants, respectively. Both studies reported mean quality-adjusted 
life years (QALYs) of the 18-month study period. Fautrel 2016 (STRASS) found that the anti-
TNF disease activity-guided dose tapering group gained fewer QALYs during the 18-month 
study period than the anti-TNF continuation group (MD −0.158). No confidence intervals 
were available. van Herwaarden 2015 (DRESS) reported no difference between the anti-TNF 
disease activity-guided dose tapering group versus the anti-TNF continuation group (MD 
−0.02, 95% percentiles −0.06 to 0.02).
• Costs: Of the three studies included in this comparison (365 participants), two studies, 
Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS), reported on this outcome, with 98 
and 180 participants, respectively. Both studies reported lower costs in the anti-TNF disease 
activity-guided dose tapering group compared to the anti-TNF continuation group after 18 
months’ follow-up (Fautrel 2016 (STRASS): MD EUR −8440. No confidence intervals were 
available. van Herwaarden 2015 (DRESS): MD EUR −9051, 95% percentiles −10,278 to −7731 
(rectification submitted)).
• Decremental cost-effectiveness ratio: Of the three studies included in this comparison (365 
participants), two studies, Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS), reported 
on this outcome, with 98 and 180 participants, respectively. Fautrel 2016 (STRASS) reported 
a decremental cost-effectiveness ratio (DCER) of EUR 53,417 per QALY loss. van Herwaarden 
2015 (DRESS) reported a DCER of EUR 379,433 per QALY loss (rectification submitted).
• Time to flare: None of the three included studies reported data on this outcome.
• Change in other medication: Of the three studies included in this comparison (365 
participants), one study with 180 participants reported on this outcome (van Herwaarden 
2015 (DRESS)). No difference was found between the anti-TNF disease activity-guided dose 
tapering group and the anti-TNF continuation group after 18 months concerning use of 
intramuscular or intra-articular glucocorticosteroids (RR 1.50, 95% CI 0.89 to 2.51); use of oral 
glucocorticosteroids (RR 0.65, 95% CI 0.24 to 1.79); DMARD initiation or dose escalation (RR 
3.90, 95% CI 0.93 to 16.41); and use of a DMARD (RR 0.88, 95% CI 0.71 to 1.10). The proportion 
of participants that reduced the dose of their DMARD or discontinued the DMARD after 18 
months’ follow-up was lower in the anti-TNF disease activity-guided dose tapering group 
compared to the anti-TNF continuation group (RR 0.37, 95% CI 0.19 to 0.72).
Subgroup and sensitivity analyses
We planned to perform a subgroup analysis as described in the Subgroup analysis and 
investigation of heterogeneity section. However, because of the small number of included 
studies, analyses were not informative. We also planned to perform sensitivity analyses 
as described in the Sensitivity analysis section. However, because of the small number of 
included studies, analyses were not informative.
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Discussion
This is the first update of the original Cochrane Review first published in 2014. We identified 
eight new studies for inclusion in this update and additional data on old studies, which 
changed some results. We retrospectively excluded one study that had been included in the 
original review. Our main conclusions remained largely the same.
Summary of main results
This systematic review summarises evidence from 14 studies (13 RCTs and one CCT) of down-
titration of anti-TNF agents in people with RA with low disease activity. We considered three 
down-titration strategies to be sufficiently different to warrant separate reviewing: (1) anti-
TNF dose reduction, (2) anti-TNF discontinuation, and (3) anti-TNF disease activity-guided 
dose tapering. We presented the available data on these strategies separately.
Anti-TNF dose reduction compared with anti-TNF continuation
Six studies (three on etanercept, one on etanercept and adalimumab, one on certolizumab 
pegol, and one on all anti-TNF agents) reported data on fixed anti-TNF dose reduction 
compared with anti-TNF continuation. After pooling of data where possible, we can conclude 
that anti-TNF dose reduction leads to little or no difference in mean disease activity, the 
proportion of participants with persistent remission, number of serious adverse events and 
withdrawals due to adverse events compared to continuation. Also, anti-TNF dose reduction 
does not result in an important deterioration in function but probably slightly increases the 
proportion of participants with minimal radiographic damage. Next to this, anti-TNF dose 
reduction may slightly reduce the proportion of participants switched to another biologic. We 
found no data on important outcomes like cost-effectiveness.
Anti-TNF discontinuation compared with anti-TNF continuation
Eight RCTs reported data on anti-TNF discontinuation compared with anti-TNF continuation 
for all anti-TNF agents, but mainly adalimumab and etanercept. Different types of outcome 
measures were reported, and marked heterogeneity was present. The results showed that 
anti-TNF discontinuation probably increases the mean disease activity score slightly, and that 
the risk ratio of persistent remission lies between 0.16 and 0.77 (data not pooled). Anti-TNF 
discontinuation increases the proportion participants with minimal radiographic progression 
of > 0.5 mSvdH point per year and may lead to a slight deterioration in function and probably 
slightly increases the number of withdrawals due to adverse events. It is uncertain whether 
anti-TNF discontinuation influences the number of serious adverse events due to very low-
certainty evidence. Again, we found no data on cost-effectiveness.
Anti-TNF disease activity-guided dose tapering compared with anti-TNF continuation
Three studies (all anti-TNF agents, but again mostly etanercept and adalimumab) compared 
disease activity-guided anti-TNF dose tapering with anti-TNF continuation. Anti-TNF disease 
activity-guided dose tapering may result in little or no difference in mean disease activity 
score and the proportion of participants switched to another biologic. Furthermore, anti-TNF 
disease activity-guided dose tapering results in little or no difference in the proportion of 
participants with persistent remission. Next to this, tapering may result in a slight increase in 
the proportion of participants with minimal radiographic progression and probably causes a 
slight deterioration in function. It is uncertain whether anti-TNF disease activity-guided dose 
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tapering influences the number of serious adverse events due to very low-certainty evidence. 
No data were available on withdrawals due to adverse events. In the two studies that reported 
on cost-effectiveness, costs were significantly lower, and decremental cost-effectiveness 
ratios were found to be between EUR 53,000 and EUR 379,000 per QALY lost.
Overall completeness and applicability of evidence
The number of controlled studies on this matter is increasing, although they are mostly 
limited to adalimumab and etanercept. Data were available on all three strategies, although 
discontinuation was studied most extensively. We considered the included studies to be quite 
comparable clinically and decided to accept some clinical heterogeneity in order to obtain 
more precision. One study was reported as abstract only (Bejerano 2016 (OPTIBIO)). Excluding 
the results reported in this abstract did not change our conclusions.
An important issue remains that the superiority design of the fixed-dose reduction or 
discontinuation studies hampers interpretability and generalisability to clinical practice. 
With regard to the first issue, these studies do provide point estimates about between-group 
differences in important outcomes between the strategies, but they do not compare these 
point estimates and their confidence intervals with a prespecified relevant non-inferiority 
margin. Consequently, independent of whether superiority tests demonstrate a significant 
difference, the interpretation has to be made post hoc whether this (non-)significant 
difference is relevant compared to a non-inferiority claim, although this issue might become 
less important in meta-analyses where sample sizes are large. Next to this, the preferred 
method of analysis for non-inferiority trials is per protocol, while an intention-to-treat 
analysis is favoured for superiority trials. This hampers comparison of studies with different 
approaches. With regard to generalisability, it seems important to mention that for patients 
and clinicians alike, the outcome of fixed-dose reduction or discontinuation is valuable to 
know. However, it would be much more valuable to know whether disease activity-guided 
dose reduction and discontinuation is non-inferior with regard to important outcomes, as this 
supports shared decision making with patients.
The participants included in these studies vary from early RA with short treatment duration 
and no prior DMARD treatment to longstanding, established RA patients who have been 
treated for a long time with several other DMARDs, and also include patients with and without 
concomitant DMARD. This increases generalisability, although it also has been shown that no 
clinical patient-, disease-, or treatment-related variable is clearly an effect modifier for the 
chance of successful dose reduction or discontinuation (Tweehuysen 2017).
With regard to outcome measures, we noted that domains are often missing, such as 
functioning, radiographic damage progression, or cost (effectiveness). Also, when a domain 
is included as an outcome, there is marked heterogeneity in the way the outcome is assessed, 
leaving much room for improvement of outcome standardisation.
Quality of the evidence
Anti-TNF dose reduction compared with anti-TNF continuation
Using the GRADE approach, we assessed the overall certainty of evidence as high for two of 
the seven ’Summary of findings’ outcomes in the anti-TNF dose reduction versus continuation 
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comparison: mean disease activity and function. We assessed the certainty of the evidence 
for the proportion of participants with minimal radiographic progression as moderate 
because of imprecision. We assessed the certainty of the evidence for the remaining four 
main outcomes as low. For the proportion of participants with persistent remission, this was 
the result of heterogeneity (downgraded two times). For the proportion of participants that 
switched to another biologic, this was due to concern about risk of bias in the reporting study 
(downgraded two times). We downgraded the evidence on the number of serious adverse 
events and the number of withdrawals due to adverse events one level for risk of bias and one 
level for imprecision.
Anti-TNF discontinuation compared with anti-TNF continuation
The overall certainty of the evidence was high for one of the seven ’Summary of findings’ 
outcomes in the anti-TNF discontinuation versus continuation comparison: proportion of 
participants with minimal radiographic progression. We assessed the certainty of the evidence 
for the outcomes mean disease activity and withdrawals due to adverse events as moderate. 
We performed a subanalysis for the outcome mean disease activity, since heterogeneity 
was present between the studies that could be explained by the study characteristics. We 
downgraded the evidence on mean disease activity for discontinuation without restarting or 
with restarting and with LOCF analysis one level because of imprecision. We downgraded the 
evidence for mean disease activity with restarting and without LOCF analysis one level due to 
concerns about risk of bias. We downgraded the evidence on withdrawals one level because of 
imprecision. We assessed the certainty of the evidence on the proportion of participants with 
persistent remission and function as low because of substantial heterogeneity (downgraded 
two levels). Lastly, we assessed the certainty of the evidence on the number of serious adverse 
events as very low because of (1) concerns about risk of bias, (2) moderate heterogeneity 
between effect estimates, and (3) imprecision. The included anti-TNF discontinuation studies 
did not report the proportion of participants that switched to another biologic.
Anti-TNF disease activity-guided dose tapering compared with anti-TNF continuation
The certainty of the evidence for the outcome proportion of participants with persistent 
remission was high in the anti-TNF disease activity-guided dose tapering versus continuation 
comparison. The data came from one study with a low risk of bias, and there were no other 
reasons to downgrade the certainty of the evidence. We assessed the certainty of the evidence 
on function as moderate because of imprecision. We assessed the certainty of the evidence on 
mean disease activity as low because of heterogeneity (downgraded two levels). We graded 
the certainty of the evidence on the proportion of participants that switched to another 
biologic as low because of imprecision (downgraded two levels). We graded the certainty of 
the evidence on the proportion of participants with minimal radiographic progression as low 
due to heterogeneity and imprecision. We assessed the certainty of the evidence for serious 
adverse events as very low because of substantial heterogeneity (downgraded two levels) and 
imprecision (down-graded two levels). The included studies for this comparison did not report 
on withdrawals due to adverse events.
Potential biases in the review process
Two review authors independently reviewed all titles and abstracts, extracted data, and 
performed bias and quality assessment. Consequently, errors in extraction have been 
minimised. Risk of bias could not be completely assessed for some studies due to restricted 
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information despite efforts to obtain additional information from study authors. Post-hoc 
decisions had to be made regarding the presentation and pooling of outcomes (e.g. time of 
follow-up, threshold values) which could have had implications on the results. The authors 
have tried to be as transparent as possible about choices that have been made, although they 
remain subjective.
Agreements and disagreements with other studies or reviews
A few other systematic reviews have examined anti-TNF down-titration, although the focus 
differed to some extent (Galvao 2016; Kuijper 2015; Navarro-Millán 2013; Yoshida 2014). Galvao 
2016 focused on discontinuation of biological DMARDs, and Kuijper 2015 on discontinuation of 
biologic and synthetic DMARDs. Navarro-Millán 2013 investigated discontinuation of anti-TNF 
agents specifically. The results of these reviews are comparable to the findings in our review. 
The systematic review by Yoshida 2014 looked into the design and failure definitions in anti-
TNF discontinuation studies. The review authors concluded that heterogeneity can be seen 
across studies in both study design and failure definition. This is consistent with the findings 
reported in our review.
Authors’ conclusions
Implications for practice
This review of the data has several implications for clinical practice with regard to the three 
different strategies studied: dose reduction, discontinuation, and disease activity-guided 
tapering of anti-tumour necrosis factor (anti-TNF). 
Firstly, fixed-dose reduction of anti-TNF (especially etanercept) in people with rheumatoid 
arthritis (RA) with at least three to 12 months of low disease activity is comparable with 
continuing the standard dose with regard to mean disease activity, the proportion of 
participants remaining in remission, and mean function. Consequently, an attempt to reduce 
the dose (or increase the dosage interval) in people with low disease activity with RA on full-
dose anti-TNF seems sensible in clinical practice. It should be mentioned, however, that all 
treatment changes in RA should be done carefully on a background of ’treat to target’, that 
is guided by disease activity. Dose reduction probably slightly increases the proportion of 
participants with minimal radiographic progression. Anti-TNF dose reduction may cause little 
or no difference in number of serious adverse events and withdrawals due to adverse events, 
although certainty of evidence was low. This review showed that slightly fewer participants 
undergoing anti-TNF dose reduction may switch to another biologic disease-modifying 
antirheumatic drug (bDMARD) compared to continuation. An explanation for this might be 
that temporary disease flares (inherent to the disease) are treated in the dose reduction group 
by increasing the dose, while in the continuation group patients are switched to another 
biologic. 
Secondly, this review shows that anti-TNF discontinuation (without disease activity-guided 
restarting of treatment) is an inferior strategy compared with continuation of anti-TNF in 
terms of disease control (mean disease activity and the proportion of participants remaining 
in remission), minimal radiographic damage, function and the number of withdrawals due 
to adverse events. Although a sizeable proportion of patients can stop the anti-TNF without 
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deterioration, the large majority of patients who cannot discontinue the drug are harmed if 
the treatment is not reinstated. The effect of discontinuation on the number of serious adverse 
events remains uncertain. However, given the current evidence, discontinuation should not 
be attempted without regular assessment of disease activity, setting a treatment goal, and 
reinstatement of treatment when necessary.
The abovementioned findings converge finally in the evidence on the disease activity-guided 
dose tapering strategy. This review shows that disease activity-guided tapering is comparable 
to continuation with regard to mean disease activity, the proportion of participants remaining 
in remission and the proportion of participants switched to another biologic. Tapering may 
result in a slight increase in the proportion of participants with radiographic progression and 
probably leads to a slight deterioration in function. The effect of disease activity-guided dose 
tapering of anti-TNF on the number of serious adverse events and withdrawals due to adverse 
events could not be determined with certainty. This evidence is similar to that for fixed-dose 
reduction. Because disease activity-guided dose tapering provides the opportunity to find the 
lowest effective dose for each individual patient and to discontinue treatment as the final step 
of the tapering process, this may be the most cost-effective and feasible approach in clinical 
practice. Since uncertainty remains on several important outcome measures, more data on, 
for example, radiographic damage progression, function, (serious) adverse events, and costs 
are warranted.
With respect to interpretation, it should be noted that the burden of proof in this case does not 
lie solely with dose reduction or stopping compared with continued use. To our knowledge, 
no controlled data are available on anti-TNF continued use after week 52, including all 
registration studies. Consequently, there remains equipoise on what is the best strategy after 
one year of treatment with anti-TNF.
Implications for research
Our review highlights what is already known about anti-TNF down-titration in people with 
low RA disease activity, and on the other hand identifies gaps in our knowledge. Here we 
would like to mention a number of aspects that could be targeted in future studies. Of note, 
most of these points are currently being addressed in several ongoing studies.
• The design selected for studies comparing an anti-TNF down-titration strategy versus an 
anti-TNF continuation strategy should include a non-inferiority approach instead of the 
classical superiority analyses, as the aim is to maintain and not improve clinical outcomes, 
while minimising the amount of treatment that is needed. Superiority analyses can be 
reserved for domains were superiority can be expected, such as drug use, infections, and 
costs. As guidelines for performing a systematic review on non-inferiority studies are 
absent, development of such guidelines would be helpful.
• The intervention should include disease activity-guided dose tapering or stopping of the 
anti-TNF agent using tight control/treat to target instead of fixed-dose adaptation or 
stopping, as the former is more compatible with clinical practice.
• The domain in which an intervention should be non-inferior is long-term RA disease control. 
Although temporary flaring will inevitably be seen more often in the trial-and-error dose-
tapering arm, both the incidence of more severe or prolonged flaring and mean disease 
activity at study end should be comparable.
• Consequently, in addition to mean disease activity at study end, cumulative incidence of 
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a validated RA flare criterion could be used. Use of (one of) validated Outcome Measures 
in Rheumatology Clinical Trials (OMERACT) disease activity score in 28 joints (DAS28)-
based flare criteria should be considered (van der Maas 2013 Flare). Use of a validated flare 
criterion also increases standardisation for future meta-analyses.
• Other outcomes besides disease activity that should be included are cost, quality of life, 
cost-effectiveness, and (long-term) safety, because these constitute the reason why down-
titration is contemplated in the first place.
• The drugs that are studied should preferably also include other anti-TNF agents like 
certolizumab pegol, golimumab, and infliximab.
• Prediction of (un)successful dose tapering would perhaps further improve outcomes of 
individualised disease activity-guided dose tapering, and prediction modelling should be 
considered, using, for example, genetics, imaging, biomarkers, and drug levels. Possible 
gains when using a good prediction rule include (1) prevention of unnecessary flaring in 
patients that cannot be dose reduced; and (2) prevention of months of slow dose tapering in 
patients that can be stopped directly.
• Finally, although outside the scope of this review, efforts should be (and already are) 
directed toward other non-anti-TNF biologicals (abatacept, tocilizumab) and toward other 
inflammatory diseases in which biologicals are used, both within rheumatology (ankylosing 
spondylitis, psoriatic arthritis) and within other medical specialties (gastroenterology, 
dermatology).
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Differences between protocol and review
• We removed the sentence: “The intervention should include the option for a patient to 
restart the anti-TNF agent in case of loss of response.” from Types of interventions. We did 
this because the largest study included in this review did not include the option to restart 
the anti-TNF agent in case of loss of response. It was not always clear for the other included 
studies whether participants could restart the anti-TNF agent. We believe the possibility of 
restarting an anti-TNF agent in case of loss of response is important.
• Different review authors for selecting studies: BJFvdB replaced AAdB in selecting studies, 
abstracting data, and assessing risk of bias. AAdB was the referee. This change was made 
because AAdB had time limitations.
• Switch in primary outcome: We made “Proportion of patients with persistent low disease 
activity” a major outcome and “Proportion of patients with a flare” a minor outcome. We 
switched these outcomes because the two are highly comparable. Most included studies 
used the first outcome.
• Additional types of studies: Both superiority and non-inferiority trials were included. One of 
the studies included in this review was reported to be a non-inferiority study. Also, some of 
the identified ongoing trials were reported to be non-inferiority studies. A non-inferiority 
design is the best study design for a down-titration strategy.
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• Additional types of participants: standard (or lower) anti-TNF dose. We added the “or 
lower dose” because some studies might also include participants who used a lower-than-
standard dose before entering the study.
• Addition to other sources of bias: We added imbalance in prognostic variables as another 
source of bias, as we believe this is an important addition for the ’Risk of bias’ assessment in 
our review.
• The outcome “proportion persistent loss of response, refractory to re-instalment of the 
tapered anti-TNF” was changed to “proportion of participants that switched to another 
biologic due to persistent loss of response, refractory to re-instalment of the tapered anti-
TNF in the intervention group”. We made this change since the definition was not specific 
enough and insufficiently distinct from the other outcome measures.
• For the outcome “proportion participants with persistent low disease activity” we have 
chosen to report the proportion of participants in persistent remission to have more data 
available for this outcome. Since remission is more stringent than low disease activity, we 
might be more sensitive to differences between continuation and down-titration of anti-
TNF.
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Abstract
Objective
To investigate the cost-effectiveness of five different tumour necrosis factor inhibitor tapering 
strategies in patients with rheumatoid arthritis (RA) and stable low disease activity, using a 
modelling design.
Method
Using Markov models based on data from the DRESS and STRASS randomized controlled trials, 
and the Nijmegen RA cohort, five tapering strategies for etanercept and adalimumab were 
tested against continuation: 1, four-step tapering (DRESS strategy); 2, five-step tapering; 
3, tapering without withdrawal; 4, use of a stricter flare criterion; and 5, use of a theoretical 
predictor for successful tapering. We also examined how well a biomarker should be able to 
predict in order for strategy 5 to become cost-effective compared to the other strategies.
Results
All examined tapering strategies were cost saving (range: EUR 5128 to 7873) but yielded more 
short-lived flares compared to continuation. The change in utilities compared to continuation 
was minimal and not clinically relevant (range: −0.005 to 0.007 quality-adjusted life-years). 
Strategy 1 was cost-effective compared to all other strategies [highest incremental net 
monetary benefit (iNMB)]. However, there was a large overlap in credible intervals, especially 
between strategies 1 and 2. Scenario analyses showed that 50% reduction of drug prices would 
result in the highest iNMB for strategy 2. A biomarker only becomes cost-effective when it is 
inexpensive and has a sensitivity and specificity of at least 84%.
Conclusion
Because our study showed a comparable iNMB for tapering in four or five steps (including 
discontinuation), we recommend a choice between these strategies, based on shared decision 
making.
Introduction
Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the 
treatment of rheumatoid arthritis (RA) and their use is mostly safe and effective.1 However, 
these drugs are also associated with rare side-effects, high costs, and burden for patients (e.g. 
injecting themselves or visiting the hospital for an infusion).2-4 Because of these downsides, 
many studies have investigated the possibility of dose reduction in cases patients have reached 
low disease activity or remission.5,6 Current evidence on bDMARD dose reduction shows that 
direct discontinuation of the drug is inferior to continuation, but that fixed dose reduction or 
disease activity-guided tapering is safe and effective for a large proportion of patients.7,8 The 
principle of bDMARD dose reduction has thus been incorporated in international guidelines 
for RA treatment.9,10 They recommend: ‘If a patient is in persistent remission after having 
tapered glucocorticoids, one can consider tapering bDMARDs’10 and ‘If done, tapering must be 
conducted slowly and carefully, watching for increased disease activity and flares’.9 Other than 
this, the guidelines do not describe a specific strategy for dose reduction in clinical practice
Two large randomized controlled trials have investigated disease activity-guided tapering 
of etanercept and adalimumab: Dose REduction Strategy of Subcutaneous TNF inhibitors 
(DRESS) and the Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS).11,12 
In these trials, the interval of injections was increased stepwise until stopping. When a 
patient experienced a flare, the dose was increased again to the previous effective dose. The 
DRESS study, in which four tapering steps were used, showed that tapering was non-inferior 
regarding major flares compared to continuation. Since there was no relevant loss in quality-
adjusted life-years (QALYs) and a large cost saving was observed, the tapering strategy was 
found to be cost-effective.13 The STRASS, with five tapering steps, showed a higher risk of 
major flare in the tapering group but without affecting structural damage progression.11 In the 
STRASS, there was a loss of QALYs in the tapering group, and the savings due to tapering were 
lower than in the DRESS study, which makes the probability of cost-effectiveness dependent 
on the willingness to accept (WTA) QALY loss.14
Several suggestions have been made to optimize the dose-reduction strategy. These include 
a tapering protocol with more tapering steps, maintaining the medication at a low dose (i.e. 
no complete withdrawal)15, and the use of a stricter flare criterion16, mainly to reduce the 
chance of flaring and to make the strategy more acceptable for rheumatologists and patients. 
However, these adaptations may not be as effective as expected, and can be accompanied 
by less cost reduction and probably a negative effect on the cost-effectiveness. Finally, many 
studies have focused on finding a biomarker for successful dose reduction.17 An important 
question is whether addition of a biomarker would improve the outcomes of a trial-and-error 
tapering strategy, and how well a biomarker should be able to predict in order to make a model 
with guidance of a biomarker cost-effective. 
Considering these questions from clinical practice, the objective of this study is to investigate 
the cost-effectiveness and flare risk of several tapering strategies for the tumour necrosis 
factor (TNF) inhibitors adalimumab and etanercept in patients with RA and stable low disease 
activity.
Cost-effectiveness of tapering strategies
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Method
Modelling design
Since it is not feasible to investigate the different optimization scenarios in new trials 
and because there is already a considerable amount of data available, we decided to use a 
modelling design based on available trial and cohort data. Markov modelling was considered 
the most suitable approach, since this type of model fits well with a chronic disease, the 
different states of the disease, the repetition of treatment, and probabilities that change over 
time.18,19
First, the continuation and tapering arm of the DRESS study were modelled, and validated with 
the outcomes of the DRESS study (Figure 1). Outcomes that were assessed for the validation of 
the model were the proportions of patients in each outcome group (withdrawal, reduction, 
no reduction possible), the number of short-lived flares, mean costs, and QALYs. The DRESS 
tapering model was adjusted in four ways to answer our research questions (Figure 1). All the 
Markov models were built in Microsoft Excel 2010.
The following strategies were tested (Figure 1):
0. DRESS continuation: The DRESS continuation arm was modelled and used as a comparator.
1. DRESS tapering (four-step tapering): The four dosage steps in the DRESS study were 100%, 
67%, 50%, and 0% of the dose regimen of adalimumab or etanercept. Flare was defined as 
an increase in Disease Activity Score based on 28-joint count–erythrocyte sedimentation 
rate (DAS28-ESR) score of more than 1.2, or an increase of more than 0.6 compared with 
baseline scores, with a current score of at least 3.2.16
2. Five-step tapering: An extra tapering step of 33% of the normal dosage was added [see 
STRASS strategy11].
3. No withdrawal: Tapering without the final step of complete withdrawal.
4. Stricter flare criterion: The implementation of a stricter criterion for flare, and thus for the 
decision to increase the dosage again (current DAS28 > 2.6).16
5. Predictor: The implementation of a theoretical predictor (EUR 100 per test) which is 80% 
specific and 80% sensitive for the lowest dose that patients can reach (dosing patients 
directly, according to the predictive dose).
 
Figure 1. Modelling design
DRESS, Dose REduction Strategy of Subcutaneous TNF inhibitors; DAS28-ESR, Disease Activity Score based 
on 28-joint count–erythrocyte sedimentation rate.
Structure of the models
Figure 2 shows the structure of the Markov models. A cohort of RA patients (n was set on 120 
to facilitate comparison with DRESS trial data) with stable low disease activity (DAS28 ≤ 3.2) 
moves between health states according to a set of transition probabilities. All patients enter 
the model with a 100% dosage of adalimumab or etanercept. The time horizon equals the 18 
months duration of the DRESS and STRASS trials and a cycle length of 3 months was chosen, 
in accordance with the frequency of visits in the trials. Every cycle, patients have a chance to 
develop a flare of disease activity or not. Flare or no flare are the two possible health states in 
each dosage step. Average costs and effects, calculated from the DRESS, are assigned to those 
health states. These values are different for strategy 4, since a stricter flare criterion is used.
Transition between different health states is driven by patients’ response to treatment. When 
a flare occurs, patients go to a higher dose or remain in the same dose and when no flare occurs, 
patients go to a lower dose or remain in the same dose. Furthermore, in all dosages, patients 
can go back to the standard dose without the occurrence of a flare. Since we based the model 
on clinical data, not all these transitions fit within the ideal DRESS tapering strategy. Only one 
attempt at dose reduction was possible for each patient and in case of persistent flare, despite 
reintensification of the medication to 100%, patients switch to another bDMARD. 
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Figure 2. Structure of the Markov models. Strategy 1 (four-step tapering) is shown as an example.
Input parameters
Transition probabilities were different for all strategies and were calculated using the number 
of patients in each health state from both DRESS and STRASS data. Small differences between 
the populations (Supplementary file S1) were accepted, since no predictors have yet been 
identified for successful dose reduction.17 The probabilities for strategy 1 were based on the 
DRESS data, for strategies 2 and 3 on data from both DRESS and STRASS (STRASS data were 
used for dosing steps 33% and 0%), and for strategy 4, the probabilities from the DRESS 
data were adjusted based on an increase in the chance of flare by 20%, which would be the 
consequence of a stricter flare criterion in the DRESS data. For strategy 5, it was assumed that 
80% of the patients could be set directly on their optimal dose, corresponding to the outcome 
in the DRESS strategy (true positives and true negatives). Twenty per cent of the patients who 
were able to taper stayed on the 100% dosage (false negatives) and 20% of the patients who 
were predicted to be able to taper failed (false positives). It was assumed that even in this 
population flare could still occur because of the disease course of RA, and this percentage was 
extracted from the Nijmegen Inception Cohort of Early RA.20 All transition probabilities were 
split into flare or no flare and change of dosage or not. Since patients could always return to the 
standard dose (without the occurrence of flare), sometimes three transition probabilities were 
possible (Figure 2). A Dirichlet normalization was applied to the beta distributions belonging 
to these probabilities in order to prevent a sum which is not exactly one. All parameters that 
were used in the models are reported in Supplementary file S2 (not included in this thesis). 
Effects are expressed as health-related quality of life (HRQoL) and the number of short-lived 
flares. Short-lived flares were counted for each strategy since these showed the biggest 
difference in the DRESS study between the dose reduction and the continuation group, and 
therefore seem to be the most sensitive measure for differences between strategies. Utilities, 
as a value assigned to HRQoL, were based on the 5-level EuroQol 5 Dimensions (EQ-5D-5L) 
answers in the DRESS study and were calculated using the Dutch tariff for the EQ-5D-5L.21 
With these utilities, QALYs were calculated by multiplying utility and duration. 
Costs were calculated from a societal perspective using the DRESS trial data.22 With the 
help of the Dutch Guideline for Costs Analyses23 and the Dutch national tariff list4, the direct 
costs of medication, RA-related consultations and travelling costs, and the indirect costs of 
RA-related absence from work [measured by questionnaire and valuated by the friction cost 
method (3 month friction period)] were obtained from the DRESS.13 All prices were converted 
to 2016 using the general Dutch price index rate and are expressed in euros (EUR). Both costs 
and effects were discounted to correct for the fact that people generally value future costs 
and effects lower than current costs and effects and their value diminishes the farther in the 
future they occur.24 Constant discount rates were used according to the Dutch guideline, i.e. 
4% and effects 1.5% per year.23 The costs of using a biomarker (e.g. personnel and laboratory 
costs) in strategy 5 were arbitrarily chosen at EUR 100 per patient through expert opinion.
Analyses
A probabilistic sensitivity analysis was conducted by drawing at random from the assigned 
beta and gamma distributions, using Monte Carlo simulation with 5000 iterations. Based 
on these simulations, mean values and 2.5th and 97.5th percentiles (95% credible intervals) 
surrounding the mean values of the outcomes were calculated. 
To compare the strategies, the incremental net monetary benefit (iNMB) per patient for each 
strategy compared to strategy 0 at a willingness to pay (WTP) threshold of EUR 80 000 was 
given. A WTP of EUR 80 000 per QALY gained is considered as the upper limit that society is 
willing to pay in the Netherlands.25 In strategies that involve QALY loss over strategy 0, WTP 
changed to WTA in euros per QALY lost. The following formula was used: iNMB = WTP (or 
WTA) * Incremental QALYs − Incremental costs. The iNMB was chosen as a parameter over the 
incremental cost-effectiveness ratio (ICER) because this measure facilitated comparison of all 
strategies at the same time and because ICERs are less easy to interpret when differences in 
QALYs are small and around zero. To visualize the incremental costs and QALYs with respect to 
strategy 0, a scatterplot was created. Cost-effectiveness acceptability curves of the strategies 
were produced to show the probability of each strategy for obtaining the highest iNMB 
over a range of WTP/WTA thresholds.26 To anticipate the lower drug costs of the bDMARDs in 
the future, due to the introduction of biosimilars and other market effects on drug pricing, 
scenario analyses with 30% and 50% drug price discounts were also executed. Another 
scenario analysis with no discount rates on either costs or effects was executed to verify the 
robustness of the results.27 Finally, by trying a range of values for sensitivity and specificity, we 
investigated how well a biomarker should be able to predict in order for strategy 5 to become 
cost-effective compared to the other strategies, and how this threshold changes when the 
price of a biomarker is EUR 50 or EUR 0. 
Ethical approval for this study was not requested since we only used the anonymous data 
from completed trials and a trial register. In the Netherlands, this type of research does not 
fall under the scope of the Medical Research Involving Human Subjects Act (WMO).
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Results
Validation of the model
Table 1 shows that the model of the DRESS strategy closely matches the outcomes observed in 
the DRESS trial, when looking at the 95% confidence intervals (CIs) and 95% credible intervals. 
The differences in costs and QALYs were accepted since not the absolute values but only the 
differences between the tapering strategies were of interest. The validation status of the 
model according to the Assessment of the Validation Status of Health-Economic decision 
models (AdViSHE) is described in Supplementary file S3.28 
Table 1. Validation of the Dose REduction Strategy of Subcutaneous TNF inhibitors (DRESS) model
Outcome Observed11,12 (95% CI) Modelled (95% credible 
interval)
Continuation Tapering Continuation Tapering
% of patients 
Withdrawal
Reduction
No reduction
-
-
-
20 (13-28)
43 (34-53)
37 (28-46)
-
-
-
19 (12-27)
45 (36-53)
36 (28-45)
Number of short-lived flares 52 128 53 (35-73) 116 (100-134)
Mean costs of the strategy 
in (EUR)*
21 256 
(20 369-22 066)
12 222
(11 291-13 155)
21 612
(21 126-21 939)
13 493
(12 722-14 285)
Mean QALYs* 1.26 (1.22-1.29) 1.23 (1.20-1.26) 1.20 (1.18-1.22) 1.19 (1.18-1.21)
*Comparison of the non-discounted values. 
CI: confidence interval; QALY: quality adjusted life years.
Base-case analysis 
Table 2 shows the main outcomes for all strategies. All tapering strategies were found to be 
cost-saving compared to continuation (savings between EUR 5128 and EUR 7873). The change 
in QALYs ranged from −0.005 to 0.007 and the credible intervals had a large overlap. Strategies 
4 and 5 seem to result in a QALY gain compared to continuation. However, this is accompanied 
by clearly smaller cost savings. All strategies yielded more short-lived flares compared to 
continuation. Strategy 1, with the highest iNMB, is cost-effective compared to all other 
strategies, but is comparable to strategy 2 in terms of cost-effectiveness owing to the large 
overlap between their credible intervals (Table 2). 
Figure 3 shows that virtually all data points from the strategies lie around the y-axis, denoting 
that differences in QALYs compared to continuation are close to zero. However, a trend is 
visible from strategy 1 to 5, with an increasing number of data points upwards in the right 
quadrant, which indicates that a small improvement in QALYs is more likely, but with much 
lower savings.
 
The whole range of WTP/WTA thresholds shows that the certainty of strategy 1 being the most 
cost-effective strategy decreases as the threshold of WTP/WTA increases (Figure 4). Strategy 2 
has an increasing probability of obtaining the highest iNMB. The probability of strategies 3, 4, 
and 5 reaching the highest iNMB is lower than the probability of both strategies 1 and 2 across 
the entire range of WTP/WTA to a maximum of EUR 80 000.
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Figure 3. Incremental costs and quality-adjusted life-years (QALYs) with respect to continuation 
(strategy 0).
Figure 4. Cost-effectiveness acceptability curves of the strategies. 
The graph shows the probability of the different tapering strategies obtaining the highest incremental 
net monetary benefit (iNMB) (compared to continuation) over a range of willingness to pay/willingness to 
accept (WTP/WTA) from EUR 0 to EUR 80 000. 
Scenario analyses
Having no discount rates on costs and effects hardly affects the results. Scenario analyses 
with 30% lower bDMARD prices show that the iNMB of strategy 1 remains the highest within 
this range of WTP/WTA. Lowering the bDMARD prices by 50% results in the highest iNMB for 
strategy 2 from a WTP/WTA threshold of EUR 63 000. A model with a biomarker of EUR 100 
(strategy 5) becomes cost-effective compared to the other strategies at a sensitivity and 
specificity of 85.2% or higher from a WTP/WTA threshold of EUR 80 000. When lowering the 
price of the biomarker, we found that this threshold moves to 84.6% (EUR 50 per test) and 84% 
(free test) (Supplementary file S4).
Discussion
This Markov modelling study showed that, as expected, all dose-reduction strategies 
dominated continuation regarding cost-effectiveness but resulted in more short-lived flares. 
When comparing the different tapering strategies, tapering in four steps (DRESS strategy) 
showed the highest iNMB at a WTP up to EUR 80 000. A strategy with five tapering steps 
(including the 33% dosage) showed a comparable cost-effectiveness. With the other three 
strategies (no withdrawal, use of a stricter flare criterion, and use of a predictor), a minimal 
gain in QALYs was seen at the expense of much smaller cost savings. This shows that there 
is little room for improvement. The differences in QALYs between the strategies may be not 
clinically meaningful since a relevant difference over a period of 1.5 years would lie around 
0.075.29,30 Scenario analyses showed that a 50% reduction in bDMARD costs would result in 
the five-step strategy being the most cost-effective and that a predictor would only have 
an added value, in terms of costs-effectiveness, when the test is inexpensive and is able to 
predict with a sensitivity and specificity of at least 84%. Our finding that four-step tapering is 
more cost-effective than five-step tapering is consistent with the cost analyses of the DRESS 
and STRASS trials.13,14 However, the STRASS trial showed a larger loss in QALYs, which does not 
match our results. This is probably caused by the fact that STRASS data were only used for 
the last two dose-reduction steps and that tapering was attempted multiple times for some 
STRASS patients, which may have caused lower QALYs in these patients. In this study, we 
did not model direct bDMARD discontinuation without tapering since this was shown to be 
inferior to continuation regarding disease activity, function, quality of life, and radiographic 
damage.5,7 In the long run, a discontinuation strategy (including reinstating therapy in case 
of flare) would probably not be cost-effective compared to tapering since this strategy would 
only identify those patients who are able to stop their treatment and not patients who are 
able to taper treatment. 
Tapering of bDMARDs is already recommended care for RA patients who have reached low 
disease activity or remission. However, the guidelines are not specific on which strategy should 
be used.9,10 Furthermore, the use of lower than registered doses of TNF inhibitors in clinical 
practice is limited.31 This study found that four- and five-step tapering is comparable regarding 
cost-effectiveness. Since five-step tapering seems to result in a slightly reduced chance of 
short-lived flare (without a clinically relevant impact on quality of life), the choice between 
these two might best be based on shared decision making between rheumatologist and 
patient. Since a strategy without a withdrawal attempt is more expensive and does not lead 
to clear improvements in QALYs or reduced chance of flare, this is not a recommendable option 
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in clinical practice. The use of a stricter flare criterion (DAS > 2.6) is not cost-effective compared 
to the other strategies as it seems too sensitive and results in much less tapering with almost 
no effect on quality of life. The finding that a predictor would need to be inexpensive and at 
least 84% sensitive and specific to be cost-effective is interesting in the light of many studies 
trying to find such a predictor in this specific context.17 It is sobering to note that currently 
no predictor comes close to such test characteristics, and looking at biomedical research in 
general, it is questionable whether any biomarker will ever reach these predictive thresholds.
This is the first modelling study on the optimal treatment strategy for disease activity-guided 
dose reduction of TNF inhibitors in RA. Strengths of this approach are the face validity of 
the conceptual model, input data and outcomes by clinical experts and external validity by 
modelling experts (Supplementary file S3).26-28 Also, the input of data from two pragmatic 
clinical trials and a cohort ensured that the model is customized to real clinical practice, which 
sometimes also includes suboptimal protocol adherence. A limitation of this study is the time-
horizon of 18 months. We decided not to model beyond 18 months because, first, this would 
introduce a lot of uncertainty into the model, since we did not have data to calculate long-
term transition probabilities; and, secondly, the differences between tapering strategies are 
mainly visible in the tapering phase, and less so in the maintenance phase. A longer duration 
of the model may benefit five-step tapering because patients can stay on the 33% dosage 
instead of having to return to 50%, and the strategy with a predictor because lost savings (due 
to fewer patients trying tapering) can be spread over a longer time weighted against the longer 
benefits of correct prediction. The reverse is true for the strategy without withdrawal, because 
some patients who are able to discontinue will continue low-dose use. Furthermore, some 
important domains such as radiographic outcomes and adverse effects were not included 
in this study. Lastly, our results may not be generalizable to settings in which medication 
costs, travelling distances, and WTP/WTA thresholds are not comparable. However, scenario 
analyses showed that a 30% price reduction would not change the results, and it is unlikely 
that travelling costs would outweigh the large cost savings due to tapering. In this study, we 
used a WTA threshold of EUR 80 000 based on the upper limit of WTP in the Netherlands for 
situations with maximum disease burden. As a reference, one can compare this with the WTP 
that is commonly used in Britain, which is GBP 30 000 (EUR 34 590). A lower WTA/WTP would 
in general benefit the more rigorous tapering strategies. Extreme cost reductions of >50% 
(conceivable with biosimilars) would result in the opposite effect.
Conclusion
This study showed the highest iNMB for disease activity-guided tapering in four or five steps 
(including the final step of discontinuation). Therefore, we recommend a choice between 
these two strategies based on shared decision making.
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Supporting information
Supplementary file S1. Baseline patient characteristics of data included from both DRESS and STRASS
Patient characteristics DRESS STRASS
Age 59 (10.0) 54.3 (10.7)
Female sex* 74 (62) 53 (83)
Disease duration (years) 12.0 (12.2) 8.3 (5.4)
DAS28-ESR score 2.5 (0.6) 1.9 (0.6)
Treatment (etanercept/adalimumab)* 78/42 (65/35) 35/29 (55/45)
Data are mean (standard deviation) unless stated otherwise.
*Number (%) of patients
Supplementary file S2 and S3.
Not included in this thesis. Available online.
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Supplementary file S4. Scenario analyses
30% lower TNFi prices
No discounting
50% lower TNFi prices
Highest iNMB of strategy 5 with €100 predictor at a 
85.2% specificity and sensitivity
Highest iNMB of strategy 5 with €50 predictor at 84.6% 
specificity and sensitivity
Highest iNMB of strategy 5 with €0 predictor at 84% 
specificity and sensitivity
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Abstract
Background
A standard low-dosing schedule of rituximab (RTX; 2 × 500 mg or 1 × 1000 mg) is as effective 
for active rheumatoid arthritis (RA) as the registered dose (2 × 1000 mg). Moreover, several 
small uncontrolled studies suggest that even lower-dosed treatment with RTX also leads to 
good treatment response in patients with RA. Retreatment with such an ‘ultra-low’ dose RTX 
in patients who responded well to RTX induction treatment is of special interest, as long-term 
use of lower RTX doses may lead to shorter infusion duration, lower risk of adverse events and 
lower costs. However, the effect of ultra-low dose of RTX has not been investigated using a 
controlled trial of proper design and dimensions.
Methods/Design
REDO is an investigator driven six-month pragmatic, double-blind, randomised controlled 
non-inferiority trial on the effects of ultra-low-dose RTX (1 × 500 or 1 × 200 mg) compared 
to standard low dose (1 × 1000 mg) in RA patients who are being retreated with RTX. A total 
of 140 RA patients, having reached low disease activity (DAS28CRP < 2.9) after the previous 
RTX infusion and DAS28CRP < 3.5 at moment of retreatment, are randomised in a ratio of 1:2:2 
to 1 × 1000 mg, 1 × 500 mg or 1 × 200 mg. The primary objective is testing non-inferiority of 
the ultralow-dose vs. standard low-dose RTX, by comparing mean change in DAS28CRP from 
baseline to six months to the non-inferiority margin of 0.6. Secondary outcomes over the 
same period are: function; quality of life; safety; costs; and pharmacokinetics and dynamics 
as process measures.
Discussion
This study protocol shares characteristics of both early dose finding trials as well as late 
pragmatic clinical studies. Several choices in the design of this trial are described and possible 
consequences for RA treatment and expected biosimilar introduction are discussed.
Trial registration
Dutch Trial Register, NTR6117. Registered on 15 November 2016 (CMO NL57520.091.16, 8 
November 2016)
Keywords
Rheumatoid arthritis, Dose reduction, Rituximab, Low dose, Retreatment, Randomised 
controlled trial, Non-inferiority, Design, Decremental cost-effectiveness ratio (DCER)
Background
Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody authorised for use in patients 
with severe active rheumatoid arthritis (RA) in combination with methotrexate (MTX) when 
patients have an inadequate response or intolerance to other disease-modifying antirheumatic 
drugs (DMARDs), including one or more tumour necrosis factor inhibitors (TNFi). Two large 
systematic reviews confirmed the effectiveness of RTX in patients with RA in combination 
with MTX compared to MTX alone.1,2 In addition, long-term safety has been confirmed up to 11 
years, with infection risk comparable to other biological DMARDS (bDMARDs).3,4
The dose-finding phase of RTX has some interesting aspects. Since RTX was originally developed 
as a treatment for non-Hodgkin’s lymphoma, its optimal dose was initially determined for 
that indication.5 The first two studies of RTX in RA indeed used treatment protocols based on 
experience in the treatment of lymphoma.6,7 Both studies were open-label and consisted of a 
limited number of patients. It was reasoned that RA could be seen as a low-grade lymphoma 
of synovial tissue, caused by an oligoclonal (instead of monoclonal) proliferation of B cells 
exhibiting malignant behaviour by destroying local tissues. Using this comparison, patients 
were treated with a single remission-induction treatment course, identical to that for non-
Hodgkin’s lymphoma, combining four weekly RTX infusions of 750 mg/m2 with prednisone 
and cyclophosphamide. The treatment goal was to achieve disease remission by eradication 
of pathogenic B cells. Only adriamycin was omitted as co-medication to decrease the chance 
on treatment-related side toxicity. These two open-label case series showed that a single 
RTX-based treatment course could induce disease remission in a proportion of patients with 
RA. Although no formal dose-finding efforts were done, Leandro et al. concluded in their 
uncontrolled study of 22 RA patients that doses below 600 mg/m2 were less effective, but 
this conclusion was based on only four patients. The first randomised controlled trial (RCT) to 
examine the efficacy of RTX in RA patients aimed at obtaining a treatment regimen without 
cyclophosphamide instead of dose-finding and used a simplified RTX dosing regimen of 1000 
mg on treatment days 1 and 15.8 This dose is now the registered dose for treatment of RA 
patients.
Thereafter, dosing schedules of 2 × 500 mg and 1 × 1000 mg have been tested in several phase-
three and phase-four studies; a recent large systematic review showed that these were non-
inferior to regular-dose RTX. Therefore, the current recommended RTX doses are 2 × 500 mg 
or 1 × 1000 mg (standard low-dose RTX) at least every six months. The second infusion is 
commonly given with an interval of two weeks (e.g. for 2 × 1000 mg).9 Although there have 
been no high-quality strategy studies to establish what is the best retreatment strategy, either 
fixed six-month interval retreatment or disease activity guided treat-to-target retreatment 
seem the optimal strategy.
However, even lower doses of RTX may be effective for treatment of RA. In three case studies, 
ultra-low doses of RTX (1 × 50 to 2 × 100 mg) were surprisingly associated with deep peripheral 
B-cell depletion and, in general, adequate RA disease control.10-12 Adding to these observations, 
a recent small, prospective open label study in 14 RA patients showed that a single dose of 100 
mg RTX led to peripheral B-cell depletion in 11 patients (79%) after two weeks.13 In that study, 
mean (± SEM) DAS28 score of all patients decreased from 6.2 ± 0.8 at baseline to 2.9 ± 0.8 at 24 
weeks after infusion, although two patients needed additional RTX treatment. 
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The use of ultra-low-dose RTX for retreatment could especially be effective. First, B-cell 
depletion by RTX can persist during the entire interval between infusions.8,14 It was shown that 
that lower baseline B-cell counts were associated with complete B-cell depletion following a 
first 500-mg dose of RTX.15 This suggests that the (partially) persisting B-cell depletion induced 
by an earlier infusion could reduce the dose of RTX needed for retreatment infusions.
A final argument for possible effectiveness of ultralow-dose RTX is the fact that similar 
monoclonal antibodies have been shown to be effective well below the authorised doses for 
RTX. For ocrelizumab and ofatumumab, two humanized anti-CD20 monoclonal antibodies, it 
was concluded that doses of 2 × 200 mg and 2 × 300 mg, respectively, provide optimal B-cell 
depletion as well as the best clinical responses.16 Although these much lower doses compared 
to RTX might also be possible due to higher affinity or cytotoxic efficacy of the drug, it lends 
further credibility to study the efficacy of similar ‘ultra-low’ doses of RTX.
The use of ultra-low RTX could present several advantages over standard low-dose RTX. First, 
infection risk should be lower, as RTX use is associated with a dose-dependent – although 
still low – risk of serious infection.17,18 Also, shorter infusion duration and less administered 
drug could lead to less patient burden and perhaps lower risk for infusion reaction.19 Further, 
RTX treatment currently is relatively expensive, with costs for low-dose 1 × 1000 mg every 
six months being in the range of €4000–7000 per year. Although RTX was proven to be cost-
effective in patients with an inadequate response to TNFi20, use of ultra-low doses will further 
decrease costs and thereby improve cost-effectiveness. A combination of a possible effective 
dose of 200 mg every six months and expected price reductions due to upcoming availability 
of a rituximab biosimilar, could result in a bDMARD option availability for under €1000 per 
patient per year.
The use of an ultra-low dose of RTX might, however, also lead to increased disease activity in 
the subset of patients whose minimal effective RTX dose is 1000 mg. Therefore, prediction of 
response to ultra-low-dose RTX would be key to prevent patients from flaring experiencing 
accelerated joint damage.21 Interesting baseline (at the moment of considering RTX 
retreatment) candidates for predicting the chance of good response on an ultra-low dose 
include higher RTX drug levels, absence of anti-RTX-antibody levels and low peripheral B-cell 
counts, as it might be hypothesised that these are all indicators for lower RTX need.22
In conclusion, although the use of ultra-low doses of RTX seems promising, its effects have 
never been studied in a trial of proper design and size. We therefore aim to perform a RCT to 
study whether retreatment with one of two ultra-low RTX doses (1 × 200 mg or 1 × 500 mg) is 
non-inferior to retreatment with the standard low-dose RTX (1 × 1000 mg) for patients with 
RA who were already successfully treated with standard low-dose RTX. Also, we will analyse 
whether there are differences between retreatment with ultra-low dose and standard low 
dose in the occurrence of serious and non-serious adverse events and cost-effectiveness, 
and we will analyse whether (non-)response to (ultra-)low dose of RTX at six months can be 
predicted at the moment of initiating retreatment.
Methods
Design
The REDO study (REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome 
after Dose Optimisation) is an investigator-driven, pragmatic, double-blind, non-inferiority 
RCT of six months’ duration (Fig. 1, SPIRIT checklist as Additional file 1). The trial is funded 
by two healthcare insurance companies in the Netherlands, Centraal Ziekenfonds (CZ) and 
Menzis, and independent from the manufacturer of RTX (Roche). The study is expected to be 
performed in at least three departments of rheumatology of hospitals in the Netherlands: the 
Sint Maartenskliniek, and Radboud University Medical Centre (Radboudumc) in Nijmegen; 
and Reade in Amsterdam. These centres together have approximately 400 RA patients being 
treated with RTX. Based on an earlier dose-tapering trial and similar inclusion criteria, we 
expect an inclusion percentage of 40%.
Figure 1. SPIRIT figure: trial visits and assessments 
Months
Assessment -1 -0.5 0 0* 3 6 Unplanned visit
Patient information X
Patient informed consent X
Allocation of treatment by stratified 
randomisation
X 
Baseline characteristics (including 
radiographs of hand and feet)
X 
Disease activity X X X X 
Functioning X X X X 
Quality of life X X X X 
Adverse events X X X X X 
Medication use X X X X 
Blood sample X X X X 
Costs (questionnaire on health 
related work absence)
X X X 
0*after infusion of study dose RTX
 
RA patients who are scheduled for RTX retreatment with standard low-dose RTX will be 
randomised into three groups: standard low dose (1 × 1000 mg) or one of the two ultra-low 
dose intervention groups (1 × 500 mg and 1 × 200 mg). Treatment response is assessed at 
three and six months (study end); thereafter, the allocation of patients will be revealed and 
treatment may be continued using any ultra-low or standard low dose of 1 × 1000 mg, at the 
discretion of the physician and patient in shared decision-making.
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This report has been prepared in accordance to the SPIRIT guideline. The final report will follow 
the CONSORT criteria, including its extension to non-inferiority trials. The full study protocol is 
available as supplementary material. There are no publication restrictions and publication of 
the final study results will be performed in peer-reviewed journals as well as to lay press and 
patient organisations.
Important protocol changes will be communicated to the ethics committee and trial register. 
Privacy of patients will be protected according to Dutch law, WBP (‘wet bescherming 
persoonsgegevens’), by using anonymised data and restricting access to patient identification 
logs.
Objectives
The primary objective of the REDO trial is to compare the difference in efficacy between 
two ultra-low doses (1 × 200 mg and 1 × 500 mg) and standard low dose (1 × 1000 mg) of RTX 
retreatment on the change in DAS28CRP, compared to a pre-specified non-inferiority margin 
of 0.6 DAS28 points, at three and six months. Therefore, the study has four primary endpoints. 
Although we are aware that patients are sometimes treated with longer intervals than six 
months, showing non-inferiority at six months is relevant, for ultra-low RTX dose with at least 
six-month intervals is still a lower cumulative dose as standard low-dose 1000 mg every 9–12 
months.
The main secondary objectives are: to assess the difference in efficacy between the two ultra-
low dose interventions for the same outcomes; to compare the proportion of patients with a 
DAS28-CRP < 2.9 (low disease activity), DAS28-CRP < 2.4 (remission) and remission according to 
Boolean ACR/EULAR criteria at three-month and six-month follow-up; to assess the between-
group differences in the change in functioning (HAQ-DI) and quality of life (EQ5D-5 L); and 
to compare proportion (cumulative incidence and incidence density) of patients developing 
(treatment-related) adverse events in each study group over the duration of the study, with 
special attention to infusion-related adverse events and infections. Furthermore, the cost-
effectiveness of both ultra-low RTX doses and the conventional low dose are compared for 
the six-month study period. For prediction modelling, baseline factors (including RF/ACPA 
status, CD19+ B-cell count, serum RTX, serum anti-RTX) will be tested for associations with the 
outcome of DAS28-CRP low disease activity state at six months.
 
Non-inferiority margin
In non-inferiority trials, the choice for a specific non-inferiority margin (NI margin) is critical 
for the interpretability of the study. This choice can be based on prior art (use of NI margin 
in comparable studies), expert opinion or data-driven, based on association with other (un)
intended effects. We have found three non-inferiority studies that have used the DAS28 
as a primary outcome measure. All three studies have chosen to use a NI margin of 0.6.23-25 
Although no clear explanation is given by the authors regarding the rationale for this NI 
margin, a non-inferiority margin of 0.6 points in DAS28 seems a reasonable choice, as the error 
of measurement in DAS28 is 0.6.26 This error of measurement is used in the EULAR response 
criteria to denote the difference between a non-response and a moderate response in DAS28.27 
Regarding assay sensitivity, the mean difference between placebo and RTX, added to MTX, 
in DAS28, is 1.2 according to a recent meta-analysis.1 This means that the NI margin of 0.6 
is sufficiently smaller than the treatment effect of RTX against placebo. We have therefore 
chosen to use this NI margin of 0.6, although it always remains debatable what an acceptable 
small NI margin is. This is especially important to prevent a situation where multiple non-
inferiority studies are performed after each other, each using the non-inferior treatment from 
the last study as a comparator for a new treatment. In this context, although treatment B is 
non-inferior to A, and C is non-inferior to B, treatment C can in fact be inferior to A, the so 
called biocreep.28
Assay sensitivity
Since this is a non-inferiority trial, assay sensitivity – the ability to demonstrate inferiority 
with the chosen trial design – is an important issue. Assay sensitivity could be established 
by a placebo arm showing that not retreating with RTX is inferior to retreating with RTX. 
Considering it has been shown in earlier studies that the mean disease activity of patients 
will increase when not retreated with RTX29, it seems unnecessary and unethical to include a 
placebo arm. Therefore, the comparator is a standard low-dose of RTX, while the group sizes 
should be large enough to gain a sufficient level of precision (see sample size calculation).
Patients
Inclusion criteria for patients in this pragmatic study are as non-restrictive as possible. This is 
based on the underlying principle that the results of this trial should be generalisable to all RA 
patients who are doing well on their RTX treatment. We therefore include RA patients fulfilling 
either 2010 EULAR/ACR RA30 and/or 1987 RA31 criteria and/or having a clinical diagnosis of RA 
according to the treating rheumatologist, at any time point between start of the disease and 
inclusion.
Patients are eligible if they were treated at least once with regular low-dose RTX treatment 
in the last 18 months for RA, so in a dose of 1 × 1000 mg, 2 × 1000 mg or 2 × 500 mg, and had 
received no other bDMARDs after the last RTX dose. Patients treated with innovator RTX 
(MabThera®) as well as authorised RTX biosimilars in similar doses as conventional RTX will 
also be included.
It is somewhat difficult to operationalise the criterion that patients need to be doing well 
enough on RTX because of the variety of retreatment strategies that are used in clinical 
practice. We decided on at least six months of stable, low-disease activity after the last RTX 
infusion (operationalised by either DAS28-CRP < 2.9/ DAS28-ESR < 3.2 or judgement of low-
disease activity by a rheumatologist) and a current DAS28-CRP ≤ 3.5/ DAS28-ESR ≤ 3.8. The 
latter criterion is added, because patients are often not retreated at fixed intervals, but are 
retreated either based on treat-to-target or on demand when disease activity increases. 
However, we do not want to generalise to patients being treated only when they flare severely, 
as it has been shown that the optimal strategy for RTX retreatment (although not completely 
clear yet) is either fixed interval or treat-to-target, but not treated only on demand. Also, a 
high SD in disease activity at study start would increase the required sample size.
Further inclusion criteria are chosen to ensure that we are able to study the participants and 
to measure the outcomes: patient informed consent; age ≥ 18 years and mentally competent; 
life expectancy > 6 months; no planned relocation out of reach of study centre; and able to 
read and communicate well in Dutch.
Ultra-low doses rituximab for retreatment of RAUltra-low doses rituximab for retreatment of RA
5.1 5.1
125124
For generalisability reasons, exclusion criteria are kept minimal and only exclude patients 
with known (non-)response to ultra-low-dose RTX (below 1 × 1000 mg), to prevent selection 
bias, and current corticosteroid dosing above 10 mg per day prednisolone equivalent, because 
these patients should preferably first taper their corticosteroid.
Patient recruitment
All eligible patients will be selected and approached based on information from the electronic 
health record according to the abovementioned inclusion and exclusion criteria. Patients will 
be asked to join this study by their treating rheumatologist using a letter accompanied with 
the patient information (including the informed consent form). Informed consent is obtained 
before patients receive the study medication and baseline data are collected.
 
Randomisation and blinding
Participants will be allocated to the treatment groups at a ratio of 1:2:2 (1 × 1000 mg vs. 1 × 
500 mg vs. 1 × 200 mg). The experimental groups are larger than the control group to increase 
experience with the lower dosing and with the additional benefit that a larger number of 
potential predictive factors for response can be studies in multivariate prediction modelling 
in the ultra-low dose RTX groups.
Randomisation will be performed using a computerised randomisation procedure and 
stratified to ensure equal distributions of two possible effect modifiers for response to ultra-
low-dose RTX, concomitant conventional DMARD use and RF/ACPA status. Patients will be 
randomised using block randomisation in variable block sizes (multiples of 5) to more closely 
achieve the intended allocation ratio and to ensure that the allocation of participants will 
not be predictable. Patients, physicians, nurses, researchers and data analyst/statistician will 
be blinded for treatment allocation. The allocation is kept in opaque, sequentially numbered 
envelopes; envelopes are sequentially assigned by the pharmacist to each next patient. The 
infusions for the study will be prepared by the hospital pharmacy based on the randomisation 
number, the physical appearance of the three interventions will be indiscriminate (see below). 
Unblinding is expected to be rarely necessary (all patients receive RTX and retreatment with 
1000 mg is allowed when necessary), but is possible after consulting the coordinating centres 
pharmacist.
Interventions
Patients allocated to the standard low-dose group will receive a (blinded) single 1000 mg 
RTX infusion according to the standard protocol for infusion of rituximab. Patients allocated 
to the ultra-low-dose groups will receive 500 mg or 200 mg. This dose will be diluted to 
the same volume as the standard low-dose infusion to ensure the blinding of the study, all 
premedication and procedures are identical to the standard low dose. Of note, the possible 
advantage of shorter infusion times cannot be assessed in our study, because this would lead 
to patients and healthcare providers being unblinded.
It is aimed to leave all other rheumatic treatment unaltered as much as possible during 
the study period. However, all treatment decisions are left to the discretion of the treating 
physician and (changes in) use of paracetamol (acetaminophen), tramadol, non-steroidal 
anti-inflammatory drugs (NSAIDs), oral corticosteroids and DMARDs are all allowed during 
this study to ensure good care. During each visit, patients are asked about the use of these 
medications. Suggested treatment in case of clear loss of response is escape treatment with an 
extra dose of 1 × 1000 mg RTX. This can be done without unblinding, since the authorised dose 
of RTX is 2 × 1000 mg per six months and no patients will exceed this dose as the maximum 
study dose is 1 × 1000 mg.
We have determined several medication changes that are defined as ‘treatment failure’. These 
changes are: receiving an extra dose of RTX within the six-month study period; receiving 
another bDMARD (thus switching to another type of bDMARD); and using corticosteroids in a 
dose > 10 mg/day. Starting a concomitant conventional synthetic (cs)DMARD during the study 
period is not considered a treatment failure. The reasoning behind this is that all included 
patients will have received these csDMARDs before, with little effect on their RA, and the 
concomitant csDMARD is generally given as an adjuvant to increase the effectiveness of RTX.
In case of treatment failure, the patients will remain in the study, but the last measure of 
disease activity and other outcomes will be used as outcome employing a ‘last observation 
carried forward’ strategy.
Assessments
At baseline, several characteristics of the patients will be measured, including demographics, 
disease and treatment characteristics. Also, possible predictors for response to ultra-low-dose 
RTX from peripheral blood will be collected, including (anti-)RTX drug levels and peripheral 
CD19 counts. Thereafter, visits will be performed at three and six months and when necessary 
in between (Fig. 1).
Several measures on disease activity will be collected during the study. The DAS28-CRP is a 
validated and widely accepted measure for RA disease activity and will be used as a primary 
outcome measure. It consists of four components: 28 tender joint count; 28 swollen joint 
count; CRP (mg/L); and patients VAS assessment of global disease activity (0–100).26 Remission 
is defined as DAS28-CRP < 2.4 and low disease activity by DAS28CRP < 2.9.32 In addition, patient 
VAS assessment of pain, rheumatologist VAS assessment of global disease activity, acute 
phase reactants (CRP and ESR) and the OMERACT patient flare questionnaire are collected. 
To measure functioning of patients, the HAQ-DI, a validated instrument that is widely used 
in rheumatology is applied.33 Quality of life is assessed using EQ5D-5 L, which is a validated 
instrument and comprises five questions and a visual analogue self-rating scale.34
Adverse events are assessed at every visit during the study period and classified according to 
the Common Toxicity Criteria (CTC).35 In addition, we focus explicitly on infusion reactions and 
infectious events. Patients are asked to complete a short questionnaire after the RTX infusion 
on the occurrence of infusion-related adverse events. Medication use is charted using data 
from the electronic patient records on the use of DMARDs, corticosteroids and NSAIDs.
Costs will be calculated from a societal perspective. We will include the cost of outpatients’ 
clinic visits and telephone consultations, travel expenses for patients, costs of hospitalisation 
due to RA, costs due to health-related work absence and costs of medication during the six-
month study period.
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Sample size considerations and statistical analyses
The study has four primary endpoints; multiplicity over the primary endpoints will be 
protected by a fixed testing procedure. First, the non-inferiority of the 500 mg vs. 1000 mg 
at three months will be tested at p < 0.05 (two-sided). If this is statistically significant, then 
500 mg vs. 1000 mg will be tested at p < 0.05 (two-sided) at six months. If that is statistically 
significant, then 200 mg vs. 1000 mg will be tested at p < 0.05 (two-sided) at three months 
and if that is statistically significant, the last test will be 200 mg vs. 1000 mg at p < 0.05 (two-
sided) at six months. As we have four primary endpoints, we aim to have enough power for 
each at 95% for an NI margin of δ = 0.6. Under the worst-case scenario that these four are 
not correlated (the expectation is that they are positively correlated, see Table 1) and that 
the intervention is indeed non-inferior to the control condition, then the overall power for 
rejecting the null hypothesis of inferiority on all four is at least 95% × 95% × 95% × 95% = 
81%. We calculated the sample size for one endpoint (e.g. the comparison of 500 vs. 1000 mg 
at six months). For 2:1 randomisation and a non-inferiority test assuming the true difference 
between treatments is 0, the total sample size for a t-test having a power 1-β when testing at 
significance level α (two-sided) and a non-inferiority margin δ is Ntot = (4.5)2 × (z1-α/2 + z1-β)
2 × 
SD2/δ2, where z denotes the normal quantiles which are correct for non-small sample sizes. 
When correction for baseline is incorporated, this sample size is reduced by (1-r2) where r is the 
correlation in DAS28 between baseline and follow up (formula 7 with n = 1, π0 = 1/3, π1 = 2/3, 
and section 2.3 of Teerenstra S, et al.36). Note that the two groups then have sizes Ntot/3 and 2 
× Ntot/3. To determine the correlation r between baseline and follow-up measurement of the 
DAS28, the following assumptions were used. Baseline DAS28 has a SD = 0.7 and the change 
from baseline to three (or six months) has a standard deviation of SDchange = 0.6 based on 
data from an earlier dose reduction trial.37 As SD2change = 2× (1-r2)× SD2, it follows that r = 0.63. 
Then a total trial size of 80 participants would be enough. Table 1 illustrates the total trial size 
when the correlation between endpoints is smaller than anticipated.
 
To protect for a too optimistic correlation, we therefore choose a total trial size of 130 and this 
is further increased to 140 patients to account for patient drop-out.
Table 1. Total trial sample size at various correlations between endpoints
SD change r Sample size 
1000mg arm
Total trial size (5 x sample size
in 1000 mg arm)
0.9 0.17 26 130
0.8 0.35 24 120
0.7 0.5 20 100
0.6 0.63 16 80
Primary analyses will be done per protocol (PP), as this is the most conservative approach for 
a non-inferiority study. In addition, analyses will be performed on an intention-to-treat basis 
(ITT). For PP analysis, we will include patients who have received the study medication and 
completed follow-up of six months or until treatment failure (and last observation of disease 
activity carried forward).
 
The primary endpoints will be tested using 95% confidence intervals based on linear regression 
with the change in DAS28-CRP as outcome, dose group as determinant and baseline values of 
DAS28-CRP as covariate (ANCOVA). 
To find predictors (including age, sex, disease duration, RF/ACPA status, CD19+ B-cell count, 
serum RTX, serum anti-RTX), patients will be categorised into responders (DAS28-CRP < 2.9 at 
six months and no treatment failure) and non-responders (all other patients). The absolute 
number (and thus also proportion) of responders will determine the number of predictors 
that is admissible for analysis, according to the rule of ten-events-per-variable given that 
predictors are predetermined. Univariate logistic regression analysis will be performed for 
the admissible predictive factors, with a deliberately liberal p < 0.20 as selection criterion. 
Univariately significant variables are entered in a full multivariate logistic regression model, 
that is step-wise reduced until all p < 0.20. Internal validation and shrinkage will be performed 
using a bootstrapping procedure with 1000 repetitions. Performance of the multivariate 
predictive model will be evaluated using discrimination (area under the receiver operator 
curve) and calibration (calibration slope, calibration plot and Hosmer-Lemeshow test). 
Costs will be calculated and quality-adjusted life-years (QALY) will be based on EuroQol-
EQ5D-5L utility scores. Decremental cost-effectiveness analyses (CEA) will be performed using 
bootstrap analyses; incremental net monetary benefit (iNMB) will be used to express cost-
effectiveness at different willingness-to-pay (WTP) values in the range of €20,000–80,000 per 
QALY.
Discussion
This study in summary is aimed at exploring the lower bound of effective RTX doses in RA, 
as there seems at least equipoise on whether ultra-low-dose RTX is effective in RA. The 
development of the current study protocol has some interesting aspects that should be 
discussed.
Because proper phase I/II dose-finding has not been done in RA for RTX in the development 
phase, and because RTX is already widely used in RA treatment, our study design shares some 
characteristics of both early dose-finding trials (small-/medium-sized blinded trial, medium 
follow-up, multiple dosing arms), as well as late pragmatic clinical studies (non-inferiority 
design, wide inclusion criteria, investigator driven, treat-to-target strategy, embedded in 
clinical practice, cost-effectiveness analyses). The lack of proper dose-finding may be caused 
by the fact that RTX was first developed for use in lymphoma. This means that the upper limit of 
toxicity was already known. Also, there was presumably less incentive for the pharmaceutical 
company to actively look for (much) lower effective RA dosing, as very different dosing 
schedules for between different diseases presents a problem when establishing drug prices. 
RTX was therefore eventually authorised in the same high dose for the treatment of RA. Indeed, 
due to the complex field of anti-cell or cytokine treatment – which is more pathophysiology 
than disease specific and might be very different in dosing across diseases – we expect this 
hybrid approach of post marketing investigator driven dose finding studies to be used more 
often in the near future.
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Of note, our trial design precludes inference of the value of long-term repeated treatment 
strategies with ultra-low-dose RTX. For example, lower dosing might lead to shorter infusion 
intervals or ultra-low dose may not be effective enough after multiple retreatments. However, 
we believe that showing non-inferiority at six months would be a valuable step forward to 
further study an ultra-low-dose RTX retreatment strategy. Also, it will remain to be established 
whether inhibition of radiographic progression is not compromised using ultra-low-dose RTX.
In the specific case of ultra-low RTX dosing, some interesting developments might make the 
results of this study perhaps even more relevant. Recently, RTX – registered only after TNFi 
failure – has been shown to be similar in efficacy to TNFi in bDMARD-naïve patients.27 Also, 
biosimilar RTX is expected to be available starting early 2017, at least in Europe. These two 
developments might make RTX as a first bDMARD a very realistic alternative. A promise of 
effective ultra-lowdose retreatment would further support this more prominent position of 
RTX in RA treatment.
Trial status: The trial started on 15 December 2016 and is currently recruiting.
Additional file 1: SPIRIT checklist. Not included in thesis, available online.
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Abstract
Background
Rituximab is an effective treatment of rheumatoid arthritis (RA) at doses of 2x1000mg 
(authorised dose) and 2x500mg/1000mg (standard low-dose). Several small uncontrolled 
studies suggest that lower doses might be sufficient for maintenance treatment, potentially 
improving safety and reducing costs.
Methods
In a 6-month randomised, double-blind, three arm non-inferiority trial (REDO study), we 
aimed to compare efficacy of RTX retreatment with ultra-low doses (1×500mg or 1×200mg) 
to standard low dose (1×1000mg). Patients with RA responding well to RTX were randomised 
(1:2:2) to 1×1000mg, 1×500mg or 1×200mg RTX respectively. Primary analysis was a hierarchical 
testing procedure comparing ultra-low doses (1×500mg at 3 and 6 months, then 1×200mg at 3 
and 6 months) to 1×1000mg) using a non-inferiority margin of 0.6 on Disease Activity Score 28.
Results
The projected inclusion was met (n=142). The 500mg dose was non-inferior to 1000mg at 3 
months but not at 6 months (0.29, 95% CI -0.08 to 0.65 p=0.09). Because of the hierarchical 
procedure, non-inferiority could not be tested for the 200mg dose. Mean disease activity 
remained low in all groups. In both ultra-low dose groups two patients received extra 1000mg 
rituximab due to a flare and more patients in the 200mg group used glucocorticoids (not 
significant). The ultra-low dose groups showed a significantly lower incidence of infections.  
Conclusions
Non-inferiority of retreatment with 1×500mg or 1×200mg rituximab versus 1×1000mg after 6 
months could not formally be established. However, ultra-low doses appear similarly effective 
in the majority of RA patients with a better safety profile. www.trialregister.nl: NTR6117.
Introduction
Rheumatoid arthritis (RA) is a chronic auto-immune disease affecting between 0.5 and 1.0% of 
the population in western countries.1,2 Current guidelines for RA recommend treatment with 
biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) if response to conventional 
synthetic DMARDs (csDMARDs) is insufficient.3,4 Furthermore, RA treatment should follow the 
treat-to-target principle (setting a treatment goal, measuring disease activity and changing 
treatment in case the treatment target in not reached) since this leads to the best outcomes.5 
Because many available pharmacological treatment options for RA are costly, a major 
challenge is to assure that treatment remains affordable and accessible. Several studies have 
shown that dose reduction of bDMARDs, after patients have reached their treatment goal of 
low disease activity or remission, is effective and safe.6-8 Consequently, the risk on side effects 
(mainly infections9,10) and the burden for patients can be minimised, while on top of that 
substantial cost savings can be realised.11,12
Rituximab (RTX) - a bDMARD targeting CD20 on B-cells - has shown to improve the symptoms 
of RA and prevent disease progression.13 Since RTX was originally developed as a treatment for 
non-Hodgkin’s lymphoma, its dose for RA was derived from this indication.14,15 The authorised 
dose of RTX is 2 × 1000mg (2 weeks apart) every 6 months16, which was the dosing scheme used 
in the first randomised controlled trial in RA.17 However, a systematic review showed that low-
dose RTX (2x500mg or 1x1000mg) is as effective as this high-dose.18 Both doses are currently 
used in clinical practice.19
 
Interestingly, three case reports and a small observational open-label study have indicated 
that much lower doses of RTX (50mg to 200mg) unexpectedly led to deep peripheral B-cell 
depletion and in several cases also adequate disease control in RTX naive patients.20-23 In 
addition to these promising results, it may be hypothesised that a lower dose of RTX is needed 
for retreatment compared to initial treatment, due to lower B-cell load.24 However, the use of 
very low doses of RTX for retreatment of RA has never been studied in a randomised controlled 
trial of proper design and size. Therefore, the aim of the current study was to assess the 
difference in efficacy between two ultra-low doses (500mg and 200mg) and standard low dose 
(1000mg) of RTX retreatment on the change in disease activity (measured with the DAS28-
CRP) in RA patients responding well to RTX. A non-inferiority (NI) design was chosen to assess 
whether ultra-low doses RTX are non-inferior to standard low-dose RTX treatment, using a 
pre-specified NI-margin of 0.6. 
 
Methods
Trial design 
The REDO study (RE3DO2: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: 
Disease Outcome after Dose Optimization) was a 6-month double-blind randomised 
controlled non-inferiority trial carried out at five centres in the Netherlands from December 
2016 until March 2019. The rationale and design have been described extensively elsewhere25, 
and are summarised here.
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Patients 
Eligible patients were 18 years or older with a diagnosis of rheumatoid arthritis (1987 or 2010 
ACR criteria, or clinical diagnosis of treating rheumatologist) with sufficient response to RTX. 
RTX use was defined as a dose of RTX (innovator or biosimilar; 1×1000mg, 2×500m or 2×1000mg, 
monotherapy or combined with methotrexate or another csDMARD) in the last 18 months and 
no other bDMARDs received afterwards. Response to treatment was operationalised as at least 
6 months of stable, low disease activity after the last RTX infusion (operationalised by either 
DAS28-CRP<2.9 (DAS28-BSE <3.2) or judgement of low disease activity by a rheumatologist) 
AND a current DAS28-CRP ≤3.5 (DAS28-BSE≤3.8) at screening. Patients with known (non-)
response to ultra-low dose RTX (below 1 × 1000mg) or current corticosteroid dosing above 10 
mg per day prednisolone equivalent were excluded. 
Trial oversight
The trial was conducted in accordance with Good Clinical Practice guidelines of the 
International Conference on Harmonization and with the principles of the Declaration of 
Helsinki. The study was approved by the local ethics committee (Commissie Mensgebonden 
Onderzoek region Arnhem-Nijmegen and the competent authority (CCMO) NL57520.091.16). 
All the patients provided written informed consent. This investigator initiated study received 
funding from two Dutch health insurance companies (Menzis and CZ [grant number 
201600033]), and is registered in the Dutch trial register (www.trialregister.nl, NTR6117).
Randomization and masking
Allocation was stratified by possible effect modifiers RF/ACPA status (positive/negative) and 
concomitant csDMARD use (yes/no). Patients were allocated in a ratio of 1:2:2 to 1x1000mg, 
1x500mg and 1x200mg respectively using random sized blocks of 5 or 10. The randomization 
sequences were generated (using www.randomization.com) by a pharmacist/senior researcher 
of the Sint Maartenskliniek (BvdB). The randomization lists were kept at the pharmacies of 
the participating centres that also prepared the study medication guaranteeing that the 
randomization sequence was concealed before allocation and during the study. Researchers, 
care providers and patients were blinded during the study period. The physical appearance 
of the three interventions was indiscriminate. Allocation was revealed to each patient (and 
others involved) by the treating rheumatologist after the last study measurement (at 6 
months) using an opaque envelope prepared by the pharmacy and registered in the health 
record.
Procedures
Patients received their allocated study dose RTX (1000mg, 500mg or 200mg) with the usual co-
medication (specified in supplementary file S1) through infusion at study start (baseline visit). 
Apart from the study dose, treatment and measurements were the same for all participants. 
Follow-up visits with a nurse (performing the measurements) and/or a rheumatologist/
physician assistant were planned at 3 months and 6 months after baseline. In case of an 
increase in disease activity, patients were encouraged to contact the hospital to plan an extra 
visit in which disease activity could be measured following the treat-to-target principle. 
Treatment decisions were at the discretion of the treating rheumatologist, but a treatment 
advice was provided by the study team. It was aimed to keep all anti-rheumatic medication 
constant during the study period. In case of a disease flare, it was advised to start with 
glucocorticoid bridging (mostly intramuscular methylprednisolone 120mg). When this had 
insufficient effect, extra RTX (1000mg intravenously, open-label) could be given. 
Several medication changes were defined as ‘treatment failure’: receiving extra RTX within the 
six-month study period; switching to another type of bDMARD; and using oral corticosteroids 
in a dose > 10 mg/day. In case of treatment failure, the patient remained in the study, but the 
last measure of disease activity and other outcomes was used as outcome employing a ‘last 
observation carried forward’ (LOCF) strategy.
Outcomes
Disease activity as primary outcome was measured at baseline, 3 months and 6 months 
follow-up using the 28-joint Disease Activity Score on the basis of levels of C-reactive protein 
(DAS28-CRP).26 Function was measured using the Health assessment questionnaire disability 
index (HAQ-DI)27, quality of life was measured using the EuroQol five dimension scale with 
five levels (EQ5D-5L)28. Medication use and adverse events were also recorded. Additionally, 
patients were asked to complete a questionnaire on infusion related reactions two weeks after 
infusion of the study medication. At each visit also peripheral CD19+ B-cells were measured. 
Several baseline characteristics were collected: demographics, disease- and treatment 
characteristics, baseline joint damage (SENS score29) and the expectations of patients and 
rheumatologists of efficacy of a lower dose RTX. 
Statistical analyses 
Statistical analyses were performed by LV, NdB and AdB. The study team received advice from 
a statistician during protocol development and data analysis. 
Primary endpoints
In order to compare the different dosing groups at the different time points, this study had 
four primary endpoints using change in DAS28-CRP from baseline. Multiplicity over the 
primary endpoints was protected by a fixed hierarchical testing procedure in which the next 
step could be taken only if the previous showed a significant result. These endpoints were 
tested (two-sided, α=0.05) using linear regression with the change in DAS28-CRP as outcome, 
dose group as determinant, and baseline values of DAS28-CRP as covariate. Furthermore, this 
regression was corrected for our randomization strata, ACPA/RF positivity and concomitant 
DMARD use. A NI-margin of 0.6 was chosen based on earlier trials30,31 and the fact that 0.6 
marks the measurement error of the DAS28 and the difference between European League 
Against Rheumatism (EULAR) non-response and moderate response32. The hierarchical testing 
steps were: 1) testing of non-inferiority of the 500mg vs. 1000mg at three months. 2) 500mg 
vs. 1000mg at six months. 3) 200mg vs. 1000mg at three months. 4) 200mg vs. 1000mg at six 
months. Primary analyses were done per protocol (PP), the most conservative approach for a 
non-inferiority study. In addition, analyses were performed intention-to-treat (ITT) to assess 
the strategy aspect of the study. For PP analysis, we included patients who had received the 
study medication and completed follow-up of six months or until treatment failure (with 
disease activity LOCF). The sample size calculation for this trial (described extensively by den 
Broeder et al.25 and reported in supplement S2) showed a sample size of 140 patients was 
needed for this trial, including 7% dropout.
Secondary endpoints
Differences in secondary outcomes between study groups (ITT) at three and six months follow-
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up were investigated using chi-squared test (dichotomous variables), univariate regression 
analysis (continuous variables with a normal distribution) or Kruskal-Wallis test (continuous 
variables without a normal distribution). Safety outcomes (ITT) were compared between 
study groups by Poisson regression (incidence densities) or chi-squared test (cumulative 
incidences). No correction for type I error was performed. 
Results
In total, 143 patients were randomised in the REDO study and received the allocated 
medication. One of these patients did not fulfil the inclusion criteria (high disease activity) and 
was retrospectively excluded. From the 142 correctly randomised patients, 29 were included 
in the 1000mg control group, 58 in the 500mg intervention group and 55 in the 200mg 
intervention group (participant flow is depicted in figure 1). The demographic and disease 
characteristics were similar across groups (table 1). 
Figure 1. Participant flow
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In the 200mg group, one patient was lost to follow-up due to a serious adverse event (SAE) 
(acute coronary syndrome). Treatment failure occurred in five patients. Four patients (two in 
the 500mg group and two in the 200mg group) received extra RTX due to disease flare and 
for them LOCF was applied for the primary analysis. One patient (1000mg group) received 
high dose glucocorticoids for immune thrombocytopenia and it was decided to exclude this 
patient from the PP analysis because there were no useful efficacy measurements. Thus, 142 
patients were included in the ITT full analysis set/safety set and 140 in the PP set (in which 
LOCF was applied for 4 patients). Two cases of protocol violation occurred, in which patients 
received their regular infusion of RTX a few days before the six month visit due to a logistic 
failure. These patients were included without LOCF in the analyses because the infusion was 
not expected to have an effect on disease activity at the six months measurement. 
Efficacy
The primary analysis showed that at 3 months, the 500mg dose was non-inferior to the 
1000mg dose regarding mean change in DAS28-CRP (-0.07, 95% CI -0.41 to 0.27, p<0.001). At 6 
months, non-inferiority could not be established for the 500mg dose compared to the 1000mg 
dose (0.29, 95% CI -0.08 to 0.65, p=0.09). The 200mg dose was non-inferior compared to the 
1000mg dose at both time-points, but because of our pre-defined hierarchical test procedure, 
this cannot formally be concluded. ITT analyses resulted in both ultra-low doses being non-
inferior to the 1000mg dose after 3 and 6 months (figure 2).
Mean DAS28-CRP scores remained below the threshold of low disease activity (DAS28-CRP ≤ 
2.9) for all groups during the study period (figure 3 and table 2). Analysis of peripheral CD19+ 
B-cells showed clear B-cell depletion for all three groups after three months follow-up (figure 
3). No significant differences were seen in proportion of patients reaching EULAR Boolean 
criterion of remission, remission or low disease activity based on the DAS28-CRP, number of 
patients with a flare33 or changes in HAQ-DI and EQ5D score from baseline. Use of concomitant 
csDMARDs and oral glucocorticoids remained stable during the study period (table 2). Seven 
patients (5%) received intra-articular injection(s) and 27 (19%) intramuscular injection(s) of 
glucocorticoids in the study population during the study period. The proportion of patients 
using glucocorticoids (especially intramuscular) was higher, but not significantly so, in the 
200mg group compared to the other groups (combined use of glucocorticoids as well as 
separate use (oral, intramuscular and intra-articular)).
 
Figure 2. Forest plot of primary analyses*
*Based on linear regressions corrected for baseline DAS28-CRP, RF/ACPA status and concomitant csDMARD use. P-values 
based on NI-margin of 0.6. 
ACPA denotes anti-citrullinated protein antibody, CRP C-reactive protein, csDMARD conventional synthetic disease 
modifying anti-rheumatic drug, DAS28 disease activity score in 28 joints, ITT intention-to-treat, NI non-inferiority, PP per-
protocol, RF rheumatoid factor.
Figure 3: Mean DAS28-CRP scores and peripheral CD19+ B-cells at baseline, 3 months and 6 months
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Safety 
SAE(s) were reported for 13 patients of which three in the control group of 1000mg (3/29, 10%), 
six in the 500mg group (6/58, 10%) and four in the 200mg group (4/55, 7%). No deaths occurred 
during the study period. The incidence density of infections was significantly lower in the 
500mg group (rate ratio 0.42 (95% CI 0.21 to 0.83, p=0.01)) and in the 200mg group (rate ratio 
0.44 (95% CI 0.22 to 0.88, p=0.02)), compared to the 1000mg group (table 3). 
Table 3. Summary of safety events*
Event 1000mg 
(n=29)
500mg 
(n=58)
200mg
(n=55)
Total group
(n=142)
Any adverse event – incidence per 
patient year 
4.26
(62/14.57)
4.63
(134/28.95)
4.62
(127/27.49)
4.55
(323/71.01)
Serious adverse event(s) – no (%)† 3 (10%) 6 (10%) 4 (7%) 13 (9%)
Deaths - no (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Adverse events of special interest 
Infections - incidence per patient year ¶ 1.24
(18/14.57)
0.52
(15/28.95)
0.55
(15/27.49)
0.68
(48/71.01)
Serious infections ≥ grade 3 – no (%) ¥ 2 (7%) 1 (2%) 1 (2%) 4 (3%)
Infusion related complaints – incidence 
per patient year $
0.75
(11/14.57)
1.14
(33/28.95)
0.58
(16/27.49)
0.84
(60/71.01)
Serious infusion related complaints ≥ 
grade 3 – no (%) ¥
0 (0%) 1 (2%) 0 (0%) 1 (1%)
* Analyses were performed with data from the safety analysis set, which was the same as the full analysis set and included 
all patients who received the study dose or RTX. Adverse events from any cause were included in the analyses. Safety 
outcomes (ITT) were compared between study groups by Poisson regression (incidence densities) or chi-squared test 
(cumulative incidences). No correction for type I error was performed.
† Cumulative incidence of serious adverse events. One patient in the 500mg dose group experienced two serious adverse 
events (hospital admissions). 
¶ Infections were labelled as such by the study team based on the adverse event description.
¥ Cumulative incidence. Grading was done according to the Common Terminology Criteria for Adverse Events version 5.0, 
grade ranged from 0 – 5 and higher scores indicate worse events. 
$ Infusion related complaints were labelled as such by the study team based on the adverse event description. 
Discussion 
This is the first randomised controlled study investigating doses of RTX below the standard 
low dose of 1000mg for retreatment of patients with RA. With the primary PP analysis non-
inferiority of retreatment with ultra-low doses could not be established at 6 months. ITT 
analyses showed that a strategy of ultra-low dose RTX and treatment escalation in case of 
disease flare is non-inferior for both 500mg and 200mg compared to 1000mg up to 6 months 
follow-up. In addition, a lower incidence of infections was seen in the ultra-low dose groups. 
These findings confirm the results of small studies on very low doses of RTX for RA20-23,34 and 
even surpass the results of other bDMARD dose reduction studies showing that approximately 
60% of patients can reduce the dose or discontinue bDMARD treatment.8,35
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The results of our PP analysis cannot exclude the possibility that a 500mg dose leads to worse 
outcomes than 1000 mg. However, in light of the 200 mg results and assuming a dose-related 
response, this seems unlikely. Possible explanations are 1) the 500mg dose indeed results in a 
small deterioration in DAS28 compared to 1000mg and the true effect of 200mg is attenuated 
by co-medication or 2) we incorrectly failed to reject the null hypothesis of inferiority for 
500mg after 6 months due to coincidence and possibly insufficient sample size. We think 
both explanations might be partly true as (although not significant) more glucocorticoids 
were used in the 200mg group (supporting the first) but the course of disease activity and 
B-cells are similar for all groups with very few treatment failures and in addition not all of the 
assumptions of the sample size calculation were reached (supporting the second). 
Strengths of this study are the randomised, double-blind study design that minimizes the risk 
of bias, together with the low numbers of missing data and drop-outs. Furthermore, patient 
entry criteria were chosen to ensure that results are generalizable to clinical practice. A 
limitation of this study is the potential for a carry-over effect of the previous higher dose of 
RTX, which cannot be ruled out in this study with fairly short follow-up. Bio-creep36 compared 
to the authorised dose of 2x1000mg does not seem likely since the estimated difference in 
change in DAS28 between 2x1000mg and 1x1000mg was 0.07 at 6 months.18
Thus, our study shows that retreatment with ultra-low dose RTX is a feasible option to consider 
in clinical practice, at least up to 6 months and in treat-to-target context. Shared decision 
making is necessary about whether the advantages of an ultra-low dose strategy (reduced risk 
of infections, shorter infusion time, lower costs) outweigh the chance of flare and subsequent 
medication adjustments. Additional analyses of the REDO trial into cost-effectiveness and 
potential predictors of successful retreatment with ultra-low dose will help patients and 
clinicians make a balanced choice. Looking at the future, this study might indicate the start 
of an era in which bDMARD treatment will be available below 1000 euro per patient per year 
(ultra-low dose strategy in combination with biosimilar associated cost reductions). However, 
further research on a strategy with ultra-low dose RTX is needed to determine the effects over 
a longer period of treatment with more than one infusion, on radiographic outcomes and to 
confirm its safety, for which a 2-year observational extension of the REDO is ongoing.
In conclusion, although this trial could not establish formal non-inferiority of retreatment 
with 1×500mg or 1×200mg RTX versus 1×1000mg after 6 months and the proportion of 
patients using glucocorticoids was possibly higher in the 200mg group, ultra-low doses 
appear effective in the majority of RA patients with a better safety profile.
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Supplementary files
S1. Co-medication administrated before study medication in participating centres
Centre
Sint Maartenskliniek cetirizine 10mg po methylprednisolone 
50mg IV
acetaminophen 
1000 mg
Radboudumc clemastine 2mg IV methylprednisolone 
100mg IV
acetaminophen 
1000mg
Reade Amsterdam clemastine 2mg IV methylprednisolone 
100mg IV
acetaminophen 
1000mg
Maasstad Ziekenhuis clemastine 2mg IV dexamethasone 
20mg IV
acetaminophen 
1000mg
Ziekenhuisgroep Twente clemastine 2mg IV dexamethason 
20mg IV
acetaminophen 
1000mg
S2. Sample size calculation (den Broeder et al.)
The study has four primary endpoints; multiplicity over the primary endpoints will be 
protected by a fixed testing procedure. First, the non-inferiority of the 500 mg vs. 1000 mg 
at three months will be tested at p < 0.05 (two-sided). If this is statistically significant, then 
500 mg vs. 1000 mg will be tested at p < 0.05 (two-sided) at six months. If that is statistically 
significant, then 200 mg vs. 1000 mg will be tested at p < 0.05 (two-sided) at three months and if 
that is statistically significant, the last test will be 200 mg vs. 1000 mg at p < 0.05 (two-sided) at 
six months. As we have four primary endpoints, we aim to have enough power for each at 95% 
for an NI margin of δ = 0.6. Under the worst-case scenario that these four are not correlated 
(the expectation is that they are positively correlated, see Table 1) and that the intervention 
is indeed non-inferior to the control condition, then the overall power for rejecting the null 
hypothesis of inferiority on all four is at least 95% × 95% × 95% × 95% = 81%. We calculated 
the sample size for one endpoint (e.g. the comparison of 500 vs. 1000 mg at six months). For 2:1 
randomisation and a non-inferiority test assuming the true difference between treatments 
is 0, the total sample size for a t-test having a power 1-β when testing at significance level α 
(two-sided) and a non-inferiority margin δ is Ntot = (4.5)2 × (z1-α/2 + z1-β)2 × SD2/δ2, where z 
denotes the normal quantiles which are correct for non-small sample sizes. When correction 
for baseline is incorporated, this sample size is reduced by (1-r2) where r is the correlation in 
DAS28 between baseline and follow up (formula 7 with n = 1, π0 = 1/3, π1 = 2/3, and section 2.3 
of Teerenstra S, et al. (Teerenstra et al.)). Note that the two groups then have sizes Ntot/3 and 2 
× Ntot/3. To determine the correlation r between baseline and follow-up measurement of the 
DAS28, the following assumptions were used. Baseline DAS28 has a SD = 0.7 and the change 
from baseline to three (or six months) has a standard deviation of SDchange = 0.6 based on 
data from an earlier dose reduction trial. As SD2change = 2 × (1-r2) × SD2, it follows that r = 0.63. 
Then a total trial size of 80 participants would be enough. Table 1 illustrates the total trial 
size when the correlation between endpoints is smaller than anticipated. To protect for a too 
optimistic correlation, we therefore choose a total trial size of 130 and this is further increased
to 140 patients to account for patient drop-out. 
1. Den Broeder et al. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a 
randomised controlled trial. Trials. 2017;18(1):403
2. Teerenstra et al. A simple sample size formula for analysis of covariance in cluster randomized 
trials. Stat Med. 2012;31(20):2169–78.
Table 1: Total trial sample size at various correlations between endpoints
SD change r Sample size 1000mg arm Total trial size 
(5 x sample size in 1000mg arm)
0.9 0.17 26 130
0.8 0.35 24 120
0.7 0.5 20 100
0.6 0.63 16 80
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Abstract
Objectives
The aim of this study was to identify the factors that play a role for patients with RA when 
considering dose reduction (i.e. gradual tapering until discontinuation) of biological DMARDs 
(bDMARDs), and to determine their relative importance.
Methods
A mixed methods design was used in which we identified influencing factors by performing 
semi-structured interviews and ranked these factors using a Maximum Difference Scaling 
questionnaire. Also, we looked at the influence of several patient characteristics on this 
ranking.
Results
For sub study 1 and 2, 22 and 192 patients with RA were included, respectively, in the analyses. 
Thirty factors were identified from the interviews - characterized into nine themes - and 
appraised in the questionnaire. Most respondents had a positive attitude towards bDMARD 
dose reduction. The study showed that patients are concerned that dose reduction will lead 
to a disease flare that affects their daily life (pain, function). It is important for them to know 
that it is possible to increase the dose if (further) reduction fails and that the bDMARD will be 
effective again. Patients value the opinion of their rheumatologist, and being involved in the 
decision to start tapering is highly ranked as well. The most important factors were consistent 
between different groups of patients.
Conclusion
The results from this study facilitate implementation of bDMARD dose reduction; they inform 
care providers on what is important for patients and provide a basis for shared decision 
making.
Rheumatology key messages
• Patients with RA are positive about biological DMARD dose reduction but perceive several 
barriers and facilitators.
• Important for RA patients are potential worse outcomes, possible dose escalation, the 
rheumatologist’s opinion and patient involvement.
• The most important topics are consistent between different subgroups of patients with RA.
Introduction
Biological DMARDs (bDMARDs) are effective and safe in the treatment of RA.1 However, their 
use is also associated with side-effects, high costs and practical burden for patients (e.g. self-
injection, storing medication).2-4 Dose reduction (i.e. gradual tapering until discontinuation) 
of bDMARDs, after low disease activity is reached, is proven to be safe and non-inferior 
to continuation.5,6 Therefore, dose reduction is recommended in current (inter)national 
guidelines.7,8
To date, only two small studies have focused on (b)DMARD dose reduction from the perspective 
of the patient.9,10 Markusse et al. performed a structured interview study among 20 RA 
patients to explore their opinion about tapering and discontinuing of anti-rheumatic drugs 
in general. This study provided information on patients’ positive and negative expectations 
of dose reduction (e.g. hope, happiness and relief versus fear and disappointment) but, due 
to the structured design of the interviews, failed to explore all themes/concepts that may 
play a role among patients when considering tapering themselves.9 Furthermore, Wallis et al. 
performed a focus group with nine patients with RA on their concerns and attitudes towards 
dose reduction. The main concerns they found were loss of disease control, delay in access to 
the previous dose and potential loss of efficacy of a previously successful treatment. Perceived 
benefits were a lower risk of adverse effects and reduced frequency of injection.10 
These small studies provide useful information on attitudes and expectations of patients, 
however verification of their results in a larger sample is warranted and information on which 
factors are most important for patients is still lacking. Therefore, the primary aim of this study 
was to identify the factors that play a role for patients when considering dose reduction of 
bDMARDs, and to determine their relative importance. The secondary objective was to 
investigate the influence of patient characteristics (e.g. age, gender, disease duration) on the 
ranking of factors, as it is conceivable that subgroups of patients have different preferences.11,12
Methods
A mixed methods design was used consisting of two consecutive sub studies. Both studies were 
presented to the Medical Ethical Committee of the region Arnhem-Nijmegen (file numbers 
2015-1845 and 20162559). An exemption was obtained, as ethical approval for these types of 
studies is not required under Dutch law. This study complies with the declaration of Helsinki 
and all patients gave their written informed consent for participation.
Sub study 1
To gain insight into the influencing factors as perceived by patients, semi-structured 
interviews were performed to explore attitudes and experiences in health care.13
Recruitment of participants
For the interviews, we recruited patients from the rheumatology department of a hospital 
specialized in disorders of posture and movement (rheumatology, orthopaedics and 
rehabilitation medicine) in the Netherlands (Sint Maartenskliniek), by purposive sampling.13 
This means that we aimed to include a variety of patients looking at type of bDMARD 
Patient perspective on bDMARD dose reduction
6
155154
(including mode of administration), treating rheumatologist and experience with dose 
reduction of a bDMARD, to get insight into the whole range of experiences and attitudes on 
bDMARD dose reduction. Patients had to be ≥18 years, diagnosed with RA (clinical diagnosis), 
using (or having used) a bDMARD and able to communicate well in Dutch. Patients were 
selected by the researchers (L.M.V., A.A.dB.) and approached by their rheumatologist during an 
outpatient visit. Recruitment of patients was stopped when data saturation was reached (no 
new information emerging from the last three interviews).
 
Interviews
A semi-structured interview guide was developed (using the framework of Flottorp14, a 
checklist for identifying factors that prevent or enable improvements in health care). This 
guide focused on the experience with tapering and discontinuing bDMARDs, the barriers and 
facilitators regarding bDMARD dose reduction and preferences and suggestions for optimal 
implementation of bDMARD dose reduction. Telephone interviews (unless the patient 
preferred a face-to-face interview) were performed by one researcher (L.M.V.). All interviews 
were audio-recorded and transcribed verbatim. A summary of the interview was sent to the 
interviewee to assure the validity of the data (member check).
Analysis
The transcribed interviews were analysed by inductive thematic analysis using the qualitative 
data analysis software MAXqda (version 11). Three analysis steps were used: open, axial and 
selective coding.15 Two researchers (L.M.V., E.M.H.S.) analysed the first six transcripts separately. 
All other transcripts were coded by one researcher (L.M.V.) and checked by a second researcher 
(E.M.H.S.). Differences were discussed until consensus was reached and if necessary, the 
codebook was adapted (adding, removing or changing codes). Results and saturation were 
discussed during the process.
The result of the inductive thematic analysis was a list of barriers and facilitators that was 
afterwards summarized into factors that play a role for RA patients when considering dose 
reduction [neutrally formulated from the patient perspective by consensus among two 
researchers (L.M.V., E.M.H.S.) and one researcher/rheumatologist (A.A.dB.)].
Sub study 2
To investigate the relative importance of the factors from the interview study, we used a 
Maximum Difference Scaling (MaxDiff) survey. MaxDiff produces preference scores for 
multiple factors. Respondents are shown several subsets of the possible factors in the 
questionnaire and are asked to indicate (among this subset) the most and least important 
factor16. This method simplifies the ranking task for participants, enables discrimination 
between ratings of different factors involved in complex decisions and is not influenced by 
scale related biases.16,17 The MaxDiff method was successfully used for similar studies in 
rheumatology.18,19
Recruitment of participants
For MaxDiff, there is no formal sample size calculation available.20 Based on other MaxDiff 
studies and following the advice of a statistician, we decided on a minimum of 100 respondents 
needed for a reliable assessment of preferences with the MaxDiff questionnaire. Because we 
also wanted to explore the influence of several patient characteristics, we aimed to include 
200 patients in total. Patients were selected from the electronic patient files and from trials 
that had been performed into bDMARD dose reduction. Patients were screened for eligibility 
and approached for the study with a letter on behalf of their rheumatologist in random order. 
Permission of the treating rheumatologists was asked before patients were approached. One 
reminder was sent in case patients did not respond.
Patients were recruited at the rheumatology department of three different medical centres 
in the Netherlands (an academic hospital, a hospital specialized in disorders of posture and 
movement and a general hospital). Patients had to be ≥18 years, diagnosed with RA, using (or 
having used) a bDMARD, should have basic computer skills and an email address, and should 
be able to read and write in Dutch. Patients that had no experience with dose reduction 
additionally needed to have low disease activity during the last visit to the hospital (DAS28CRP 
< 2.9/ DAS28ESR < 3.2 or judgement of rheumatologist) so the option of dose reduction would 
be better conceivable.
Designing the survey
The MaxDiff questionnaire was designed and fielded using the Sawtooth Software’s Lighthouse 
Studio (version 9.3.1). The MaxDiff exercise consisted of 18 questions in which five factors were 
shown to ensure that every respondent would rank every factor three times (18 x 5/ 30 = 3). An 
example of a MaxDiff question is shown in Fig. 1. Questions on patient characteristics (gender, 
age, hospital, disease duration, number of bDMARDs used, experience with dose reduction 
and attitude towards dose reduction) were added to the survey. The final questionnaire was 
tested by two patients with RA to ensure all items were understandable and to determine the 
time needed to complete the survey.
Figure 1. Example of a MaxDiff question
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Analyses
The MaxDiff software produced a utility (preference score) for every factor in the survey. The 
higher the utility, the more likely the factor was chosen as most important (and not as least 
important). Using Hierarchical Bayesian methods, the software estimated individual level 
utilities by combining information from individuals’ specific choices with the distribution 
of utilities across participants. Average scores were generated by iteration. To facilitate 
interpretation, the scores were subsequently rescaled to a Rescaled Probability Score (RPS) 
on a scale from 0 to 100; the higher the score, the more important the factor. For example, 
a factor with an RPS of 5 is twice as important as a factor with an RPS of 2.5.17 In our study, 
these scores represent the relative importance of a factor for patients considering bDMARD 
dose reduction. Patients that gave inconsistent answers on the MaxDiff questionnaire (Root 
Likelihood below the recommended cut-off of 0.26921) were excluded from the analyses.
We investigated whether there were any differences between patient groups in the RPS scores 
by descriptive statistics and linear regression analyses. We selected the most important 
factors by taking a cut-off at half of the highest RPS.19 With descriptive statistics we compared 
the most important factors of patients from different subgroups (age divided by ≤65/>65 
years, disease duration by ≤10/>10 years and number of biologicals by 1/>1). Next to this, 
several linear regression models were made using the RPS as the dependent variable and 
the seven characteristics as independent variables. Dependent variables were transformed 
when data were not normally distributed (judged by histograms and skewness/kurtosis) 
and homoscedasticity was investigated with the Breusch-Pagan/Cook-Weisberg test. All 
statistical tests were performed with STATA (version 13.1) and corrected for multiple testing 
by dividing the significance level α (0.05) by the number of regression models that were made 
(Bonferroni correction).
Figure 2. Flowchart of inclusion in sub study 2
RLH: Root Likelihood 
Results
Sample characteristics
For sub study 1, saturation was reached when 22 patients were interviewed (after 30 
patients were invited, response rate 73%). For sub study 2, 444 patients were invited and 195 
completed the survey (response rate 44%, see Fig. 2 for flowchart of inclusion). Of the 100 
patients that indicated they did not want to participate, 42 mentioned a reason for this; the 
two most frequently mentioned reasons were no computer/email address (n = 11) and not 
wanting to taper the bDMARD, thus misunderstanding the objective of the study (n = 19). 
Table 1 shows the characteristics of the participants for both sub studies. Most respondents 
were female, mean age was around 60 and most patients had established RA (long disease 
duration). Of respondents in the MaxDiff survey, 61% indicated that they had experience 
with dose reduction of a bDMARD and 73% of patients were positive or very positive about 
dose reduction in case of low disease activity. The ratio between patients that were positive/
very positive about dose reduction and negative/very negative about dose reduction did not 
differ substantially between patients with and without experience with dose reduction: 91/ 
8 = 11.4 for patients with experience and 50/5 = 10 for patients without experience (data not 
shown). Three patients had a Root Likelihood below 0.269 and were therefore excluded from 
the analyses.
Table 1. Patient characteristics 
Characteristic Sub study 1 (n=22) Sub study 2 (n=192)
Female 15 (68) 125 (65)
Age, mean (S.D.), years 62 (7.6) 59 (12.1)
Disease duration, mean (S.D.), years 13 (9.4) 16 (10.0)
Number of respondents per centre Hospital specialized in 
posture and movement:  
22 (100)
Hospital specialized in 
posture and movement:  
67 (35)
Academic hospital: 64 (33)
Large general hospital: 
61 (32)
Experience with bDMARD dose reduction Yes: 16 (73)
No: 6 (27)
Yes: 117 (61)
No: 71 (37)
I don’t know: 4 (2)
General attitude towards bDMARD dose 
reduction
Not applicable Very positive: 64 (33)
Positive: 78 (41)
Neutral: 27 (14)
Negative: 11 (6)
Very negative: 2 (1)
I don’t know: 10 (5)
Values are presented n (%) unless otherwise stated. bDMARD: biological DMARD.
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Sub study 1
The interviews provided a broad overview of all the factors that play a role for patients when 
considering dose reduction and inductive thematic analysis resulted in a list of 43 barriers 
and facilitators within nine themes. These themes were: disease activity, functioning/
pain, adverse effects, practical use of the bDMARD, attitude towards medication, previous 
experience(s) with dose reduction, social aspects, organizational aspects and costs. Table 2 
shows two exemplary quotes from interviewees per theme. The 43 barriers and facilitators 
were summarized into 30 factors that were used in the MaxDiff survey.
Table 2. Themes and quotes from sub study 1
Themes Quotes
1. Disease activity “Because the rheumatism flares up every now and then, meaning it’s more 
active. But there are also periods when the disease is less ‘active’. Then you feel 
good. At those moments you feel alright. If everything is okay, you can cut back 
on the medicine.”
“Because you have to overcome a certain fear: I know what I have. I know how 
I feel right now. And I am risking it all.”
2. Functioning/pain “I still have a job, you know. I still work. And I won’t take the risk of having to 
report sick.”
“That I am capable of doing the things that I like doing. I have been riding a 
motorcycle you see, and I want to keep on doing that. And if I am no longer 
able to ride this motorcycle... I’d rather just take that Enbrel a week earlier... or 
take that Humira instead of having to give up riding my motorcycle.”
3. Adverse effects “On the one hand I am glad that these medicines exist, on the other hand, er, ... 
they may likely cause side effects in the future.”
“It did [the bDMARD] have one negative effect: it reduced my resistance. When 
I had a cold, for example, I could not fight it off. So I had to take a course of 
penicillin to get better.”
4. Practical use of 
the bDMARD
“... and in the beginning you just can’t do it, it’s scary to do it yourself.” 
[injecting yourself with a bDMARD]
“You must keep it refrigerated. Next week I will go on a holiday and then I will 
take two syringes with me. If you are going on a long trip, you must put them 
in a small fridge.”
5. Attitude towards 
medication
“I take multiple medications and I often think about how to reduce the use of 
these medications. I make that assessment almost every day.”
“But on the other hand: life is in constant motion. You can no longer say: you 
have a job for the rest of your life. Likewise, you can no longer say: you are on 
medication for the rest of your life. It doesn’t work like that anymore. And, er, I 
accept that this is constantly changing.”
6. Earlier 
experiences with 
bDMARD dose 
reduction
“I am afraid I will always need some medication. I did try to stop using 
anything at all one time and this ended up being a disaster. So I have already 
had that experience.”
“Maybe it’s just the feeling. The fact that you have cut back on your 
medication also changes your mind-set. At the moment you stop taking your 
medication you have the feeling that you are a little healthier. It’s a kind of 
small victory.”
7. Social aspects “At that time, so many people said to me: ‘Why would you want to participate 
in that experiment [dose reduction of the bDMARD]? Would it be a wise thing 
to do? You feel good now, don’t you? [...]’ The people around me discouraged 
me a lot.”
“I rely entirely on my physician. Yes, I put great trust in her. I think she knows 
what’s best for me. Yes, I find that extremely important.”
8. Organizational 
aspects
“We have agreed on the following: if I fail [to cut back on the bDMARD], I can 
call the physician. I find that quite helpful.”
“I think the entire staff are very nice people and I like working with them but 
when it comes to my rheumatism, I prefer the rheumatologist.”
9. Costs “Yes, but that [the costs] is surely not the most important aspect in my 
opinion. It’s my health we’re talking about.”
“Yes, I think that healthcare costs are too high. If I could do something about 
it, I would gladly do so.”
bDMARD: biological DMARD.
Sub study 2
Ranking of factors
The 30 factors and their RPS are shown in Table 3. The three highest ranked factors were: ‘27. 
The possibility to increase the dose when disease symptoms worsen’; ‘2. The risk that my 
disease activity will increase’; and ‘1. My current disease activity’, with a mean RPS (S.D.) of 
8.11 (1.82), 7.27 (2.11) and 6.92 (2.29), respectively. The three least important factors were: ‘18. 
What others in my environment think of dose reduction’; ‘25. The way I receive information on 
dose reduction (e.g. through a leaflet or through the internet)’; and ‘23. The moment at which I 
receive information on dose reduction’, with a mean RPS (S.D.) of 0.03 (0.07), 0.31 (0.37) and 0.45 
(0.56), respectively.
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Table 3. Ranking of factors based on Rescaled Probability Score (RPS) 
Rank RPS (s.d.) Factor number and description Theme
M
os
t i
m
po
rt
an
t f
ac
to
rs
1 8.11 (1.82) 27. The possibility to increase the dose when 
disease symptoms worsen 
Organizational 
aspects
2 7.27 (2.11) 2. The risk that my disease activity will increase Disease activity
3 6.92 (2.29) 1. My current disease activity Disease activity
4 6.27 (2.59) 4. The risk that my physical function will 
deteriorate (e.g. I won’t be able to work)
Functioning/pain
5 6.23 (1.97) 16. The confidence I have in my rheumatologist Social aspects
6 6.11 (2.48) 19. To what extent I’m involved in the decision 
on bDMARD dose reduction 
Social aspects
7 6.05 (2.13) 11. Whether the bDMARD is (still) necessary for 
the RA
Attitude towards 
medication
8 5.73 (2.48) 17. The advice of my rheumatologist regarding 
bDMARD dose reduction
Social aspects
9 5.72 (2.45) 5. The risk that I will experience more pain Functioning/pain
10 5.42 (2.13) 14. The efficacy of the bDMARD after increasing 
the dose 
Attitude towards 
medication
11 4.97 (2.53) 3. The effort it has cost to reach low disease 
activity
Disease activity
12 4.76 (2.45) 13. The certainty that the bDMARD gives me Attitude towards 
medication
13 4.71 (2.78) 7. The potential future side effects of the 
bDMARD 
Adverse effects
14 3.38 (1.98) 12. The availability of other drugs to treat 
possible worsening of the RA due to dose 
reduction
Attitude towards 
medication
15 2.82 (2.19) 20. The support I receive during dose reduction Social aspects
16 1.91 (1.82) 15. My earlier experience(s) with dose 
reduction/discontinuation of a bDMARD
Earlier experiences 
with dose reduction
17 1.75 (2.42) 10. My attitude towards taking medication Attitude towards 
medication
18 1.62 (2.17) 26. The availability of the outpatient clinic 
during dose reduction (being able to call or visit 
in case of worsening symptoms)
Organizational 
aspects
19 1.57 (2.01) 29. The reimbursement of the bDMARD by the 
healthcare insurer in the future
Costs
20 1.55 (2.15) 21. Which care provider discusses the dose 
reduction with me (e.g. the rheumatologist or 
the nurse)
Social aspects
21 1.52 (1.28) 6. My earlier experience(s) with side effects of 
the bDMARD
Adverse effects
22 1.24 (1.40) 24. The situation in which dose reduction is 
discussed
Organizational 
aspects
23 1.10 (1.74) 28. The responsibility to contribute to savings 
in the national healthcare budget
Costs
24 0.84 (0.70) 22. What information I receive on dose 
reduction (e.g. about which subjects)
Organizational 
aspects
25 0.65 (0.99) 30. The extent to which cost reduction is the 
main motivation of the hospital to reduce the 
dose of my bDMARD
Costs
26 0.54 (1.14) 8. The practical use of my bDMARD (e.g. storing 
the syringes, the frequency of injections/visits 
to the hospital)
Practical use of 
bDMARD
27 0.45 (0.77) 9. The administration mode of my bDMARD 
(injection or infusion)
Practical use of 
bDMARD
28 0.45 (0.56) 23. The moment at which I receive information 
on dose reduction 
Organizational 
aspects 
29 0.31 (0.37) 25. The way I receive information on dose 
reduction (e.g. through a leaflet or through the 
internet)
Organizational 
aspects
30 0.03 (0.07) 18. What others in my environment think of 
dose reduction
Social aspects
RPS scores are presented as mean (S.D.). RPS: Rescaled Probability Score; bDMARD: biological DMARD.
Differences in ranking between patient groups
Using a cut-off value of 4.06 (half of the highest RPS), a top-13 of most important factors was 
selected (number 1, 2, 3, 4, 5, 7, 11, 13, 14, 16, 17, 19 and 27). For these factors, we investigated 
whether several patients’ characteristics were associated with the RPS. With descriptive 
statistics we found that the group of factors in the top-13 was consistent between all subgroups 
except for attitude towards dose reduction, in which factor 15: ‘My earlier experience(s) with 
dose reduction/stopping a bDMARD’, was included in the top-13 of patients with a negative 
attitude instead of factor 7: ‘The potential future side effects of the bDMARD’.
For the regression analyses, we investigated the distribution of the 13 most important factors. 
Eight of them showed a sufficiently normal distribution. The five remaining factors (number 
2, 3, 7, 13 and 27) were subjected to the most suitable transformation (square, cube or square 
root). Thirteen regression models were made based on records with informative data on all 
variables (excluding patients that answered ‘I do not know’ for experience with dose reduction, 
and/or ‘I do not know’ or ‘neutral’ on attitude towards dose reduction) (n = 154) and P-values of 
the coefficients were investigated using an α of 0.05/ 13 = 0.0038.
The regression models showed that gender, age, hospital, experience with dose reduction and 
attitude towards dose reduction were associated with one or more of the 13 factors (see Table 
4). Disease duration and number of bDMARDs used were not significantly associated with any 
of the top-13 factors.
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Table 4. Significant associationsa between patient characteristics and RPS of top-13 factors 
Characteristic Factor CIb p-value Betac Direction of association
Age 4. The risk that my 
physical function will 
deteriorate (e.g. I won’t 
be able to work)
-.09 to -.02 0.001 -.28 More important to 
younger patients
16. The confidence 
I have in my 
rheumatologist 
.02 to .07 0.001 .29 More important to older 
patients 
17. The advice of 
my rheumatologist 
regarding bDMARD 
dose reduction
.04 to .10 <0.001 .34 More important to older 
patients
Gender 5. The risk that I will 
experience more pain
-2.03 to -.58 0.001 -.25 More important to 
women
Experience 
with dose 
reduction 
5. The risk that I will 
experience more pain
-2.04 to -.49 0.002 -.24 More important to 
patients without 
experience with dose 
reduction
Attitude 
towards dose 
reduction
2. The risk that my 
disease activity will 
increase 
-38.72 to 
-10.31
0.001 -.26 More important to 
patients that have a 
negative attitude towards 
dose reduction
3. The effort it has cost 
to reach low disease 
activity 
-1.02 to -.35 <0.001 -.31 More important to 
patients that have a 
negative attitude towards 
dose reduction
7. The potential future 
side effects of the 
bDMARD
.20 to .98 0.003 .24 More important to 
patients that have a 
positive attitude towards 
dose reduction
13. The certainty that 
the bDMARD gives me
-.90 to -.18 0.003 -.24 More important to 
patients that have a 
negative attitude towards 
dose reduction
Hospital 5. The risk that I will 
experience more pain 
.54 to 2.28 
and .97 to 
2.70
0.002 
and 
<0.001
.26 
and 
.35
More important to 
patients from general 
and specializedd hospital 
compared to academic 
hospital
27. The possibility to 
increase the dose when 
disease symptoms 
worsen
55.02 to 
262.47
0.003 .28 More important to 
patients from specialized 
hospital compared to 
general hospital
a Significance was tested using an α of 0.0038 [0.05/13 (number of tests)]; b CI of coefficient from linear regression model; 
c Standardized beta coefficient from the various regression analyses; d Hospital specialized in disorders of posture and 
movement. RPS: rescaled probability score; bDMARD: biological DMARD.
Discussion
In this mixed methods study, most RA patients indicated that they are positive towards 
bDMARD dose reduction when low disease activity is reached. However, patients are mainly 
concerned that dose reduction will lead to a disease flare that affects their daily life (pain, 
function). It is important for them to know that they can increase the dose if (further) reduction 
is not possible and that the bDMARD will be effective again. Patients value the opinion of their 
rheumatologist, and being involved in the decision to start tapering is highly ranked as well. 
With explorative linear regression modelling, we found that age, gender, experience with 
dose reduction, attitude towards dose reduction and hospital setting seem to influence the 
importance of some factors. However, the 13 most important factors were very consistent 
throughout different patient groups, which makes us conclude that the overall ranking of 
factors found in this study is quite robust and valid for a large group of RA patients. This study 
confirms the results from earlier small studies on this subject that found that most patients 
are positive about bDMARD dose reduction but fear a disease flare and have concerns about 
being able to return to higher dosages.9,10 Our results are also consistent with the barriers and 
facilitators that were found in a systematic review on deprescribing in general.22 Furthermore, 
the importance of the rheumatologist’s opinion and a patient’s trust in him/her was also shown 
by Martin et al.23 and van Hulst et al.18 and the wish of patients to be involved in decisions on 
DMARD changes is consistent with the findings of Nota and colleagues.24
Studies into the attitude of patients to bDMARD medication show that patients are generally 
very positive about the effect of bDMARDs25,26 and reluctant to changes in DMARD treatment27. 
When looking at overcoming the barriers that are perceived by patients, the results of this 
study might be used to inform care providers on the topics that are most important for 
patients. During consultations, care providers should address possible fears and concerns and 
put these in context with recent evidence on dose reduction. Through this, shared decision 
making on bDMARD dose reduction and implementation of this principle can be stimulated. 
Furthermore, the most important topics that were found in this study could be included in 
patient information on bDMARDs, to prepare patients on the option of dose reduction and 
adjust expectations from the start of bDMARD use. Other possibilities are to incorporate the 
(most important) topics in a tool or questionnaire for patients to elicit their preferences and 
prepare for a consultation in which dose reduction is discussed, or a tool for both patients and 
health care providers that might be used during consultation (e.g. a decision aid).
This study has several strengths. It is the first study with a considerable sample size looking 
into bDMARD dose reduction from the patient perspective. Furthermore, the mixed methods 
design and recruitment of patients in different (type of) centres improves the generalizability 
of our results. A possible weakness of our study might be the rephrasing of the factors 
for the MaxDiff questionnaire by the research team. However, we consider the risk of 
misunderstandings low, as the factors were derived from interviews with patients and tested 
by two patients to ensure understandability. Also, this type of research inevitably relies on 
self-reported factors, whereas there might be other influencing factors of which patients are 
unaware, or that are not mentioned due to social desirability. Next to this, some selection bias 
might be present, as the response rate in sub study 2 was 44%. However, our sample seems 
to be representative for the general RA population. Furthermore, the results we found might 
not be generalizable to patients from other countries with, for example, other cultural values, 
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reimbursement systems or traveling distances to the hospital. Therefore, it is important to 
replicate this study in different settings and when possible with a longitudinal design to be 
able to investigate attitudes over time. Finally, assessing the influencing factors from the 
perspective of health care providers would also be important to facilitate implementation of 
bDMARD dose reduction. For future studies on this topic, we recommend recruiting patients 
in a face-toface manner to increase response rate and avoid misunderstanding of the study 
objective.
In conclusion, patients with RA are positive about the option of bDMARD dose reduction in 
case of low disease activity but perceive several barriers and facilitators. This study shows 
that a major concern of patients is a possible increase in disease activity and its influence on 
pain and function. Next to this, it is important for patients to know they can return to a higher 
dose if (further) reduction fails and that the bDMARD will be effective again. These results are 
important to facilitate implementation of bDMARD dose reduction and can be used in clinical 
practice as a starting point for shared decision making.
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Abstract
Objectives
To assess the effects of education, guideline development, and individualized treatment 
advice on rheumatologist adherence to tight control-based treatment and biological dose 
optimization in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthropathy 
(SpA) patients.
Method
This pilot study, among two rheumatologists and two specialized nurses in a general hospital, 
combined education, feedback, local guideline development, and individualized treatment 
advice. Outcomes (baseline and 1 year post-intervention) were the percentage of patients 
with a Disease Activity Score in 28 joints (DAS28) or Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) measured during the visit, mean DAS28/BASDAI, and the percentage of 
patients using a reduced biological dose. DAS28 outcomes only applied to RA and PsA patients, 
BASDAI outcomes only applied to SpA patients whereas outcomes on biological dose applied 
to all patients.
Results
A total of 232 patients (67% RA, 15% PsA, 18% SpA; 58% female, mean age 56 ± 15 years) 
were included in the study. The percentage of DAS28 and BASDAI measurements performed 
increased after the intervention [DAS28 15–51%, odds ratio (OR) 3.3, 95% confidence interval 
(CI) 2.1–5.5; BASDAI 23–50%, OR 2.2, 95% CI 1.0–5.5], with mean DAS28 and BASDAI scores 
remaining similar (DAS28: mean difference 0.1, 95% CI −0.3 to 0.5; BASDAI: mean difference 
0.03, 95% CI −1.8 to 1.9). Use of a reduced biological dose increased from 10% to 61% (OR 3.9, 
95% CI 2.4–6.5).
Conclusions
A multicomponent intervention strategy aimed at rheumatologists can lead to improved 
adherence to tight control-based treatment and a reduction in the use of biologicals in RA, 
SpA, and PsA patients.
Introduction
Treatment of rheumatoid arthritis (RA) is based on tight control principles: setting a target, 
frequent assessment of disease activity, and a structured protocol to make treatment changes. 
This strategy leads to lower disease activity and less functional damage compared to usual 
care.1,2 Unfortunately, the dissemination of tight control-based guidelines has insufficient 
influence on the daily practice of rheumatologists.3 For example, treatment is not always 
changed on time in case of active disease or patients are not receiving the correct disease 
modifying anti-rheumatic drugs (DMARDs).3 
According to the 2014 treat-to-target recommendations: ‘maintenance of the treatment 
target does not in itself imply maintenance of treatment’. This refers to biological DMARD 
(bDMARD) dose optimization, that is dose reduction or cessation of bDMARDs.4 In recent years, 
several studies have shown that this strategy can be successful in patients while preserving 
low disease activity.5,6 The high costs and dose-related side-effects of bDMARDs make dose 
optimization a desirable goal for implementation in daily practice. Nevertheless, actual 
adherence does not seem to be optimal.7
To date, tight control based-treatment and biological dose optimization have mainly been 
studied in RA. However, there is evidence that the same principles might be applied for 
patients with psoriatic arthritis (PsA) and spondyloarthropathy (SpA)8,9 and treat-to-target 
recommendations have been published recently.10
In view of all the existing evidence, we conducted a pilot study to improve RA, PsA, and SpA 
tight control treatment and bDMARD optimization using a multicomponent intervention 
strategy.
Table 1. Outcome measures
Outcome measure Patient population
Percentage of patients with a disease activity measure
    DAS28 RA and PsA patients
    BASDAI SpA patients
Mean score of the disease activity measures
    DAS28 RA and PsA patients
    BASDAI SpA patients
Percentage of patients using a reduced dose of their bDMARD All patients using a bDMARD
Percentage of patients using a concomitant cDMARD All RA patients using a bDMARD
DAS28, Disease Activity Score in 28 joints; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological 
disease-modifying anti-rheumatic drug; cDMARD, conventional disease-modifying anti-rheumatic drug.
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Method
This pilot study was conducted in a general hospital in The Netherlands with two 
rheumatologists and two specialized nurses between May and October 2014. Although the 
intervention was aimed at clinicians, outcomes were measured in patients. All adult patients 
with an ICD-9 code of 714.0 (RA), 696 (PsA), and 720 (SpA) who were using a bDMARD at study 
start and had visited their rheumatologist during the pre- and post-intervention periods were 
eligible for inclusion.
The intervention strategy consisted of: (i) an educational meeting combined with feedback and 
local guideline development (bDMARD dose optimization and tight control-based treatment 
of RA, PsA, and SpA), (ii) individualized treatment advice for all bDMARD users, written in their 
electronic health record (EHR), and (iii) feedback after 3 and 6 months. An example of the 
PowerPoint slides used during the educational meeting can be found in the Supplementary 
Material. This strategy was developed and provided by a rheumatologist–epidemiologist, a 
rheumatology PhD student, and an administrative assistant (AdB, NL, and LN, respectively) 
from the Sint Maartenskliniek, a specialized rheumatology clinic in The Netherlands, with 
experience in using tight control-based guidelines and dose optimization. The choice of the 
different steps was based on Cochrane reviews on effective interventions11,12 and previous 
experience of the authors. The various steps of the intervention took place between May and 
October 2014.
The outcome measures used in this study are outlined in Table 1. All outcomes were compared 
between the pre- and post-intervention periods. As the intervention took place between May 
and October 2014, the patients’ visits most closely situated before and after this time period 
were used as pre- and post-intervention visits, respectively. For all patients, a single visit in 
each period was used for data collection (data as recorded in the EHR).
The study hospital approved this study. The rheumatologists were informed beforehand about 
this study and asked if they would participate. As this was a quality assessment performed 
in the hospital where two authors of this study worked, no written informed consent was 
obtained from the patients. In addition, data collection was performed within the study 
hospital and directly afterwards all patient data were anonymized.
Depending on the type of variable, descriptive statistics are presented as percentages with 
the accompanying absolute numbers or as means with standard deviations. Outcome 
comparisons between the two time periods were made using appropriate statistics (t-test or 
McNemar; two-sided, α = 0.05). As bDMARD dose optimization, according to local guidelines, 
should only be conducted in patients with low disease activity (DAS28 < 3.2/BASDAI < 4 or, if 
not available, the judgement of the rheumatologist) and bDMARD use of minimally 6 months, 
a post-hoc sensitivity analysis was carried out on the percentage of patients using a reduced 
bDMARD dose, only including patients fulfilling both criteria. All analyses were performed 
using STATA version 13.
Results
The four rheumatologists and nurses who participated in this study undertook all of the 
intervention steps. At study start, 258 RA, SpA, and PsA patients were using a bDMARD. Of those 
patients, 24 were lost to follow-up (eight had moved to another city; 16 had not visited the 
study clinic during the post-intervention period). The remaining 232 patients were included in 
the final analysis (Table 2).
Table 2. Description of the patient population (n=232)
Female, % (n) 58 (131)
Age (years), mean ± sd 56 ± 16
Disease duration (years), mean ± sd 9 ± 8
Diagnosis, % (n)
    RA 
    PsA 
    SpA 
67 (153)
15 (34)
18 (40)
Type of bDMARD, % (n)
    Adalimumab 
    Etanercept 
    Tocilizumab 
    Other
42 (98)
22 (50)
13 (30)
23 (54)
RA, Rheumatoid arthritis; PsA, psoriatic arthritis; SpA, spondyloarthropathy; bDMARD, biological  
disease-modifying anti-rheumatic drug; sd, standard deviation.
Table 3. Outcomes on DAS28, BASDAI, and bDMARD use
Pre-
intervention
(n = 232)
Post-
intervention
(n = 232)
MD or OR (95% CI) p-value
DAS28 performed*, % (n) 15 (29) 51 (97) OR 3.3 (2.1 to 5.2) < 0.01
BASDAI performed†, % (n) 23 (9) 50 (20) OR 2.2 (1.0 to 5.5) 0.04
DAS28*, mean ± sd 2.2 ± 0.9 2.1 ± 0.9 MD 0.1 (−0.3 to 0.5) 0.51
BASDAI†, mean ± sd 4.4 ± 2.5 4.3 ± 2.1 MD 0.03 (−1.8 to 1.9) 0.97
Patients using a reduced 
bDMARD dose‡, % (n)
10 (21) 61 (124) OR 3.9 (2.4 to 6.5) < 0.01
Patients using a concomitant 
cDMARD§, % (n)
42 (63) 52 (72) OR 1.1 (0.7 to 1.5) 0.79
DAS28, Disease Activity Score in 28 joints; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological 
disease-modifying anti-rheumatic drug; cDMARD, conventional disease-modifying anti-rheumatic drug; MD, mean 
difference; OR, odds ratio; CI, confidence interval. *Outcome only assessed in patients with rheumatoid arthritis (RA) and 
psoriatic arthritis (PsA). †Outcome only assessed in patients with spondyloarthropathy (SpA). ‡Outcome assessed in all 
bDMARD users. §Outcome only assessed in RA patients using a bDMARD.
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After the intervention, more disease activity measurements (DAS28 and BASDAI) were 
performed and more patients were using a concomitant DMARD (Table 3). Similarly, after the 
intervention, more patients were using a reduced biological dose while the disease activity 
remained stable (Table 3 and Supplementary Tables S1 and S2). Of note, after the intervention, 
20 of the 232 included patients (9%) stopped taking bDMARDs. Nine of them stopped for 
reasons other than dose optimization (pregnancy, infection, ineffectiveness), leaving 11 
patients who successfully stopped their bDMARD after dose optimization (5%).
Finally, the results of the sensitivity analysis on reduced bDMARD use, including only patients 
with data on disease activity and duration of bDMARD use (71% available), were no different 
from those of the primary analysis.
Discussion
To our knowledge, this is the first study within rheumatology describing an improvement 
strategy on tight control-based bDMARD dose optimization combining education, feedback, 
and individualized treatment advice. Our results suggest that the implementation of relatively 
new treatment principles in daily practice is feasible, resulting in increased adherence to tight 
control-based treatment and a sizable reduction in bDMARD use.
The main strengths of this study are the short time between the publication of positive trial 
results on bDMARD dose reduction and the conduct of this pilot study, the combined focus 
on tight control and dose optimization (with tight control being a necessary prerequisite 
for safe and patient-friendly tapering), and the inclusion of RA, PsA, and SpA patients to aid 
generalizability. The main limitation of our study is its small scale, indicating the need to 
replicate our trial in a larger sample of rheumatologists. In addition, our uncontrolled study 
design means that we are not able to comment on which part of our strategy was most 
effective or to infer a definite causal relationship between the intervention strategy and 
the results as other events in the same time period might have contributed to the observed 
results. However, we are not aware of any external factors during the study that could have 
influenced our results.
Within rheumatology, only very few comparable intervention studies on tight control 
implementation exist. One Canadian study also used education and feedback to improve 
daily practice13, and found that education and feedback resulted in more disease activity 
measures being collected by the rheumatologists (DAS28 measurement increased from 43% 
to 57%). These results are in line with our study, although the increase in number of DAS28 
measurements was higher in our study and the mean DAS28 lower (2.1 vs. 3.05).13
Of note, with our intervention strategy we were able to replicate the results from the only two 
randomized controlled trials on bDMARD dose optimization: the DRESS and STRASS studies.5,14 
For example, in the DRESS study, 43% of the RA patients could taper their adalimumab or 
etanercept dose and 20% could stop their bDMARD.5 In our pilot study even more patients used 
a reduced bDMARD dose (61%); however, fewer patients completely stopped their bDMARDs 
(9%). This might be explained by a shorter follow-up in our study (12 months vs. 18 months) and 
the inclusion of SpA patients, in whom stopping is probably less successful.15 Nevertheless, our 
study shows that replication of trial results in daily practice is possible, if sufficient attention 
is paid to optimal implementation of the required changes.
In other settings the separate components of our strategy have previously been shown to 
be effective11,12, but we cannot discriminate between the effects of the different components 
of our intervention strategy. To gain some insight into this issue, a short interview with 
the participating rheumatologists and nurses was conducted after the study. During this 
evaluation it was suggested that the individual treatment advice in the EHR of included 
patients was crucial because it acted as a reminder. In addition, the educational session 
and the development of local guidelines were seen as necessary prerequisites to changing 
behaviour. Finally, the feedback acted as a trigger to improve their practice and the close 
contact with the research team was evaluated positively.
Despite the use of our strategy in only one centre, our study has important practical 
implications as it shows that implementation of tight control and bDMARD dose optimization 
in daily practice is feasible. The enthusiasm of the rheumatologists and nurses at the study 
centre has strengthened our view that rheumatologists are able to apply new treatment 
strategies if they receive assistance in this regard. In our opinion, this study emphasizes 
the fact that implementation research is important in the field of rheumatology to bridge 
the gap between theory and practice. Therefore, we are planning a randomized controlled 
trial to assess the effectiveness of our intervention strategy in a multicentre study aimed 
at tight control-based bDMARD dose optimization: the RAINBOW (Rheumatoid Arthritis 
ImplemeNtation of Biological dose Optimization in the real World) study.
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Main findings
Dose reduction of biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) seems 
feasible for a large proportion of patients with rheumatoid arthritis (RA) after the treatment 
target of low disease activity or remission is reached. Main benefits of dose reduction are 
potentially a lower risk of adverse events, relief of practical burden for patients and cost 
savings. In this thesis, we narratively and systematically reviewed the clinical effects of 
bDMARD dose reduction for patients with RA (chapter 2 and 3) and investigated the cost-
effectiveness of several tapering strategies (chapter 4). Furthermore, we studied the effects 
of ultra-low doses (1 × 500mg or 1 × 200mg) of rituximab for retreatment of RA patients 
(chapter 5). To facilitate implementation, we determined what the most important issues are 
for patients when considering reducing the dose of their bDMARD (chapter 6) and performed 
a pilot study with a multicomponent implementation strategy aiming at treat-to-target and 
bDMARD dose optimisation (chapter 7). Below, we describe the five main findings that are 
derived from these studies. 
Main finding 1: Fixed dose reduction and disease activity-guided tapering of bDMARDs are 
effective and safe. Direct discontinuation of a bDMARD is inferior to continuation (chapter 2 
and 3). 
Main finding 2: A dose reduction strategy of anti-tumour necrosis factor (anti-TNF) agents 
adalimumab and etanercept with four of five tapering steps until discontinuation shows the 
best cost-effectiveness (chapter 4). 
Main finding 3: Retreatment with an ultra-low dose (1 × 500mg or 1 × 200mg) of rituximab 
is effective for the majority of patients, although non-inferiority after six months cannot be 
established at group level (chapter 5). 
Main finding 4: The main issues for RA patients when considering reducing the dose of their 
bDMARD are 1) the possibility to increase the dose in case of a disease flare, 2) the risk of 
deterioration in function/pain and 3) the extent to which patients are involved in the decision 
making process (chapter 6). 
Main finding 5: A multicomponent implementation strategy can lead to improved adherence 
to treat-to-target by health care providers and a reduction in the use of bDMARDs in patients 
with RA, psoriatic arthritis and axial spondyloarthritis (chapter 7).
In the following discussion, I will elaborate on several questions that can be raised regarding 
the findings from this thesis and the applied methodology. I will end with several conclusions, 
implications for clinical practice and suggestions for future research. The questions addressed 
are:
• Why is dose reduction possible?
• Can the principle of dose reduction be translated to other diagnoses?
• Who is responsible for dose reduction research?
• Is (dose reduction of) anti-TNF treatment cost-effective?
• What should be the position of rituximab in RA treatment?
• How can bDMARD dose reduction best be implemented in clinical practice?
General discussion
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• Is it time for a ‘light’ version of systematic reviews?
• What is the optimal design for dose reduction studies?
Discussion 
Discussion of main results
Why is dose reduction possible?
Although the data in this thesis has strengthened the idea that dose reduction of bDMARD 
medication is feasible for a large proportion of RA patients, it is still debatable which 
mechanisms underlie these findings. In the introduction of my thesis I have proposed several 
potential mechanisms that can be classified in three categories: 
1. Suboptimal dose finding: in case of suboptimal dose-finding, the authorized dose might lead 
to overtreatment of most or all patients;
2. Interpersonal variation in dose-response: the authorized dose of a bDMARD will lead to 
overtreatment in some patients because of the variation between patients in dose-
response relationship. Furthermore, the (perceived) response after start of a bDMARD might 
sometimes be exclusively attributable to other factors such as concomitant DMARD use or 
spontaneous improvement;
3. Intrapersonal variation in dose-response: a shift in dose-response relationship within 
patients might occur over time, for example leading to a lower bDMARD dose needed for 
maintenance treatment compared to induction treatment. 
Probably all three mechanisms played a role in the REDO trial, in which we investigated ultra-
low doses of rituximab (chapter 5). 
From the reviews in chapter 2 and 3 it becomes apparent that most studies investigating 
dose reduction do not elaborate on the possible mechanisms behind this but merely state the 
potential advantages (e.g. less adverse events, cost reduction).1-3 We found only two studies 
that did elaborate on this. A narrative review by Fautrel et al. describe the different dose-
response curves that might be conceivable for individuals, providing more insight into the 
variation between patients.4 Next to this, the author of the POET study provided a theoretical 
framework in her thesis in which several factors are described that might influence the 
outcome of stopping or tapering: 1) solid RA diagnosis, 2) the so called ‘window of opportunity’ 
at onset of the disease, 3) pathophysiology 4) remission criterion and 5) the natural course 
of the disease (spontaneous improvement).5 These aspects might contribute to inter- or 
intrapersonal variation in dose-response. 
The extent to which intrapersonal variation plays a role in dose reduction of bDMARDs needs 
further exploration. It is assumed that patients within the window of opportunity, with certain 
sub-types of RA or with ‘true’ remission have more chance of drug-free remission.6 This could 
be explained by a qualitatively different disease in this period in time or in these patients 
(i.e. other type of synovitis) or a quantitatively different disease (i.e. a certain threshold of 
synovitis beneath which treatment is more effective).6 However, a recent systematic review 
did not identify disease characteristics (including time since diagnosis and (duration of) 
remission) as reliable predictors for successful dose reduction.7 To further unravel this, it 
would be interesting to investigate whether a patients’ dose-response can shift over time 
by attempting tapering more than once for the same patient and seeing if this results in a 
different outcome regarding the lowest effective dose. To illustrate, in the STRASS study eight 
patients underwent a second tapering attempt, of which four could be tapered successfully.8 
Unfortunately, the STRASS authors did not elaborate on this and it is uncertain whether other 
factors such as co-medication could have played a role.
 
In summary, I propose that the large proportion of RA patients that is able to taper or stop their 
bDMARD treatment after reaching low disease activity or remission is the result of several 
mechanisms causing interpersonal and intrapersonal (time dependant) variation in dose-
response curves. In addition, sub-optimal dose finding by pharmaceutical companies might 
play a role for specific drugs, as seen for rituximab.9
Can the principle of dose reduction be translated to other diagnoses?
The evidence that dose reduction of bDMARDs is possible for RA patients (chapter 2, 3 and 5), 
poses the question if this principle can be translated to other diagnoses. Indeed, deprescribing 
(the process of withdrawal or dose reduction of medications which are considered 
inappropriate) is an emerging field in medicine.10 For example, several uncontrolled 
studies show that dose reduction and even discontinuation of anti-TNF is possible in other 
inflammatory rheumatic diseases such as psoriatic arthritis and spondyloarthritis.11-15 However, 
evidence from randomized controlled studies is warranted. As a matter of fact at least two 
randomized studies are currently being executed.16,17 Next to this, randomized controlled trials 
are ongoing on disease activity guided tapering of anti-TNF after achievement of remission for 
patients with psoriasis and Crohn’s disease as well.18,19 Furthermore, retrospective evidence 
from 20 patients with atypical haemolytic uremic syndrome showed that a large proportion 
of patients are able to discontinue treatment with eculizumab after achievement of disease 
remission.20 The savings on eculizumab – a very expensive but effective treatment for this 
rare disease - were estimated to be approximately €11.4 million for these 20 patients in the 
Netherlands. 
Dose reduction is particularly a topic of interest for patients with chronic diseases in which 
long-term use of these (often expensive) medications is indicated. Logically, the question of 
dose reduction pops up when patients have achieved a state of remission and issues such as 
adverse events and costs gain more attention. The most important aspects of dose reduction 
to consider are the risk of disease relapse and whether this might induce irreversible damage 
(e.g. organ rejection when tapering immune suppressive drugs after transplantation), the risk 
of adverse events like withdrawal symptoms (such are known for opiates, selective serotonin 
reuptake inhibitors and benzodiazepines21,22) or the possibility that patients develop some 
type of resistance for treatment after dose reduction.23 All in all, dose reduction of a drug can 
be investigated relatively safely if withdrawal symptoms are manageable, no irreversible 
damage can occur due to dose reduction and when it is likely that the drug will be effective 
after reinstatement.
From the above mentioned studies it can be concluded that dose reduction of biological 
treatment is under investigation for several diseases other than RA with the same intent of 
maintaining effectiveness while minimizing harm and reducing costs. Ongoing trials will need 
to show whether dose reduction is also feasible for these diagnoses. 
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Who is responsible for dose reduction research?
When authorizing a new bDMARD treatment, pharmaceutical companies perform efficacy 
studies mostly up to 12 months follow-up. After authorization, these companies are usually 
obliged to monitor ‘real-world’ information about the drug’s (long-term) safety and efficacy 
in so called phase IV studies.24 However, it is often forgotten that although a treatment was 
proven to be effective for RA up to a certain follow-up, this does not automatically imply that 
treatment should be continued indefinitely. In fact, there is absence of proof for both long-
term continuation and dose reduction (including discontinuation) until trials have proven 
otherwise. The general belief, however, is that continuation is indicated unless proven 
otherwise.
 
The fact that dose reduction is possible due to inter- and intrapersonal variation in dose-
response and (in some cases) suboptimal dose finding leads me to the conclusion that research 
into the possibility of dose reduction should be an integral and mandatory part of the (post)
authorization of new bDMARD treatments in RA, for example after several years of use. This 
would prevent situations in which companies do not perform thorough disease specific dose 
finding, such as for rituximab, of which half the authorized dose was shown to be equally 
effective for RA treatment9, and even far lower doses seem effective for retreatment in the 
majority of patients (chapter 5).
The reviews performed in this thesis (chapter 2 and 3) show that bDMARD dose reduction 
research is currently performed at the initiative of (or funded by) both pharmaceutical 
companies1-3,25-28 and investigators independent of industry8,29-32. Obligating pharmaceutical 
companies to investigate dose reduction of their own product would prevent spending of 
government funds on these trials. Of course objective and scientifically sound interpretation 
of findings should be ensured when leaving dose reduction trials to the responsibility of the 
pharmaceutical industry. Next to funding the dose reduction studies, companies should be 
encouraged to produce suitable packages (e.g. low dosed syringes) at lower prices after dose 
reduction is proven effective and safe, preventing flat pricing schedules where high and low 
dose quantities are the same price which, for example, is known for golimumab (100mg and 
50mg syringes) and baricitinib (2mg and 4mg tablets).33
Is (dose reduction of) anti-TNF treatment cost-effective?
Chapter 4 in this thesis shows that all investigated bDMARD tapering strategies are cost-
effective compared to continuation of treatment. This result can be explained by the small 
losses in quality of life, that do not outweigh the large savings observed in the DRESS and 
STRASS studies.34,35 These results are confirmed by other cost analyses from dose reduction 
studies.36-38 For example, a 5-year Markov modelling study based on the PRESERVE study and 
a Swedish RA registry showed that dose reduction or withdrawal are most advantageous 
regarding cost-effectiveness.37 A 5-year Markov study based on 14 trials concluded that dose 
tapering or withdrawal of anti-TNF treatments results in similar reduction of health care 
costs but less time spent in sustained disease control compared to maintaining therapy.36 The 
cost analysis of the POET study (anti-TNF withdrawal) showed mean saved cost of €368k per 
Quality Adjusted Life Year (QALY) lost.38
 
These cost-effectiveness results have to be interpreted in the current context regarding 
bDMARD costs. Prices can be heavily influenced by new developments, such as the 
introduction of biosimilar drugs that compete with the originator. An extreme example is 
the >80% discount that was provided by AbbVie for Humira in the Netherlands, to compete 
with the lower priced adalimumab biosimilars.39 Conversely, new and often costly drugs are 
entering the market that might increase the price of treatment. An example are JAK-inhibitors 
tofacitinib and baricitinib that are now authorized for use in RA.40 In general, dose reduction 
will become less cost-effective when costs of treatment are reduced and cost reduction will 
probably - on the long-term - benefit less rigorous tapering strategies (e.g. no withdrawal, 
more tapering steps, more strict flare criterion) as these minimize losses in quality of life.
An interesting aspect of cost-effectiveness regarding dose reduction is the willingness to 
accept (WTA) losses in quality of life. Mostly, a willingness to pay (WTP) threshold is used in 
cost-effectiveness research which reflects how much society is willing to pay to gain one QALY. 
No universal WTP threshold can be defined because this varies across countries and depends 
on the type of patients it concerns (e.g. the level of disease burden).41 Because dose reduction 
might lead to minor losses in quality of life, instead of a WTP we need to define a WTA. There 
is ongoing debate about whether the WTA should be symmetrical with the WTP.42,43 On the 
one hand people reason that one QALY lost should be compensated by a higher sum than 
we are willing to pay to gain one QALY because it is worse to lose what you have than not 
to gain something (the psychological principle of loss aversion44). On the other hand, when 
considering a fixed health care budget, hypothetically every euro saved somewhere while 
losing QALYs can be used elsewhere to gain QALYs.42 However, given the large savings seen with 
dose reduction, the threshold of WTA - although it may be higher than the WTP - will probably 
be exceeded anyway.
 
Lastly and provokingly, is bDMARD treatment on itself currently cost-effective?42,45,46 A 
systematic review by Joensuu et al. shows that bDMARD treatment for csDMARD naïve or 
csDMARD resistant patients is not cost-effective (at a WTP threshold of €35,000). bDMARDs 
might be cost-effective for csDMARD resistant patients at thresholds of €50,000 to 100,00045 
which is around and above the highest level (€80,000) we are willing to pay in the Netherlands 
but only for patients with maximum disease burden.41 When following these results, almost 
every form of dose reduction will prove to be cost-effective, because the intervention was not 
cost-effective to start with. Nonetheless, other harms and benefits of bDMARD treatment and 
subsequent dose reduction (e.g. improvement in function, prevention of joint damage, patient 
burden and side effects) should be considered as well, regardless of cost-effectiveness.
What should be the position of rituximab in RA treatment?
The REDO study (chapter 5) showed that a retreatment strategy (providing extra medication 
in case of flare) with ultra-low doses of the bDMARD rituximab (i.e. 500mg or 200mg) is non-
inferior for RA patients regarding disease activity up to six months. These results are promising, 
showing that much lower doses might be used in clinical practice for retreatment of these 
patients, improving safety, reducing infusion time and saving costs. Rituximab is registered as 
treatment option for RA after failure of at least one anti-TNF agent.47 However, evidence has 
shown that rituximab is superior to anti-TNF after failure of an anti-TNF agent48,49 and can be 
used as first bDMARD treatment option as well50. In the Netherlands, the Dutch Rheumatology 
Association has included this in their consensus statement on the use of rituximab, and also 
others have adapted this point of view.51,52
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Since almost all bDMARD options for RA show similar effectiveness53, the choice for a certain 
sequence of bDMARDs mainly depends on other factors like safety, costs and ease of use. 
Regarding safety, rituximab has a good and, compared to some bDMARDs, even superior safety 
profile on serious infections (the main concern when using bDMARDs).54 Additionally, the 
standard-low dose of rituximab is associated with a reduced risk of infections compared to the 
authorized dose55, and our REDO study shows additional reduced infection risk for ultra-low 
doses (chapter 5). This is especially important as a particular concern with rituximab, which 
arose after introduction, is the occurrence of progressive multifocal leukoencephalopathy 
(PML), a very rare but often deadly condition.56 This was the reason for the European Medicines 
Agency not to authorize rituximab as first bDMARD. The risk of PML might, however, be lower 
than thought at that time since rituximab was authorized in a higher dose than can be used 
currently (2000mg versus 1000mg or even lower) and was initially used in the more severe RA 
cases. Estimations show a PML incidence of approximately 1 in 500,000 for rheumatic diseases 
after bDMARD treatment (rituximab but also infliximab) although causality is difficult to 
establish.57 The very small chance of PML infection might therefore be outweighed by the 
reduced infection risk seen with standard low-dose and ultra-low doses of rituximab (chapter 
5).
 
In the Netherlands, standard low-dose of rituximab costs approximately 5,000 euro per 
patient per year33, which will be reduced further when a retreatment strategy with ultra-low 
doses would prove to be feasible for a longer period of time. These costs are lower than all 
other bDMARDs currently available, although discounts and future price developments will be 
of influence. Regarding usability, rituximab is a special case since it requires only two infusions 
per year because of its long-lasting effect on B-cells. Consequently, there are no issues with 
therapy adherence or the need for patients to inject themselves or keep syringes cooled. When 
patients have reached their treatment target, two visits to a hospital could be sufficient per 
year for seeing the rheumatologist and administration of RTX. For certain countries and/or 
patient groups this might be preferable to the usability of other bDMARDs. Combined, the 
ease of use and low costs of rituximab might make it an ideal treatment option especially for 
developing countries.58
 
In conclusion, standard low-dose rituximab therapy - and possibly in time a retreatment 
strategy with ultra-low doses - should be recommended early on in RA treatment because of 
its favourable profile on efficacy, safety, usability and costs. 
How can bDMARD dose reduction best be implemented in clinical practice?
While the evidence on the effects of bDMARD dose reduction is accumulating, less is known 
about how to implement these new insights into daily patient care. In chapter 6 of this thesis, 
the patient perspective on dose reduction was investigated. This study showed patients’ need 
of information about some therapeutic aspects of dose reduction (the risk of flare, whether 
therapy could be reinstated in case of flare and whether this would be effective again) and 
patients’ need for reassurance from and shared decision making with their rheumatologist.59 
I think patients’ concerns should be addressed in daily practice by introducing the topic of 
dose reduction at start of the bDMARD treatment, for example during the first prescribing 
consultation and in the patient information leaflet. Informing on dose reduction possibilities 
and providing expectation management prevents the idea that bDMARDs are used for a 
lifetime. When a patient is eligible for dose reduction, the rheumatologist should initiate a 
conversation on the topic with specific attention to the main issues (as described in chapter 
6) that are important for patients, leading to a shared decision.
In the mixed methods study described in chapter 6, we included both patients that had 
experience with bDMARD dose reduction as patients that did not. In this cross-sectional study 
we found that the risk of experiencing pain from the rheumatoid arthritis was more important 
for patients without experience with dose reduction. It would be interesting to explore in a 
longitudinal study whether a shift in perspective occurs for individuals after they have 
experienced reducing the dose of their bDMARD.
In chapter 7, we learned that a multicomponent intervention aimed at implementation 
of treat-to-target and bDMARD dose optimisation can be very effective in daily practice. 
This also shows that trial results can be reproduced in daily practice without the strict in-/
exclusion criteria and guidance of clinical trials. However, some specific aspects of our pilot 
study setting might have contributed to the large effects that were observed. Firstly, there 
was an internal demand for a project aiming at implementation of treat-to-target and 
bDMARD dose optimisation. Secondly, there was a large potential for improvement, as in 
the pre-intervention period disease activity was only measured in 15% of visits and only 10% 
of patients used lower than authorized doses. Lastly, the incentive of savings (of which the 
rheumatology department benefited as well) probably influenced the effect size. In general, 
potential savings can differ largely between settings and through time because this depends 
on the price of the bDMARDs (e.g. availability of biosimilars, contracts with pharmaceutical 
companies), the agreements with health insurance companies, national legislation and finally 
the specific arrangements within a hospital.
 
In this context, it is of interest to share the lessons from an initiative to implement bDMARD 
dose reduction in the Netherlands (the RAINBOW study) which was stopped prematurely and 
was therefore not included in this thesis. Our research team aimed to perform a randomised 
controlled implementation trial based on the pilot study described in chapter 7. As suggested 
in literature60 we developed a multifaceted implementation strategy targeting the main 
barriers for implementation in clinical practice using the framework of Flottorp et al.61 (see 
table 1). Unfortunatly, this study was not completed as we did not succeed in recruiting 
paticipating centers.
 
In my opinion, two main factors have led to the failure of the RAINBOW project. Firstly, 
there was a lack of (internal and external) motivation among the rheumatology staff at 
the potential study centers. The intervention would be applied by experts from the Sint 
Maartenkliniek which suggested that quality was suboptimal and external intervention was 
needed, possibly resulting in a ‘not invented here syndrome’. Furthermore, contact was made 
by simultaneously informing the boards of directors and the rheumatology staff of hospitals. 
This could have led to the feeling of a top-down approach where the intervention would be 
forced on the rheumatologists by the boards, just to save money on hospital level. Secondly, 
no financial incentive could be realised because health care insurers eventually did not 
particpate in a proposed shared savings model (making arrangements so that the hospital/
department would benefit from the potential savings on bDMARD costs during a pre-specified 
period). As a result of these factors, no hospitals consented to participate and the project was 
terminated prematurely. 
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Considering the information described above, I conclude that implementation is a matter 
of overcoming barriers, not only at the level of patients or care providers, but also at the 
level of hospitals and insurers. For future initiatives to implement bDMARD dose reduction 
at a national level, it could still be usefull to employ the implementation strategy that was 
developed and investigate it’s effectiveness. Also, the lessons from the RAINBOW study should 
be taken into account. The Dutch Society for Rheumatology could, for example, use (parts of) 
the developed intervention in their recommendations or trainings which would prevent the 
intervention coming from one specific hospital. 
Table 1. Proposed strategy for implementation of treat-to-target and bDMARD dose optimisation
Components of implementation strategy Barriers that are targeted61
Financial incentive
• Providing a financial incentive for the hospital 
(and if possible also for the rheumatologists) 
through a shared savings model
• Financial disincentive to change current 
performance since, without a shared savings 
model, only insurers will benefit from possible 
savings. 
Inventory 
• First meeting to draw up the specific hospital’s 
situation and make a planning for the project.
• Local situation is very specific for each hospital, 
tailoring is needed. 
Education
• Distribution of relevant documents/articles.
• Presentation about treat-to-target and disease 
activity guided bDMARD dose optimization.
• Scripting/practicing conversation on bDMARD 
dose reduction with patients
• Lack of knowledge
• Lack of awareness and familiarity
Protocols
• Development of, and agreement on relevant 
local treatment protocols
• Lack of assistance for clinicians: health care 
providers have no protocols to help them 
adhere to the recommendations.
Advice
• Advice on adaptations in patient information 
• Advice on adaptations in working processes
• Patient factors: patient information is not in 
line with the recommendations and barriers 
that are present among patients.
• Organizational factors: working processes are 
not in line with the recommendations 
Feedback 
• Feedback meetings on adherence to protocols 
and on implementation process on multiple 
time points 
• Lack of insight into own practice
Treatment advice (decision support)
• Treatment advice for rheumatologists, based 
on the local protocols, in the electronic health 
record of all bDMARD users 
• Lack of awareness and familiarity: health care 
providers need treatment advice to get familiar 
with the new protocols and recommendations. 
Methodological considerations
Is it time for a ‘light’ version of systematic reviews?
In this thesis, two types of reviews were conducted: a narrative review with systematic 
literature search (chapter 2) and an (update of a) Cochrane review (chapter 3). The experience 
with, and difference between both processes made me wonder whether systematic reviews 
are not surpassing their primary goal to “create and disseminate up-to-date review of RCTs of 
healthcare interventions in order to help health care professionals make informed decisions”.62 
Has the constant evolution of better and more rigorous review methodology, with Cochrane 
reviews at the end of the spectrum, made the process impossible to complete in a timely 
manner, and might it be time for other, ‘light’ versions of reviews?
In literature concerning meta-research (‘research about research’), the large amount of time 
spent on systematic reviews has been questioned as well.63 Mallet et al. address the benefits 
and challenges of systematic reviews and state that ‘researchers and donors need to consider 
whether the full application of a rigid systematic review approach is justified in relation to 
the time and resources required’.64 Ioannidis et al. even question the relevance of the majority 
of reviews by stating that only 3% of systematic reviews provides decent and clinically 
useful results due to the fact that many reviews are not published, redundant, flawed or 
even misleading.65 In our own experience, writing a Cochrane review was a very lengthy and 
cumbersome process. This was partly due to the methodology and partly due to the Cochrane 
collaboration’s bureaucracy and lack of funding they experience.
 
While solutions for some of the problems mentioned above already exist, such as prospective 
registration of reviews, reporting guidelines and tools to evaluate quality of studies, some 
additional measures are needed to make the process of systematic reviews less time and 
resource consuming. One solution might lie in the automatic encoding of data from clinical 
trials to facilitate inclusion in systematic reviews.63 For topics on which a complete systematic 
review is really warranted, splitting reviews into smaller parts can keep the process timely 
and focused. Lastly, other, less time consuming type of reviews should be considered that 
might vary regarding the search, appraisal, synthesis and analysis of the data.66 The narrative 
synthesis of data described in chapter 2 (based on a systematic literature search) led to roughly 
the same results as the Cochrane review described in chapter 3, while taking substantially less 
time. It would be really interesting to investigate in general whether other types of reviews are 
able to lead to the same conclusions as large systematic reviews but with a fraction of the 
time investment, and which methodological factors are decisive for final quality and/or time 
investment. 
What is the optimal design for dose reduction studies?
Chapters 2, 3 and 5 of this thesis illustrate that bDMARD dose reduction studies come in all 
shapes and sizes. Study designs varied from large double-blind or open-label RCTs2,26,30 to small 
observational studies/cohorts67. The investigated dose reduction intervention can be a fixed 
intervention (e.g. withdrawal or 50% dose reduction68) or a strategy approach (e.g. disease 
activity-guided tapering8). Furthermore, the primary question may be one of superiority27 
or non-inferiority32. Learning from this variation, what would be the optimal design when 
investigating bDMARD dose reduction?
Firstly, it is interesting that many studies chose a superiority design (or do not state their 
design choice) while a non-inferiority design is most suited for a question on bDMARD dose 
reduction in which one wants to investigate whether a lower dose is not inferior to the 
full-dose regarding effectivity.69,70 It is important to mention that, when non-inferiority is 
investigated on efficacy, the new intervention should be advantageous on another aspect for 
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example costs, usability or safety. Choosing a superiority design to answer a non-inferiority 
question might lead to insufficient sample size and clinically irrelevant conclusions.70
 
Several aspects of non-inferiority trials make their execution and interpretation complex.71 
Most important is a well-motivated and a priori choice of the non-inferiority margin that 
indicates the maximum acceptable difference between the experimental and the reference 
treatment. Furthermore, assay sensitivity (the ability of a trial to distinguish effective 
treatments from those that are less effective, or ineffective) needs to be proven/motivated 
since rejecting the null hypothesis in a non-inferiority study still leaves the option that the 
study was not suitable to demonstrate a difference in case of inferiority. Another complicating 
factor is the fact that non-inferiority trials should primarily be analysed in a per protocol 
manner, since including patients that did not undergo the allocated intervention might dilute 
the effect and lead to a false conclusion of non-inferiority. It was shown that many of these 
issues are not adequately addressed in peer-reviewed studies that were performed on the 
area of RA treatment69,71 and this presents an ongoing challenge. In designing the REDO trial 
(chapter 5) we have attempted to avoid these potential pitfalls.72 
Also the choice for a specific type of dose reduction intervention is an important aspect of 
dose reduction trials. While a fixed intervention like withdrawal (without escape medication) 
does provide evidence on the ‘real’ effect of the intervention, it will not reflect current clinical 
practice in which patients will be treated with extra/other medication in case of flare. However, 
using the treat-to-target principle, outcomes of all randomization arms will regress to each 
other and non-inferiority can always be shows on the long run.73,74 A similar problem is present 
regarding the blinding of dose reduction trials. While blinded studies provide information on 
real intervention effects, these will not be completely reproducible in clinical practice where 
expectations of care providers and patients play a role.4
 
I argue that (well-performed) randomized controlled non-inferiority studies are the desired 
type of study in case of bDMARD dose reduction. Both blinded and open-label studies and both 
fixed interventions as strategy approaches provide useful information that is needed to assess 
real effects as well as implications for daily practice. 
Conclusions and implications for clinical practice
The discussion of the main findings from this thesis described above, result in several 
conclusions and implications for clinical practice: 
• Fixed dose reduction or disease-activity guided tapering of bDMARDs should be proposed to 
RA patients with stable low disease activity or remission.
• Tapering anti-TNF agents adalimumab and etanercept can best be done using four or five 
tapering steps until discontinuation.
• Patients should be informed about the possibility of bDMARD dose reduction and the 
current evidence on benefits and risks, specifically focusing on the possibility to increase 
the dose when tapering fails and reassurance that reinstatement will be effective again.
• A retreatment strategy with ultra-low doses rituximab (i.e. 500mg or 200mg) is non-inferior 
compared to standard low dose for RA patients regarding disease activity up to 6 months. 
However, additional analyses and long-term follow-up are essential to provide efficacy and 
safety data that is needed before recommendations for clinical practice can be made. 
• When aiming to (better) implement bDMARD dose reduction in clinical practice, barriers on 
the level of patients and care providers should be addressed as well as barriers on the level 
of hospitals and insurers within the specific health care system. 
• Regulatory agencies should consider obligating pharmaceutical companies to perform dose 
reduction research several years after market entry of a new bDMARD for RA treatment. 
Future research
The research described in this thesis brings to light several topics that need further exploration: 
• Additional evidence on dose reduction of anti-TNF agents certolizumab pegol, golimumab 
and infliximab is warranted. 
• Longitudinal research on possible changes in a patients’ dose-response to a certain bDMARD 
over time would help elucidating the precise mechanisms behind dose reduction. 
• Long-term effects of bDMARD dose reduction regarding radiographic damage, adverse 
events and other unintended effects need to be studied further. 
• Additional data on ultra-low doses rituximab for retreatment of RA - needed to make 
recommendations for clinical practice - will follow from additional analyses of the REDO 
trial and a two-year observational follow-up of this study.
• Depending on further evidence regarding ultra-low doses for retreatment of RA, future 
research might address the use of ultra-low doses from start of treatment with rituximab 
and/or randomized controlled evidence on a treatment strategy using ultra-low doses of 
rituximab. 
• A longitudinal, qualitative study into the perspective of RA patients regarding bDMARD dose 
reduction could provide useful information on whether a shift in beliefs/attitude occurs 
after patients personally experience dose reduction. 
• Evidence on bDMARD dose reduction in patients with other diseases is currently expanding 
and more research on efficacy, safety, cost-effectiveness, prediction and implementation 
are needed to create a clear picture of the possibilities within these diseases. 
• Comparing the process and conclusions of systematic reviews and other, less-time 
consuming, types of reviews to evaluate whether (for certain topics) a ‘light’ form of review 
might result in comparable conclusions with far less resources needed. 
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Summary
Rheumatoid arthritis (RA) is a chronic inflammation of the joints that affects between 0.5% and 
1% of the population in Western countries. Most RA patients can reach remission or low disease 
activity when treated with Disease Modifying Anti-Rheumatic Drugs (DMARDs) following the 
principle of treat-to-target (i.e. setting a treatment target, monitoring disease activity and 
adjusting treatment when the target is not reached). Biological DMARDs (bDMARDs) are a 
relatively new class of DMARDs that - by interfering with the inflammation cascade - control 
disease activity and prevent long-term damage. Because bDMARDs have a dose-dependent 
risk of side effects (mainly infections), pose practical burden on patients (e.g. keeping syringes 
cooled, travelling to the hospital for infusion therapy) and are expensive (up to €14.000 per 
patient per year), many studies have addressed the topic of dose reduction after patients have 
reached their treatment target. It has already been shown that dose reduction is feasible and 
safe for a large proportion of patients but many questions remain. In this thesis we had the 
following research objectives:
• To provide an overview of the existing evidence on bDMARD dose reduction (chapter 2)
• To systematically review the current evidence on the benefits and harms of down-titration 
of anti-TNF agents (chapter 3)
• To investigate the cost-effectiveness of different anti-TNF tapering strategies (chapter 4)
• To assess the efficacy of ultra-low doses rituximab for retreatment of patients with RA 
(chapter 5)
• To identify which factors are important for patients with RA when considering dose 
reduction (chapter 6)
• To explore the effect of a multi-faceted strategy aimed at implementation of bDMARD dose 
reduction in clinical practice (chapter 7)
Chapter 2: Review on bDMARD dose reduction
Since bDMARD dose reduction is a fast developing field of research, we aimed to provide 
an overview of current literature. In chapter 2 we narratively summarised the evidence on 
bDMARD dose reduction based on a systematic literature search in four scientific databases 
(up to August 2016). A total of 45 studies were included in this review (15 randomised controlled 
trials and 30 observational studies). These studies show that bDMARD dose reduction can 
be considered in all RA patients who achieve low disease activity or remission for at least 
six months. The best strategies are disease-activity-guided dose tapering and fixed dose 
reduction since discontinuation (without restarting) results in a higher flare rate, worse 
physical functioning and more joint damage. Disease activity should be monitored closely 
when tapering bDMARD treatment. If a flare occurs the dose should be reinstated to the lowest 
effective dose. This has been shown to be safe and effective. Unfortunately, no clear predictors 
of successful dose reduction have been identified so far. 
Chapter 3: Cochrane review on anti-TNF down-titration
In chapter 3 an update of the 2014 Cochrane review on anti-tumour necrosis factor (anti-TNF) 
down-titration is outlined. Four scientific databases, four trial registries and two databases 
with conference proceedings were searched (up to March 2018). Ultimately, 14 studies were 
included (13 randomised controlled trials and one controlled clinical trial) that investigated 
dose reduction of anti-TNF compared to continuation of anti-TNF with a grand total of 3,315 
participants.
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 We found that fixed dose reduction of anti-TNF is comparable with continuing the standard 
dose with regard to mean disease activity, the proportion of participants remaining remission, 
and mean physical function. Fixed dose reduction probably slightly increases the proportion 
of participants with minimal radiographic progression. Anti-TNF discontinuation is an inferior 
strategy compared with continuation of anti-TNF in terms of disease control (mean disease 
activity and the proportion of participants remaining in remission), minimal radiographic 
damage, function and the number of withdrawals due to adverse events. This review shows 
that disease activity-guided tapering is comparable to continuation with regard to mean 
disease activity, the proportion of participants remaining in remission and the proportion 
of participants switched to another biologic. Tapering may result in a slight increase in the 
proportion of participants with radiographic progression and probably leads to a slight 
deterioration in function.
For clinical practice, an attempt to reduce the dose (or increase the dosage interval) in people 
with low disease activity with RA on full-dose anti-TNF seems sensible within a context of 
treat-to-target. Discontinuation should not be attempted without regular assessment of 
disease activity, setting a treatment goal and reinstatement of treatment when necessary. 
Because disease activity-guided dose tapering provides the opportunity to find the lowest 
effective dose for each individual patient and to discontinue treatment as the final step of the 
tapering process, this may be the most cost-effective and feasible approach in clinical practice.
Chapter 4: Markov modelling of five different tapering strategies
In chapter 4 we described a modelling study in which we used data from two randomised 
controlled trials and one cohort to investigate the cost-effectiveness of five different anti-TNF 
tapering strategies. Using Markov models, the following tapering strategies for etanercept 
and adalimumab were tested against continuation: 
• Tapering in four steps until discontinuation (100%, 67%, 50% 0%) 
• Tapering in five steps until discontinuation (100%, 67%, 50%, 33%, 0%) 
• Tapering without withdrawal (100%, 67%, 50%, 33%) 
• Use of a stricter flare criterion: Disease Activity Score in 28 joint (DAS28) > 2.6 
• Use of a theoretical predictor for successful tapering (€100, 80% sensitive and specific)
The results show that all tapering strategies lead to cost savings (range: €5,128 to €7,873) 
but yield more short-lived flares compared to continuation. The differences in utilities 
compared to continuation are minimal and not clinically relevant (range: -0.005 to 0.007 
Quality Adjusted Life Years). Tapering in four steps until discontinuation was cost-effective 
compared to all other strategies (highest incremental Net Monetary Benefit). However, the 
decision for tapering in four or five steps might best be based on shared decision making due 
to a large overlap in credible intervals between these strategies. A tapering strategy in which a 
biomarker for successful dose reduction is available becomes cost-effective compared to trial-
and-error tapering when the biomarker has a sensitivity and specificity of at least 84%.
Chapter 5: Efficacy of ultra-low doses of rituximab for retreatment of RA patients (REDO 
study)
Our narrative review (chapter 2) showed a lack of data on dose reduction of rituximab. 
However, several small uncontrolled studies have suggested that ultra-low doses of rituximab 
(below the standard low-dose of 1 x 1000mg) might be effective for RA treatment. In chapter 
5 we outline a six-month, multi-centre, double-blind non-inferiority trial (REDO study) to 
investigate this. RA patients with sufficient response to rituximab were randomised in a ratio 
of 1:2:2 to 1 × 1000mg, 1 × 500mg or 1 × 200mg rituximab respectively. Measurements were 
performed at baseline, three and six months. The primary analysis consisted of a hierarchical 
testing procedure comparing the ultra-low doses (1 × 500mg at three and six months, then 
1 × 200mg at three and six months) to 1 × 1000mg using a non-inferiority margin of 0.6 on 
DAS28-CRP. The projected inclusion was met (n=142). The 500mg dose was non-inferior to 
1000mg at three months (-0.07, 95% confidence interval (CI) -0.41 to 0.27, p<0.001) but not at 
six months (0.29, 95% CI -0.08 to 0.65 p=0.09). The 200mg dose was non-inferior to 1000mg 
at both time points but our pre-defined hierarchical testing precluded inferring formal non-
inferiority for the 200mg dose. Mean DAS28-CRP scores remained low in all groups throughout 
the study, and B-cell counts decreased similarly at three months. In both ultra-low dose 
groups two patients received extra 1000mg rituximab due to a flare. In the 200mg dose group 
more patients used intramuscular glucocorticoids but this was found not to be statistically 
significant. In both ultra-low dose groups, the incidence of infections was significantly lower 
than in the 1000mg group. Thus, non-inferiority of retreatment with 1 × 500mg or 1 × 200mg 
rituximab versus 1 × 1000mg after six months could not formally be established. Nonetheless, 
ultra-low doses appear similarly effective in the majority of RA patients with a better safety 
profile and possibly a limited increase of co-medication.
Chapter 6: The patient perspective on bDMARD dose reduction
Dose reduction of a bDMARD has advantages and downsides. The decision for dose reduction 
is therefore sensitive to individual preferences and might best be based on shared decision 
making between rheumatologist and patient. It is therefore important to get insight into 
the perspective of patients on this topic. In chapter 6 we described a mixed methods study 
into patients’ perspective on bDMARD dose reduction. First, semi-structured interviews were 
held with 22 RA patients to identify factors that patients feel might play a role for them when 
considering reducing the dose of their bDMARD. Using inductive thematic analysis, 30 factors 
were derived from these interviews that were subsequently used in a quantitative study 
among 192 RA patients from three Dutch hospitals. This was a maximum difference scaling 
survey in which patients completed 18 questions where they had to indicate the most and least 
important factor from a subset of all factors. Using specific software a relative importance 
score was calculated for each factor resulting in a ranking of all 30 factors. Most respondents 
(74%) had a positive attitude towards bDMARD dose reduction. The results showed that 
patients are concerned that dose reduction will lead to a disease flare that affects their daily 
life (e.g. pain, function). It is important for patients to know that it is possible to increase the 
dose if (further) reduction fails and that the bDMARD will be effective again. Patients value 
the opinion of their rheumatologist, and being involved in the decision to start tapering is 
highly ranked as well. The factors valued most important were consistent between different 
subgroups of patients. 
Chapter 7: Pilot implementation of treat-to-target and bDMARD dose optimisation
Although current guidelines include recommendations regarding bDMARD dose reduction, 
this does not guarantee implementation in clinical practice. Chapter 7 reported on the pilot 
implementation of treat-to-target and bDMARD dose optimisation using a multicomponent 
strategy consisting of education, feedback, local guideline development and individualised 
treatment advice. This pilot study was performed in a general hospital with two 
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rheumatologists and two specialised nurses. Data on bDMARD users (with a diagnosis of RA, 
axial spondyloarthritis (SpA) or psoriatic arthritis (PsA)) was retrospectively collected from the 
electronic health record before and one year after the intervention period. Outcomes were the 
percentage of patients with a disease activity measurement, mean disease activity score and 
the percentage of patients using a reduced bDMARD dose. In total 232 patients were included 
in the study (67% RA, 15% PsA and 18% SpA). The percentage of disease activity measurements 
performed increased after the intervention while mean scores remained similar. The 
proportion of patients that used a reduced bDMARD dose increased from 10% to 61%. All in 
all, our results suggest that the implementation of relatively new treatment principles in daily 
practice is feasible, resulting in increased adherence to tight control-based treatment and a 
sizable reduction in bDMARD use.
Conclusions
This thesis shows that fixed dose reduction and disease activity-guided tapering of bDMARDs, 
after patients have reached their treatment target of remission or low disease activity, are 
effective and safe. Direct discontinuation of a bDMARD is inferior to continuation (chapter 2 
and 3). A tapering strategy of anti-TNF agents adalimumab and etanercept with four or five 
steps until discontinuation shows the best cost-effectiveness (chapter 4). Retreatment with 
an ultra-low dose (1 × 500mg or 1 × 200mg) of rituximab is effective for the majority of patients, 
although non-inferiority after six months cannot be established at group level (chapter 5). The 
main concerns for RA patients when considering reducing the dose of their bDMARD are 1) the 
possibility to increase the dose in case of a disease flare, 2) the risk of deterioration in function/
pain and 3) the extent to which patients are involved in the decision making process (chapter 
6). Lastly, a multicomponent implementation strategy can lead to improved adherence to 
treat-to-target and reduced bDMARD use in patients with RA, PsA and SpA (chapter 7). 
Chapter 10
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Zinnig en zuinig gebruik van biologicals bij reumatoïde artritis
Reumatoïde artritis (RA) is een chronische ontsteking van de gewrichten die voorkomt bij 
ongeveer 0.5% tot 1% van de mensen in Nederland. Voor de meeste patiënten met RA is het 
mogelijk om de ziekteactiviteit te verminderen of zelfs (tijdelijk) te laten verdwijnen wanneer 
ze behandeld worden met reumaremmers. De behandeling met deze medicijnen werkt het 
beste wanneer een behandeldoel gesteld wordt (bijv. weinig of geen ziekteactiviteit), de 
ziekteactiviteit regelmatig gemeten wordt en de behandeling aangepast wordt wanneer het 
behandeldoel nog niet is behaald. Biologicals zijn een relatief nieuwe soort reumaremmers die 
de ziekteactiviteit verminderen en schade aan de gewichten op langere termijn voorkomen. 
Het gebruik van biologicals heeft ook nadelen. De medicijnen kunnen bijwerkingen (vooral 
infecties) geven en het gebruik kan soms praktisch lastig zijn. Injectiespuiten moeten 
bijvoorbeeld koel bewaard worden en voor sommige reumaremmers moeten patiënten naar 
het ziekenhuis voor een infuus. Bovendien zijn biologicals duur; ze kunnen tot wel €14.000 
per patiënt per jaar kosten, alhoewel de afgelopen jaren de kosten fors dalen. Vanwege deze 
nadelen hebben verschillende studies al gekeken naar de mogelijkheid om de dosering van 
een biological te verlagen, nadat patiënten hun behandeldoel hebben behaald. Uit deze 
studies blijkt dat de meeste RA patiënten hun biological kunnen afbouwen. Toch zijn er 
nog verschillende vragen over het afbouwen van biologicals. In dit proefschrift is eerst een 
overzicht gemaakt van de huidige literatuur over dit onderwerp (hoofdstuk 2 en 3). Daarna 
is onderzocht welke methode het beste gebruikt kan worden voor het stapsgewijs afbouwen 
van een biological (hoofdstuk 4). Er is ook gekeken of ultra-lage doseringen van de biological 
rituximab werkzaam zijn voor patiënten met RA (hoofdstuk 5). In hoofdstuk 6 is onderzocht 
wat patiënten belangrijk vinden wanneer ze overwegen hun biological af te bouwen zodat 
reumatologen in de praktijk het gesprek over afbouwen makkelijker kunnen aangaan. Ook 
hebben we gekeken of een interventie-programma ervoor kan zorgen dat reumatologen 
vaker biologicals afbouwen (hoofdstuk 7). 
Hoofdstuk 2: Review over het afbouwen van biologicals
Gezien de snelle ontwikkelingen op dit onderzoeksgebied is eerst een overzicht gemaakt van 
de huidige literatuur over het afbouwen van biologicals. In hoofdstuk 2 hebben we gezocht 
naar studies in vier wetenschappelijke databases (tot en met augustus 2016). In totaal 
werden er 45 studies gevonden waarin biologicals werden afgebouwd. Uit deze verzameling 
van studies bleek dat het afbouwen van een biological overwogen kan worden voor alle RA 
patiënten die al langer dan zes maanden weinig of geen ziekteactiviteit hebben. De beste 
strategie voor het afbouwen van een biological is het eenmalig verlagen van de dosering 
(bijvoorbeeld het halveren van de dosis) of het stapsgewijs afbouwen van de dosis op geleide 
van de ziekteactiviteit. Het direct stoppen van de biological leidt tot meer opvlammingen 
van de reuma, slechter functioneren en meer gewrichtsschade. Wanneer een patiënt zijn 
biological afbouwt is het belangrijk om regelmatig de ziekteactiviteit te meten. In het geval 
van een opvlamming moet de dosering weer verhoogd worden. Uit de huidige literatuur blijkt 
dat het verhogen van de dosering na afbouwen werkzaam en veilig is. Helaas is op dit moment 
nog niet te voorspellen bij welke patiënten succesvol afgebouwd kan worden en bij welke niet.
Hoofdstuk 3: Review over het afbouwen van TNF-remmers
Hoofdstuk 3 beschrijft een update van een eerdere review uit 2014 over het afbouwen van 
TNF-remmers (een specifieke klasse biological) bij RA patiënten. Vier wetenschappelijke 
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databases, vier studieregisters en twee archieven van wetenschappelijke congressen werden 
doorzocht (tot maart 2018). Uiteindelijk werden er 14 studies gevonden die het afbouwen van 
een TNF-remmer vergeleken met het doorgaan met deze TNF-remmer met in totaal 3.315 
deelnemers.
 
Uit deze studies blijkt dat het eenmalig verlagen van de dosering van een TNF-remmer 
(bijvoorbeeld het halveren van de dosis) vergelijkbaar is met het doorgaan met de standaard 
dosering wanneer gekeken wordt naar ziekteactiviteit, het aantal patiënten dat geen 
reumaklachten heeft en het functioneren van patiënten. Wel kan het eenmalig afbouwen 
leiden tot een kleine toename van het aantal patiënten met minimale schade aan de 
gewrichten. Het direct stoppen van een biological is slechter dan het doorgaan met de 
medicatie wanneer gekeken wordt naar ziekteactiviteit, het aantal patiënten met minimale 
gewrichtsschade en functioneren. Het stapsgewijs afbouwen van een biological op geleide van 
ziekteactiviteit geeft vergelijkbare uitkomsten als het doorgaan met de standaard dosering 
wanneer gekeken wordt naar ziekteactiviteit, het aantal patiënten zonder reumaklachten en 
het aantal patiënten dat naar een andere biological moet wisselen. Stapsgewijs afbouwen kan 
wel leiden tot een kleine toename van het aantal patiënten met minimale gewrichtsschade en 
een kleine verslechtering in functioneren.
 
Concluderend kan in de klinische praktijk een biological op proef afgebouwd worden bij 
patiënten met RA die een rustige ziekte hebben. Het direct stoppen van een biological is niet 
aan te bevelen zonder dat de ziekteactiviteit regelmatig gemeten wordt en de biological 
weer gestart wordt wanneer dat nodig is. De meest voor de hand liggende strategie is het 
stapsgewijs afbouwen van een biological op geleide van ziekteactiviteit, omdat zo voor elke 
patiënt de laagst mogelijke, werkzame dosering gevonden kan worden. 
Hoofdstuk 4: De kosteneffectiviteit van vijf verschillende afbouwstrategieën 
In hoofdstuk 4 hebben we gegevens uit eerdere studies gebruikt om de kosten en effecten 
van vijf verschillende methodes om een TNF-remmer af te bouwen naast elkaar te zetten. Met 
behulp van computermodellen werden de volgende methodes voor afbouwen vergeleken met 
niet afbouwen: 
1. Afbouwen in vier stappen tot stop 
2. Afbouwen in vijf stappen tot stop 
3. Afbouwen zonder te stoppen 
4. Een strategie met een strenger criterium voor een opvlamming 
5. Een strategie waarin het mogelijk was te voorspellen wie succesvol kan afbouwen
De resultaten laten zien dat alle afbouwmethodes leiden tot kostenbesparingen (tussen 
de € 5.128 en € 7.873 per patiënt over een periode van 1,5 jaar). Wel krijgen deze patiënten 
meer kortdurende opvlammingen vergeleken met de patiënten die niet afbouwen. De 
verschillen tussen de strategieën in effect (kwaliteit van leven van patiënten) waren erg 
klein en niet relevant voor de praktijk. Wanneer kosten werden afgewogen tegen effecten 
(kosteneffectiviteit) gaven methode 1 en 2 de beste uitkomsten. We concluderen daarom dat 
een TNF-remmer het beste kan worden afgebouwd in vier of vijf stappen tot stop, het liefst op 
basis van gedeelde besluitvorming tussen reumatoloog en patiënt.
Hoofdstuk 5: Ultra-lage doseringen rituximab (REDO studie) 
Uit hoofdstuk 2 bleek dat er nog geen studies waren gedaan naar het afbouwen van de 
biological rituximab. Een paar kleine studies lieten al wel zien dat ultra-lage doseringen van 
rituximab (lager dan de standaard lage dosis van 1.000mg per zes maanden) mogelijk ook 
werkzaam zouden kunnen zijn voor de behandeling van RA. In hoofdstuk 5 hebben we dit 
onderzocht in de zes maanden durende REDO studie. 142 RA patiënten die goed reageerden 
op rituximab werden door middel van loting ingedeeld in drie groepen. Zij kregen vervolgens 
1 x 1.000mg (standaard dosering), 1 x 500mg of 1 x 200mg rituximab (ultra-lage doseringen). 
Tijdens de studie wisten patiënten, onderzoekers en zorgverleners niet wie welke dosering 
had gekregen. Metingen werden uitgevoerd bij de start, na drie en na zes maanden. Tijdens 
de studie moesten twee patiënten in beide ultra-lage doseringsgroepen (500mg en 200mg) 
behandeld worden met een extra dosis van 1000mg rituximab in verband met een opvlamming 
van de reuma. Ook kregen meer patiënten in de 200mg groep injecties met prednison om 
reumaklachten te verminderen. Wel kwamen er minder infecties voor in de ultra-lage 
doseringsgroepen. Met de studie kon niet worden aangetoond dat de ultra-lage doseringen 
niet slechter zijn dan de standaard lage dosering na zes maanden. De ultra-lage doseringen 
waren wel effectief voor de meerderheid van de patiënten en de gemiddelde ziekteactiviteit 
bleef laag in alle groepen. Een strategie waarin patiënten op proef behandeld worden met een 
ultra-lage dosering rituximab en extra medicatie in het geval van een opvlamming was niet 
slechter dan de standaard dosering, en kan in de praktijk overwogen worden. Verdere analyses 
van de REDO studie en gegevens over de REDO deelnemers twee jaar na deelname aan de 
studie zullen meer uitsluitsel kunnen geven over hoe we RA patiënten het beste kunnen 
behandelen met rituximab. 
Hoofdstuk 6: Het perspectief van patiënten op het afbouwen van biologicals
Het afbouwen van een biological heeft voor- en nadelen waardoor de beslissing om wel of niet 
af te bouwen afhankelijk is van de voorkeur van individuele patiënten. Het is daarom belangrijk 
om te onderzoeken wat patiënten met RA vinden van afbouwen. In hoofdstuk 6 hebben 
we door middel van interviews met 22 patiënten inzicht gekregen in alle dingen die voor 
patiënten een rol zouden kunnen spelen wanneer zij overwegen hun biological af te bouwen. 
Door het analyseren van deze interviews werden 30 onderwerpen gevonden die vervolgens 
gebruikt werden in een vragenlijst onder 192 patiënten uit drie ziekenhuizen in Nederland. De 
patiënten beantwoordden 18 vragen waarin ze steeds het belangrijkste en minst belangrijke 
onderwerp kozen uit een groepje van vijf onderwerpen. Met speciale software kon hierna een 
rangschikking gemaakt worden van alle onderwerpen (van belangrijk naar minder belangrijk). 
De meeste respondenten op de vragenlijst (74%) gaven aan positief te zijn ten opzichte van 
het afbouwen van een biological. De rangschikking van onderwerpen liet zien dat patiënten 
met name bang zijn voor een opvlamming van hun ziekte en de mogelijke invloed daarvan op 
hun dagelijks leven (bijvoorbeeld dat ze meer pijn krijgen en/of slechter kunnen functioneren). 
Het is belangrijk voor patiënten om te weten dat de dosering verhoogd kan worden wanneer 
het afbouwen niet lukt en dat het medicijn dan ook weer werkt. Patiënten vinden de mening 
van hun reumatoloog belangrijk en willen betrokken worden bij de beslissing om wel of 
niet af te bouwen. Verschillende subgroepen patiënten (zoals bijvoorbeeld jonge en oude 
patiënten of mannen en vrouwen) vonden dezelfde onderwerpen belangrijk. Deze studie 
laat zorgverleners zien wat belangrijk is voor patiënten waardoor zij mogelijk in de praktijk 
makkelijker het gesprek kunnen aangaan over het afbouwen van biologicals. 
Nederlandse samenvattingNederlandse samenvatting
10 10
205204
Hoofdstuk 7: Afbouwen van biologicals in de praktijk
In de richtlijnen die reumatologen gebruiken, wordt aangeraden om biologicals af te bouwen 
bij patiënten die een rustige ziekte hebben. Dit betekent echter niet dat dit in de praktijk ook 
altijd gedaan wordt. Hoofdstuk 7 beschrijft een studie waarin artsen en verpleegkundigen 
werden gestimuleerd om vaker biologicals af te bouwen met behulp van een speciaal 
ontwikkeld interventie-programma. Dit interventie-programma bestond uit:
1. Het maken van lokale protocollen voor afbouwen 
2. Het geven van voorlichting over afbouwen
3. Het geven van feedback over hoe vaak er afgebouwd werd
4. Het noteren van behandel adviezen in de dossiers van patiënten
Deze studie werd uitgevoerd in een ziekenhuis met twee reumatologen en twee 
reumaverpleegkundigen. Gegevens over patiënten (met verschillende reumatische 
aandoeningen) die een biological gebruikten werden verzameld uit het elektronisch 
patiëntendossier voorafgaand en één jaar na de interventie periode. In totaal werden er 
gegevens verzameld over 232 patiënten. Het aantal visites waarbij de ziekteactiviteit werd 
gemeten nam toe na het interventie-programma terwijl de gemiddelde ziekteactiviteit van 
de patiënten gelijk bleef. Het aantal patiënten waarbij werd afgebouwd nam sterk toe. Deze 
resultaten laten zien dat een interventie-programma ervoor kan zorgen dat reumatologen 
en verpleegkundigen beter de aanbevelingen uit richtlijnen volgen en vaker biologicals 
afbouwen bij patiënten met een reumatische aandoening. 
Conclusies
Dit proefschrift laat zien dat het eenmalig verlagen van de biological dosering of het stapsgewijs 
afbouwen van een biological werkzaam en veilig is voor patiënten met reumatoïde artritis die 
weinig of geen ziekteactiviteit hebben. Het direct stoppen van de biological geeft slechtere 
uitkomsten dan het doorgaan met de medicatie (hoofdstuk 2 en 3). Afbouwen in vier of vijf 
stappen tot stop is de beste methode wanneer gekeken wordt naar de balans tussen kosten en 
effecten (hoofdstuk 4). Een ultra-lage dosering rituximab (1 x 500mg of 1 x 200mg) is effectief 
voor de meerderheid van de patiënten, al kan niet worden aangetoond dat deze ultra-lage 
doseringen niet slechter zijn dan de standaard dosering op groepsniveau (hoofdstuk 5). De 
belangrijkste onderwerpen voor RA patiënten wanneer zij overwegen de dosering van hun 
biological te verlagen zijn 1) de mogelijkheid om de dosering weer te verhogen in het geval 
van een opvlamming, 2) het risico op meer pijn en slechter functioneren en 3) de mate waarin 
zij betrokken worden bij de beslissing om wel of niet af te bouwen (hoofdstuk 6). Tot slot 
kan een interventie-programma ervoor zorgen dat zorgverleners beter de aanbevelingen 
uit richtlijnen volgen en vaker biologicals afbouwen bij patiënten met een reumatische 
aandoening (hoofdstuk 7). 
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Ik wil graag iedereen bedanken die heeft bijgedragen aan de totstandkoming van dit 
proefschrift. In het bijzonder wil ik een aantal mensen noemen.
Ten eerste veel dank aan alle patiënten, zorgverleners en onderzoekers die hebben meegewerkt 
aan de studies in dit proefschrift. 
Promotieteam
Beste Frank, bedankt voor de mogelijkheid om te promoveren bij de afdeling Reumatologie 
van de Sint Maartenskliniek. Ik kan veel leren van jouw relaxte houding en manier van 
aansturen. Leuk om aan het einde van mijn promotietraject nog wat intensiever contact 
met elkaar gehad te hebben rondom het osteoporose project. Jij zorgt dat mensen plezier 
in hun werk houden door het niet alleen tegen ze te zeggen (‘keep on smiling’) maar ze ook 
daadwerkelijk in hun kracht te zetten.
Beste Marlies, dankjewel voor alle artikelen, boeken en andere informatie die je me meegaf. 
Al werd mijn promotietraject toch wat minder implementatie-gericht dan eerst gedacht, jij 
bleef enthousiast en je input was (ook bij de klinische studies) heel nuttig. Ook waardeer ik erg 
dat jij altijd in het oog hield dat ik me niet over de kop zou werken met al die ideeën van Alfons 
en dat je optrad als hoeder van het kwalitatieve onderzoek.
Beste Alfons, wat ben jij enthousiast, slim en gepassioneerd over onderzoek! Al kom ik meestal 
niet toe aan al mijn agendapunten en ga ik soms weg met meer vragen dan antwoorden, na 
een overleg met jou zie ik het grotere plaatje en heb ik weer nieuwe energie om er voor te 
gaan. We vullen elkaar aan en zijn naar mijn idee een sterk team geworden. Bedankt voor al 
je kennis, snelle mailtjes en diepzinnige wijsheden (‘we zijn onze eigen bananenschil’, ‘je hebt 
een deadline pas goed gesteld als je hem niet haalt’, ‘je kan een paard naar het water leiden 
maar hem niet dwingen om te drinken’). Ik kijk er naar uit onze samenwerking voort te zetten!
Beste Joke, ik bewonder dat jij altijd bereid bent om met anderen mee te denken en 
onbaatzuchtig het doen van goed onderzoek voorop zet. Je bent voor veel junioren een 
betrouwbaar aanspreekpunt met veel kennis. ik vind het heel fijn (en terecht) dat jij de rol 
van tweede copromotor op je wilde nemen en in de afrondende fase ook nog zorgde voor wat 
mental support. Daarnaast ben je een gewaardeerde sfeermaker: als Joke er bij is, wordt het 
geen saaie lunch/congres/feest!
Prof. van der Hoeven, beste Hans, bedankt voor je ondersteuning als mentor. Het was altijd 
prettig om je te spreken en samen te reflecteren op mijn promotietraject.
Manuscriptcommissie
Beste leden van de manuscriptcommissie, Prof. Elke de Jong, Prof. Kees Kramers en Prof. 
Patrick Verschueren, bedankt voor het beoordelen van mijn proefschrift en jullie deelname 
in de oppositie. 
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Collega’s
Lieve collega’s van reumaresearch Aniek, Bart, Charlotte, Dirkje, Ellen, Elke, Els, Frouwke, 
Joke, Juliane, Michiel, Milou, Nathan, Tim, Vera, Yvette, Yvonne, dankjulliewel voor alle 
gezellige lunches, schrijfdagen en overleggen. Het was altijd prettig om langs te kunnen lopen 
voor een vraag of praatje. Jullie zijn een fijne groep om bij te werken! 
Nathan, met jouw super snelle inzichten, STATA-skills en betrokkenheid bij de REDO heb je 
mij veel geholpen. Ook als kamergenoot is het gezellig met putty-experimenten en ludieke 
foto-shoots. Leuk om te zien hoe jij van student(-assistent) gegroeid bent naar volwaardig 
PhD-student! 
Lieve Aniek, bijna tegelijkertijd begonnen we aan ons promotieavontuur. Ik vond het heel fijn 
en gezellig om bij jou op de kamer te mogen zitten! We kunnen veel met elkaar delen en je 
adviezen en inzichten hebben me vaak geholpen. Mooi dat we de trajecten nu ook nog eens 
vlak na elkaar afsluiten.
Lieve Tim en Bart, ik zeg het nog maar eens, jullie zijn toch wel een verademing voor 
reumaresearch tussen al die precieze meisjes zoals ikzelf. Ik ben heel blij dat ik jullie heb 
leren kennen en geniet van alle lompe grappen en gekke verhalen. Tim, op het eerste gezicht 
ben jij een stugge Achterhoeker, maar al snel blijk je een gezellige koffieleut die makkelijk 
contact maakt en oprechte interesse heeft in anderen. Ik waardeer de manier waarop jij kan 
relativeren en de sfeer positief kan beïnvloeden! Bart, ondanks dat ons eerste contact niet 
erg soepel verliep, bleken we toch een hele goede klik te hebben. Op de kamer introduceerde 
jij verschillende verbeteringen zoals StudioBrussel over de boxen, stoor-mij-nietjes, paper-
plantjes en een hoog-laag bureau (de aanhouder wint ;)). Samen kunnen we het over alles 
en niets hebben, en ik heb veel gehad aan de afleiding in de vorm van tafeltennisbattles en 
wandelingen. Ik ben heel blij dat jij mijn paranimf wilt zijn! 
Veel dank ook aan alle collega’s van de afdeling Research voor de cake van de week momentjes, 
researchlunches en praatjes bij het koffieapparaat. In het bijzonder Malou als kamergenootje 
en later buurvrouw, en Nienke als co-paranimf voor Aniek! 
Daarnaast wil ik de collega’s vanuit de afdelingen Reumatologie en Farmacie bedanken 
voor de samenwerking bij studies en het uitvoeren van projecten. In het bijzonder Lieke 
Nieboer voor onze intensieve RAINBOW samenwerking (helaas heeft de studie het boekje niet 
mogen halen), Noortje, Nienke, Chantal en Lieke Tweehuysen voor de hulp in het begin van 
mijn promotie, en Diane, Celia en Michelle voor gezelligheid bij o.a. lunches, pubquizen en 
congressen!
Beste Ank en Ben, bedankt voor jullie betrokkenheid en input als onderzoekspartners bij de 
verschillende studies. Het was heel waardevol en gezellig om met jullie over onderzoek te 
praten.
Niet te vergeten zijn de verschillende studenten en student-assistenten die mij hebben 
geholpen bij de verschillende projecten. Anje, Dian, Evy, Frederique, Kirsten, Lisa, Maike en 
Stijn dankjewel voor jullie inzet!
Vrienden
Lieve Annemiek, Iris, Jessie, Kyra en Winnie, oftewel dudes4life (kan iemand die app-naam 
nu eindelijk eens veranderen?), wat heb ik veel gehad aan al onze etentjes en weekendjes 
weg. Jullie weten goed wat het inhoudt om te promoveren en konden me altijd van nuttige 
adviezen voorzien op welk vlak dan ook. Ik vind het heel fijn om jullie als vaste waarde in mijn 
leven te hebben.
Lieve Nina en Marjet, ik ken jullie beide al sinds de middelbare school en ben heel blij dat 
het contact steeds is gebleven. Nina, de afstand tussen Nijmegen en Delft weerhoudt ons er 
niet van te blijven afspreken. Ik vind het bijzonder om met jou te kunnen bijkletsen over alle 
ontwikkelingen in onze levens. Marjet, je bent altijd geïnteresseerd in hoe het met me gaat en 
open voor diepe gesprekken. Ook al schiet het afspreken er soms bij in, het is goed om te weten 
dat je in de buurt bent voor als het nodig is. 
Lieve volleybaldames (Heyendaal veteranen en Pegasus teamies) + Johan bedankt voor 
alle gezellige trainingen, wedstrijden en uitjes! Dit heb ik soms echt even nodig na een lange 
dag achter de computer. 
Familie
Lieve familie, bedankt voor de leuke familiefeesten en interesse in mijn werk. In het bijzonder 
opa Cees en oma Monique die, ondanks dat jullie misschien niet altijd helemaal begrepen 
waar ik precies mee bezig was, wel altijd bleven vragen hoe het er mee stond.
Lieve mama, dankjewel voor je interesse en support tijdens mijn promotietraject. Jij zorgt, 
samen met Idelette, voor een gezellige en veilige haven waar er weer even voor me gezorgd 
wordt en ik afstand kan nemen van het leven in Nijmegen. 
Lieve papa, ik wil je graag bedanken voor het luisteren en meedenken. Jij en Sabine zijn 
altijd bereid om input te geven voor mijn onderzoek of loopbaankeuzes en hebben tijdens 
mijn promotie ook voor de nodige actieve afleiding gezorgd in de vorm van dagjes wandelen, 
fietsen en zelfs een weekend wadlopen. 
Lieve Floor, wat ben ik blij met jou als zus! Al was je in eerste instantie niet zo enthousiast dat 
ik ook in Nijmegen ging studeren, je moet toch toegeven dat het goed heeft uitgepakt. Samen 
kunnen we lief en leed delen en hebben we een, voor anderen vaak onnavolgbare, connectie. 
Bij jou kan ik totaal mezelf zijn en wat we ook doen (van de vierdaagse lopen tot uitgaan in 
Boedapest of Antwerpen) wij vermaken ons wel! Fijn om bij jou en Bob terecht te kunnen met 
kleine en grotere problemen of gewoon voor een gezellige avond. Ik ben heel blij dat jij mijn 
paranimf bent!
Lieve Jeroen, jij bent degene die altijd in me gelooft, naar me luistert en me rust en ruimte 
geeft als dat nodig is. Nooit was het een probleem als ik langer moest werken, jij zorgde voor 
eten en regelde een groot scherm zodat ik beter thuis kon werken. Ik geniet van alle reizen en 
weekendjes weg samen. Al is het ook erg fijn in Nijmegen. Samen in ons mooie huis, de stad in 
of samen sporten. Door jou ben ik de beste versie van mijzelf. Ik hou van je. 
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Lise Verhoef werd op 6 februari 1989 geboren in 
Amersfoort. In 2007 behaalde ze haar VWO diploma 
aan Scholengemeenschap de Amersfoortse Berg. 
Datzelfde jaar startte ze met de opleiding medische 
biologie aan de Radboud Universiteit in Nijmegen 
waarvan ze haar Bachelor diploma behaalde in 2010. 
Daarna startte ze met de master Biomedical Sciences 
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ze een wetenschappelijke stage bij de afdeling 
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Utrecht. Na het behalen van haar master diploma 
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afdeling IQ healthcare van het Radboudumc waar ze 
meewerkte aan verschillende projecten gericht op 
verbetering van de kwaliteit van zorg. 
Begin 2015 begon Lise als promovenda bij de afdeling reumatologie van de Sint Maartenskliniek. 
In dit traject werd ze begeleid door Prof. Dr. Frank van den Hoogen, Prof. Dr. Marlies Hulscher, 
Dr. Alfons den Broeder en Dr. Joke Vriezekolk. De verschillende onderzoeksprojecten naar het 
zinnig en zuinig gebruik van biologicals bij patiënten met reumatoïde artritis hebben geleid 
tot het huidige proefschrift. 
Lise werkt nog steeds als onderzoeker op de afdeling Reumatologie van de Sint Maartenskliniek. 
Ze woont in Nijmegen samen met haar vriend Jeroen. 
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Chapters 5 and 6 of thesis are based on the results of human studies, which were conducted 
in accordance with the principles of the Declaration of Helsinki. The medical and ethical 
review board Committee on Research Involving Human Subjects Region Arnhem Nijmegen, 
Nijmegen, the Netherlands has given approval to conduct these studies. Written informed 
consent was provided by all participants. The other studies did not require approval from an 
ethics committee in the Netherlands according to the Medical Research Involving Human 
Subjects Act since they concerned literature studies (chapters 2 and 3), a modelling study 
based on anonymous data (chapter 4), and a quality improvement project (chapter 7). 
The projects are stored on the department servers: H:\ or V:\ under reuma_research_studies 
and research_archief. The paper data were stored at the research department of the Sint 
Maartenskliniek (room W0.29) and will be transferred to the departments archive after 
publication of the study. Data in the REDO study (chapter 5) was collected by use of Castor 
EDC. Data in the quantitative part of chapter 6 was collected online by the use of Sawtooth 
Software. 
The privacy of the participants in the studies is warranted by use of encrypted and unique 
individual subject codes. The code was stored separately from the study data. Data where 
converged to Stata (StataCorp LLC, College Station, Texas, USA) for analyses. Data from the 
qualitative part of chapter 6 was analyzed using MAXQDA (VERBI Software GmbH, Berlin, 
Germany). Serum samples of participants from the REDO trial were stored at the laboratory of 
the Sint Maartenskliniek under their subject code. 
Data will be saved for 15 years after termination of the study concerned. Serum samples will 
be saved for 10 years after termination of the REDO study (16 April 2019). Using these patient 
data in future research is only possible after a renewed permission by the patient as recorded 
in the informed consent. The datasets analyzed during these studies are available from the 
corresponding author on reasonable request.
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